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Trypanosoma congolense is a pathogenic protozoan parasite causing animal African 
trypanosomiasis, also called nagana, in livestock in Sub-Saharan Africa. The disease results in 
economic losses with increased livestock mortality. Vaccine development is unlikely due to a lack 
of long term antibody response to trypanosomal antigens by the host and antigenic variation of 
the parasite. Effective control of the disease is thus required; however, trypanocidal drug 
treatments are inefficient in clearing the infection due to drug resistance. Current diagnostic tests 
lack specificity and use native trypanosomal proteins that require in vivo or in vitro cultivation of 
parasites which is expensive, time consuming and can lead to inconsistent results. Due to these 
challenges, recombinant trypanosomal proteins are being explored as alternative diagnostic 
antigens.  
Invariant surface glycoproteins (ISG) are transmembrane proteins located on the surface of 
trypanosome bloodstream forms and does not undergo antigenic variation. The aim of the study 
was to therefore examine T. congolense invariant surface glycoprotein (TcISG) as a potential 
diagnostic antigen for animal African trypanosomiasis. The TcISG gene coding the signal 
peptide, extracellular domain, transmembrane domain and intracellular transmembrane domain 
was cloned and expressed as a histidine tagged fusion protein within inclusion bodies in 
Escherichia coli BL21 (DE3) cells. Recombinant TcISG was solubilised with anionic detergents, 
refolded and purified using nickel affinity chromatography. Purified TcISG and an N-terminal 
peptide corresponding to immunogenic epitopes were selected and used to generate antibodies 
in chickens. Both types of antibodies demonstrated increased specificity following affinity 
purification and recognised native ISG in T. congolense lysates. TcISG was able to distinguish 
between non-infected and T. congolense infected cattle sera in an indirect antibody detection 
ELISA and was not recognised by antibodies against T. brucei ISG65 and ISG75 as well as T. b. 
gambiense VSGs RoTat 1.2, LiTat 1.3 and LiTat 1.5. These results show promise for TcISG to 
serve as a species-specific diagnostic antigen while further testing may demonstrate its possible 
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1.1 African trypanosomiasis 
Trypanosomes are unicellular protozoan parasites which cause trypanosomiasis in both animals 
and humans in Sub-Saharan Africa (Baral, 2010). Animal African trypanosomiasis (AAT) also 
locally known as ‘nagana’ is caused by Trypanosoma brucei brucei, T. congolense and T. vivax 
(Schofield and Kabayo, 2008). Human African trypanosomiasis (HAT) also known as ‘sleeping 
sickness’ is caused by two sub-species of Trypanosoma brucei, T. brucei gambiense and           
tsetse fly (Glossina spp). The location of the tsetse fly can be divided into three different groups: 
morsitans (savannah), palpalis (riverine) and fusca (forest) (Uilenberg and Boyt, 1998) according 
to their habitat to overlap with areas containing livestock and wild animals (Figure 1.1) (Weitz, 
1963). The tsetse fly is exclusively located over an area of 10 million km2 of Africa known as the 
‘tsetse belt’ (Barrett et al, 2003). The tsetse fly vector facilitates the cyclic or mechanical 
transmission of the parasite between various mammalian hosts (Baral, 2010). Trypanosomes 
transmitted cyclically include: T. brucei gambiense, T. congolense and T. vivax (Desquesnes 
and Dia, 2003). However, mechanical transmission can also occur in T. vivax and T. evansi 
(Hoare, 1972; Desquesnes and Dia, 2004). Trypanosoma brucei brucei, a subspecies of           
T. brucei which infects animals, is dispersed across sub-Saharan Africa whereas human 
pathogens, T. brucei gambiense is found in West and Central Africa while T. brucei rhodesiense 
is found in Eastern and Southern Africa (Hoare, 1972; Balmer et al, 2011). 
Of the two trypanosomes that infect humans, T. brucei gambiense causes a chronic disease 
resulting in death if untreated (Blum et al, 2012) whereas T. b. rhodesiense HAT causes an 
acute disease that develops swiftly leading to death within six months (Odiit et al, 1997 and Blum 
et al, 2012). According to the World Health Organisation (WHO), T. brucei gambiense is 
responsible for 98% of reported sleeping sickness cases (WHO, 2013).  
Tsetse fly transmitted AAT affects cattle and small ruminants (goats and sheep) and has a 
devastating effect on the economy with direct meat and milk production losses and indirect 
losses (draught power, hides and manure) amounting to a $4.75 billion annual loss in agricultural 
gross domestic product (Swallow, 2000; Chanie et al, 2013). Approximately 40 million cattle are 




African trypanosomiasis caused by the dominant T. congolense species continues to seriously 
harm livestock and the farming industry (Abera et al, 2016). 
 
 
Figure 1.1: Map of the African continent illustrating the distribution of tsetse fly populations and 
cattle raising regions. (http://www.irinnews.org/news/2009/05/12/tsetse-fly-costs-agriculture-billions-
every-year). 
 
1.2 Classification of trypanosomes 
Trypanosomes belong to the Kingdom protozoa and the family of Trypanosomatidae (Hoare, 
1972) as displayed in Figure 1.2. Trypanosomes are assembled in the order Kinetoplastida due 
to the presence of a DNA containing kinetoplast (Hoare, 1972 & Baral, 2010). The genus 
‘Trypanosoma’ is further divided into two groups: stercoraria and salivaria (Hoare, 1972 & Baral, 
2010). Stercoraria parasites develop within the intestinal tract of the vector and transmission 
occurs through the faeces of the parasite. The stercoraria group is further divided into three 




salivarian parasites develop within the vector gut and the infective metacyclic forms are injected 
into the host bloodstream during a blood meal (Hoare, 1972). The salivarian group is further 
divided into four subgenera, Trypanozoon, Duttonella, Nannomonas and Pycnomonas (Hoare, 
1972). All parasites belonging to the salivarian group are transmitted by the tsetse fly (Glossina 
spp) and are established in Africa i.e. T. vivax, T. congolense and T. brucei (Hoare, 1972 & 
Baral, 2010).  
 
1.3 Morphology of trypanosomes 
Trypanosoma congolense parasites located in the bloodstream of cattle possess a single 
elongated mitochondrion and a centrally positioned nucleus (Morrison et al, 1981; Stevens and 
Brisse, 2004). The medium sized kinetoplast containing DNA is situated towards the posterior 
end of the parasite (Figure 1.3). Trypanosoma congolense parasites are approximately 8-24 µm 
in length. The posterior ends of the small parasites appear rounded whereas in larger parasites 
the posterior ends are typically pointed (Stevens and Brisse, 2004). The parasite also possesses 
a surface coat which plays a significant role in instigating a relentless infection (Morrison et al, 
1981). The surface coat consistently covers the plasma membrane and is composed of 










Figure 1.3: Morphological features of Trypanosoma congolense in its bloodstream form. 
(Vickerman, 1969a).  
 
1.4 Life cycle of African trypanosomes 
The life cycle of African trypanosomes begin when the tsetse fly feeds on the blood of the host 
by piercing the skin with its proboscis resulting in metacyclic trypomastigotes entering the host 
bloodstream (Figure 1.4) The metacyclic trypomastigotes then develop into the infective 
bloodstream trypomastigotes known as the blood stream form (BSF) at the infection site. Blood 
stream forms appear long and slender and proliferate by the process of binary fission and enter 
various organs via the bloodstream (Hoare, 1972). 
Within the host bloodstream, BSF trypanosomes are heavily coated with approximately 107 
copies per cell of variable surface glycoprotein (VSG) (Turner, 1985). There are up to 1000 VSG 
genes coding prospective surface coat proteins, however only one VSG gene is expressed at 
any given time (Gruszynski et al, 2006). At the peak of parasitemia, BSF trypanosomes adopt a 
non-proliferative short and stumpy appearance in response to stumpy induction factor (Vassella 




blood meal. In the fly the BSFs rapidly shed their VSG surface coat (Cross, 1975; Roditi and 
Liniger, 2002). The removal of the VSG coat occurs through the action of a proteolytic enzyme, 
i.e a zinc metalloprotease in conjunction with glycosylphosphatidylinositol-specific 
phospholipase C (Ziegelbauer et al, 1993 and Gruszynski et al, 2006). 
Thereafter, the BSFs differentiate into procyclic trypomastigotes also known as procyclic forms 
(procyclics) within the midgut of the tsetse fly (Vickerman, 1985). Trypanosoma congolense 
procyclics express a procyclin coat known as protease resistant surface molecule (PRS) 
(Bütikofer et al, 2002) or glycosylphosphatidylinositol (GPI) anchored procyclic acidic repetitive 
proteins (PARPs) in addition to GPI anchored glutamate- and alanine- rich protein (GARP) 
within the midgut of the tsetse fly (Bayne et al, 1993; Urwyler et al, 2007). The PRS are 
generously expressed by early procyclics and weakly expressed during the late procyclic stage. 
The GARP is weakly expressed and decreases in expression during the early stages of the 
procyclics (Bütikofer et al, 2002). Trypanosoma brucei procyclics expressing PARPS containing 
two forms known as EP-procyclins consisting of a Glu-Pro dipeptide and GPEET-procyclins 
comprising of a Glu-Pro-Glu-Glu-Thr pentapeptide repeat (Roditi et al, 1998). During the early 
stages of the procyclics, both procyclins, EP and GPEET are expressed (Vassella et al, 2000). 
The procyclics then travel to the proventriculus of the tsetse fly, undergo asymmetric division 
and attach to the proboscis as epimastigote forms (epimastigotes) with elevated expression of 
GARP (Bütikofer et al, 2002; Coustou et al, 2010). Finally, the epimastigotes differentiate into 
infective metacyclic forms (metacyclics) which are coated in VSG molecules (Tetley et al, 1987; 
Urwyler et al, 2007). The infective metacyclics are then transmitted to a new host during a blood 
meal (Hoare, 1972). Trypanosoma brucei procyclics differentiate into epimastigotes within the 
salivary gland where they undergo proliferation and express GPI anchored brucei alanine-rich 
protein. The epimastigotes differentiate into infective metacyclics and reacquire a VSG coat 
(Tetley et al, 1987; Bütikofer et al, 2002; Matthews, 2005).  
The life cycle of T. vivax begins by the ingestion of BSF trypanosomes from the host blood 
during a blood meal. Unlike T. congolense BSFs which travel to the midgut of the vector and 
differentiate into procyclics, T. vivax BSFs migrate directly to the proboscis of the vector and 
differentiate into epimastigotes thereby missing the procyclic stage in the vector gut (Hoare, 
1972). The absence of a vector gut stage made it possible for T. vivax to spread to other 






Figure 1.4: Diagrammatic representation of T. congolense life cycle. Image is courtesy of Genome 
Research Limited (Adapted from http://www.yourgenome.org/facts/what-is-african-sleeping-sickness). 
 
 
1.5 Clinical features of animal African trypanosomiasis 
When infective trypanosomes are injected into the host, a chancre develops, which is evident by 
swelling and inflammation after 2-3 weeks. At this site of infection, trypanosomes reproduce and 
differentiate into bloodstream forms which invade the lymph nodes and eventually the 
bloodstream of the host (Morrison et al, 1981; Uilenberg and Boyt, 1998).  
Inflammatory responses experienced by the infected animal include oedema, vascular 
congestion and extravasation of polymorphonuclear leukocytes (Morrison et al, 1981). The 
infection begins with hyperthermia followed by host antibody production against parasite surface 
proteins (Uilenberg and Boyt, 1998). Although some parasites are destroyed by these 
antibodies, a few trypanosomes survive due to their ability to alter their surface coats which 
prevents the antibodies from destroying them (Uilenberg and Boyt, 1998; Barry and Carrington, 
2004). The remaining active parasites reproduce and an increased parasitemia level along with 
hyperthermia generates a new set of antibodies against the new surface coat of the parasite in 
the host. This process is known as antigenic variation and continues until either the parasite 

















The acute stage of AAT is characterised by a range of symptoms including weakness, 
intermittent fever, roughness of the coat, weight loss, abortion, enlargement of peripheral lymph 
nodes, pyrexia, and low milk yield (Conner, 1994). Lack of treatment can lead to death of the 
animal (Taylor and Authié, 2004). During chronic infection, anaemia can be prevalent for 3 to 4 
months post infection (Morrison et al, 1981). During this stage, haemolytic anaemia results from 
escalated erythrocyte death by the process of phagocytosis in the lungs, bone marrow, spleen, 
liver and haemal nodes (Morrison et al, 1981). The erythrocytes are believed to be coated with 
the lysed parasites which allow the phagocytes to remove the foreign material causing a 
depletion of haemoglobin and consequently oxygenated blood leading to deterioration and 
wasting of the animal (Uilenberg and Boyt, 1998).   
Progression of the disease results in nutritional deficiencies, immunosuppression and 
simultaneous infections (Morrison et al, 1981). During trypanosomal infections, many tissues 
and organs are damaged such as the heart resulting in heart failure (Morrison et al, 1981). 
Bodily systems affected by the infection include: skeletal muscle, endocrine organs and 
reproductive tract leading to premature births, abortions, testicular impairment and perinatal loss 
(Morrison et al, 1981).  
 
1.6 Diagnosis of trypanosomiasis 
Effective control of AAT can be provided by early detection of the disease followed by treatment. 
There are several diagnostic tests available for use however; each test varies in sensitivity 
specificity as well as cost and applicability for field use. Direct detection of parasites in infected 
sera provides increased specificity, whereas indirect tests detect more parasites (Uilenberg and 
Boyt, 1998; Büscher et al, 2009). Serological diagnostic tests such as indirect fluorescent 
antibody test (IFAT), enzyme-linked immunosorbent assay (ELISA) and card agglutination test 
(CATT) detect parasite antigens or anti-trypanosomal protein antibodies in infected animal sera 
(Voller et al, 1975; Songa and Hamers, 1988; Nantulya and Lindwvist, 1989). Molecular 
diagnostic tests have been explored to provide species differentiation thereby providing 







1.6.1 Direct detection 
Motile parasites are observed microscopically in wet blood films from infected animals 
(Uilenberg and Boyt, 1998; Eisler et al, 2004). This is a simple and inexpensive diagnostic 
method. However, species identification cannot be performed and test sensitivity is limited to 
approximately 104 parasites per ml of blood (Uilenberg and Boyt, 1998). Thick blood smears 
involve staining a sample of infected blood with Giemsa on a slide followed by visualisation of 
parasites under a microscopic lens (Figure 1.5, panel A). Thin blood smears entail spreading 
the blood sample on the slide followed by staining with Giemsa for identification of parasites 
(Figure 1.5, panel B), however, the test sensitivity is very low (Eisler et al, 2004). Although these 
methods are commonly used, they are not sensitive enough to identify parasites at low 
parasitemia levels in large animals or after cure. Collecting blood samples during the early 
hours of the morning and from the ear or underside of the animal may increase the chance of 
parasite detection (Eisler et al, 2004). 








Figure 1.5: Trypanosomes stained with Giemsa in blood smears. (A) Thick and (B) thin blood smears 
for the detection of parasites. (Cottle et al, 2012; Centre of Disease Control and Prevention, 
https://www.cdc.gov/dpdx/trypanosomiasisAfrican/gallery.html). 
 
The microhaematocrit centrifugation technique also known as the Woo method is based on the 
separation of the blood components according to their individual gravity (Woo, 1970). Blood 
samples are collected in heparinised capillary tubes and centrifuged. The buffy coat is studied 
through the capillary tube for the presence of motile trypanosomes using long microscopic focal 





This technique is considered highly sensitive and inexpensive in comparison to blood film 
methods and the diagnosis of anaemia can be performed. However, specialised equipment is 
required and species identification is not possible (Uilenberg and Boyt, 1998). The sensitivity of 
the method is 6525 parasites/ml (Paris and McOdimba, 1982).  
The buffy coat (BCM) or Murray method is similar to the microhaematocrit centrifugation 
technique, however the capillary tube is cut and the buffy coat and erythrocyte layer are 
dispersed onto a microscope slide. Using dark-ground or phase-contrast microscopy, motile 
trypanosomes can be observed. Trypanosoma congolense parasites appear small, slow-moving 
and cling to erythrocytes through their anterior end (Murray et al, 1977).  Similar to the Woo 
method, the BCM can also detect the presence of anaemia and both methods are considered 
highly sensitive (Desquesnes, 2004). Another technique used for rapid detection of 
trypanosomes is the quantitative buffy coat (QBC) (Bailey and Smith, 1992) which uses 
centrifugation to separate the components of infected blood and acridine orange is used to stain 
DNA (Bailey and Smith, 1994).  
Sub-inoculation of infected blood into laboratory animals such as mice, rats, rabbits or guinea 
pigs can be employed to detect low levels of parasitemia (Morrison et al, 1981). Briefly, animals 
are injected intraperitoneally with the infected blood and parasitemia levels are monitored by 
tails pricks and microscopic analysis of the blood using the wet blood film method (Uilenberg 
and Boyt, 1998). Parasitemia levels are monitored for approximately two months after 
inoculation. This method is commonly avoided since results are not immediate and the animals 
have to be cared for which raises ethical concerns (Morrison et al, 1981; Uilenberg and Boyt, 
1998).  
 
1.6.2 Indirect detection 
The miniature anion-exchange chromatography technique (m-AECT) is commonly used to 
diagnose HAT caused by T. brucei rhodesiense and T. brucei gambiense. Infected blood is 
collected and allowed to pass through a diethyl amino-ethyl (DEAE) cellulose matrix. 
Erythrocytes adhere to the resin since they are more negatively charged than the trypanosomes 
whilst the trypanosomes pass directly through the resin. The collected trypanosomes are 
centrifuged at a low speed and examined microscopically for motility in a transparent tube 
(Lumsden et al, 1979). This technique allows for the detection of fewer than 50 




al, 2009). Since 2006, the collection tubes, column racks and microscope viewing compartment 











Figure 1.6: Illustration of miniature anion-exchange centrifugation technique. (A) Elution of 
parasites from blood into collector tubes using columns mounted onto a rack. (B)  Visualisation of motile 
parasites by mounting the collector tube in the microscope viewing chamber. (C) Enlarged image of the 
collector tube tip (Büscher et al, 2009). 
 
 
1.6.3 Serological testing 
Serological testing uses antibody detection methods to detect antibodies produced by the host 
against trypanosomal proteins circulating in the bloodstream of the host (Uilenberg and Boyt, 
1998). Antibody based techniques include IFAT and ELISA which were initially used for 
detection of antibodies against T. brucei rhodesiense (Voller et al, 1975). The detection of 
antibodies against the parasite does not demonstrate the presence of active infections as these 
antibodies can persist in the host bloodstream for long periods of time after cure (Uilenberg and 
Boyt, 1998).  
The IFAT involves the binding of anti-trypanosome antibodies from infected sera to the antigen 
which is fixed onto a microplate. The antigen can be whole parasites or specific parasite 
proteins. Since each microplate typically contains 96 wells, several sera samples can be tested 
in a short space of time (Uilenberg and Boyt, 1998). Anti-bovine IgG antibody conjugated to a 






differentiate between different species and requires expensive specialised equipment and 
reagents, making it unsuitable for field use (Uilenberg and Boyt, 1998).  
Antigen detection tests use a polyclonal or monoclonal antibody in an ELISA to capture 
trypanosomal antigens from the blood of the infected animal (Nantulya and Lindwvist, 1989). 
The antibody-antigen complex is detected using a secondary antibody conjugated to an enzyme 
(Uilenberg and Boyt, 1998). The test may be species specific and allows for large numbers of 
samples to be processed due to its automation. This test has been used extensively, yet its 
sensitivity was shown to be very low and cross reactivity with other Trypanosoma species 
occurred (Uilenberg and Boyt, 1998). In comparison to the microhematocrit centrifugation 
technique, this assay is more effective (Masake and Nantulya, 1991).  
Agglutination tests such as CATT for trypanosomes uses whole, fixed or stained parasites as 
antigens (Songa and Hamers, 1988). The antigens cluster in the presence of anti-trypanosomal 
antibodies which indicate a positive reaction (Figure 1.7). Additionally, an antigen capture latex 
agglutination assay has been established and is based on the principle of coating the latex 
particle with the capture antibody. In the presence of the target antigen in the infected sera, the 
particles begin to agglutinate indicating a positive reaction (Songa and Hamers, 1988; Defontis 
et al, 2012). 
 
Figure 1.7: Illustration of the CATT/T. evansi test using infected cerebrospinal fluid and serum. 
The test reagent is fixed Coomassie blue stained T. evansi expressing VSG RoTat 1.2. The test reagent 
is mixed with the infected samples and an agglutination reaction occurs if antibodies against the test 
reagent are present within the infected samples and visualised by the blue dye. Well 1, positive control, 
well 2, negative control, well 6, cerebrospinal fluid (weak positive reaction), well 8, infected serum (strong 





1.6.4 Molecular testing 
Molecular testing in diagnostics refers to the detection of trypanosomal nucleotide sequences 
specific to a species, subgenus and strain (Desquesnes and Dávila, 2002). The earliest 
techniques established were DNA sequencing and DNA-probe synthesis followed by 
polymerase chain reaction (PCR) (Majiwa et al, 1994). Trypanosomes can be identified in the 
tsetse fly using PCR (Uilenberg and Boyt, 1998). 
Polymerase chain reactions target specific trypanosomal genes present in a high copy number 
which elevates the chance of DNA amplification (Desquesnes and Dávila, 2002). Trypanosomal 
DNA can be obtained from whole or fragmented parasites in the host blood. Katakura and 
colleagues demonstrated the use of three specific repetitive DNA sequences that can be 
amplified from three subgroups of T. congolense parasites. Primer set TCN1 and TCN2 were 
designed for Savanna subgroup, TCF1 and TCF2 primer set for Forest subgroup and TCK1 and 
TCK2 primer set for Kenya Coast subgroup (Katakura et al, 1997). The technique proved to be 
highly sensitive and provided species identification and recognition from mixed infections. 
Another T. congolense DNA target for PCR includes mini-chromosomes which consist of 
satellite DNA (Masiga et al, 1992). In a separate study, a single PCR was able to distinguish 
between different Trypanosoma parasites affecting livestock (Desquesnes et al, 2001). 
However, the test was disregarded for field use due to the lack of sensitivity. This study was 
improved upon by using a single PCR in association with restriction fragment length 
polymorphism (Geysen et al, 2003). These molecular tests have proven superior to 
parasitological techniques since the infecting Trypanosoma species can be identified 
(Desquesnes and Dávila, 2002). Due to the presence of ‘ghost DNA’ i.e. DNA from dead 
trypanosomes, active infections cannot be identified (Desquesnes, 1997).  
The loop-mediated isothermal amplification (LAMP) test amplifies DNA with elevated specificity 
and efficacy using an isothermal environment (Notomi et al, 2000). The technique uses four 
specifically designed primers instead of two primer sets in the case of PCR (Notomi et al, 2000). 
This technique allows for amplification of the target DNA with increased selectivity and 
specificity (Notomi et al, 2000; Kuboki et al, 2003). Moreover, LAMP is the superior technique 
since the reaction result can be determined visually by the reaction turbidity and expensive toxic 
fluorescent dyes are not required (Mori et al, 2001).  
A fluorescence in situ hybridisation test using peptide nucleic acid PNA probes offer a rapid and 




fluorescein-labelled probe which target 18S rRNA sequences not present in other protozoan 
parasites and is resistant to nucleases and proteases. Due to the specificity of the technique, a 
single parasite can be identified with a detection limit of 500 trypanosomes/ml of blood which 
proves superior to other direct detection tests (Radwanska et al, 2002). 
 
1.7 Vector control  
Trypanocidal drugs such as diminazene, isometamidium and homidium have been used to treat 
cattle for over 50 years (McDermott and Coleman, 2001). Numerous doses of these drugs are 
administered by livestock owners in an attempt to control trypanosomiasis (Geerts et al, 2001). 
However, due to the development of drug resistance, eradication of the vector appears to be the 
most suitable option as a long term solution (Van den Bossche and Delespaux, 2011).  
Insecticides are frequently sprayed on vegetation where tsetse flies rest during the dry season. 
Dichlorophenyl-trichloroethane (DDT) was employed to control the vector population using 
aerial or ground spraying. However, such techniques had posed a health risk to the spraying 
team and the environment (Figure 1.8) (Holmes, 1997). Due to the high risks and increased cost 
factor, sequential aerosol spraying was introduced. Small volumes of non-residual insecticides 
for aerial spraying in combination with other control methods were used in a cost effective and 
efficient manner without harming the environment in Kenya, Zambia, South Africa, Zimbabwe, 
Uganda and Botswana (Grant, 2001; Vreysen et al, 2013).  
The elimination of bushes removes the resting place of the savannah species of the vector 
(Hocking et al, 1963). This method of control is risky as tsetse fly populations may follow 
transported bushes which pass by animal herds susceptible to AAT hence this method is no 
longer performed (Uilenberg and Boyt, 1998). Dark blue or black screen cloths treated with 
insecticides such as pyrethroids have been used to destroy tsetse fly populations (Vale, 1993; 
Rayaisse et al, 2010). The technique can be enhanced by using attractive cloths and pleasant 
odour mixtures to lure the tsetse flies (Holmes, 2013). Additionally, ‘pour-on’ insecticides or live 
bait control can be used on animals in combination with an adjuvant ensuring the chemical is 
evenly distributed over the belly and legs (Thompson et al, 1991; Torr et al, 2007). Some cattle 
are also tagged with insecticide-impregnated ear collars (Leak et al, 1996). Disadvantages 
associated with live bait control include: increased insecticide cost, insecticide resistance and 





Figure 1.8: Vector control methods. (A) Ground spraying of DDT using a spraying machine in 
Zimbabwe. (B) Aerial spraying of insecticide using a rotary atomizer. (C) Biconical Trap used in Kenya to 
attract tsetse flies which are apprehended in the lower cone and travel towards the light upwards where 
they are retained in a cage or bag. (D) Blue and black cloths impregnated with pyrethroids in Botswana. 
(Allsopp, 2001).  
 
The sterile insect technique uses radiation treated sterile tsetse flies in an attempt to reduce 
surviving vector populations after other control methods such as insecticides have been utilised 
(Dyck et al, 2005). The technique is based on releasing increased numbers of the sterilised 
male flies to out-compete the wildtype males. No offspring is produced upon mating of the 
sterile male fly with the wildtype female thereby reducing the prevalence of infective tsetse fly 
populations and transmission of trypanosomes. The major shortcoming of the technique is the 
high expense and logistical constraints (Holmes, 2013). 
 
1.8 Trypanotolerance 
By definition, trypanotolerance is the trait which allows an animal to tolerate trypanosome 
infection and remain productive (Murray et al, 1982; D'Leteren et al, 1998). Such animals are 
able to control the reproduction of the parasite and do not display any clinical symptoms of the 
disease. Trypanotolerance has been reported in cattle breeds located in West Africa such as 




continuous interaction with the infected tsetse flies which allow them to generate a stronger and 
swift immune response to VSG epitopes in comparison to trypanosusceptible breeds (Sileghem 
et al, 1993; Williams et al, 1996). Trypanotolerant animals are capable of reducing parasitemia 
levels, controlling anaemia and continue to remain productive (Murray et al, 1982).   
In a separate study, F2 calves derived from N’Dama and Boran grandparents were utilised to 
identify the loci associated with trypanotolerance phenotypes (Hanotte et al, 2003). The study 
identified 18 quantitative trait loci of which the majority were associated with the control of 
anaemia (Hanotte et al, 2003). Naessens and colleagues demonstrated two mechanisms of 
trypanotolerance by cross breeding the Boran and N’Dama cattle resulting in Chimeric Boran/ 
N’Dama calves. This encompassed the improvement of anaemia control using the 
haematopoietic system and an innate mechanism, independent of the haematopoietic system 
which improved the control of parasites (Naessens et al, 2003). 
 
1.9 Drug treatment for African trypanosomiasis 
There are several drug treatments commercially available for the treatment of AAT which exhibit 
toxicity towards the parasite and reduce parasite reproduction, thus allowing the host immune 
system to overcome the infection (Uilenberg and Boyt, 1998). Trypanocidal drugs remain the 
primary treatment of AAT (Holmes and Torr, 1988) and can be distinguished as therapeutic 
and/or prophylactic. Key therapeutic drugs include diminazene aceturate, homidium bromide 
and homidium chloride (Figure 1.9). Prophylactic drugs comprise of isometamidium chloride, 
homidium bromide and chloride. When AAT is detected within a herd, the entire herd is usually 
treated for the disease since the infection may not be restricted to sick animals or AAT positively 
tested animals (Holmes and Torr, 1988). 
Quinapyramine was successfully used as a prophylactic drug since the 1950s to treat infected 
cattle, however after just seven years of use; the drug was discontinued due to the rise of drug 
resistance (Curd and Davey, 1949). The drug was substituted with diminazene aceturate also 
known as Berenil®, Azidine®, Veriben®, Ganasegur® and Ganaseg® (Tsegaye et al, 2015). 
Berenil® is a therapeutic drug utilised in the treatment of animal trypanosomiasis since 1955 
(Kuriakose and Uzonna, 2014). Trypanosoma congolense infected BALB/c mice treated with 
Berenil® had demonstrated the production of anti-trypanosomal antibodies and parasitemia was 
controlled (Uzonna et al, 1999). The shortcomings of the drug include drug resistance through 




Phenanthridium compounds include Novidium® which is a mixture of homidium chloride and 
bromide and Ethidium®, a mixture of ethidium bromide and bromide salt (Tsegaye et al, 2015). 
Novidium® and Ethidium® have been available since 1952 for the treatment of T. congolense and 
T. vivax infections in cattle, horses, goats and sheep (Watkins and Woolfa, 1952; Tsegaye et al, 
2015). Isometamidium chloride (Samorin® or Trypamidium®) is both a therapeutic and 
prophylactic phenanthridium compound available for use since 1961 (Tsegaye et al, 2015). 
Pyrithidium Bromide (Prothidium®) has been extensively used as a prophylactic drug since 1956 
in East Africa to treat infected cattle. Trypanosomes had quickly established resistance to the 
drug and Berenil® was then employed to treat the Prothidium® resistant parasites (Melaku and 
Birasa, 2013).  
 
 
Figure 1.9: Structures of frequently used trypanocides in chemotherapy of AAT in Africa. (Adapted 
from Melaku and Birasu, 2013).  
 
 
Unfortunately, all trypanocides depicted in Figure 1.9 are susceptible to trypanosome 
resistance. Trypanosoma congolense is the leading parasite in developing drug resistance 




chemotherapeutic drugs and misdiagnosis of the disease resulting in only a few parasites being 
destroyed. The surviving parasites then develop resistance towards the administered drug.  
In an attempt to combat drug resistance, the anti-trypanocidal activity from Dovyalis abyssinica 
(Salicaceae) plant extracts was investigated. The extract was capable of reducing parasitemia 
levels in mice and enhanced the body weight and survival time of the animal in comparison to 
dimethylsulfoxide treatment (Tadesse et al, 2015). Similarly, extracts from the Albizia 
schimperiana (Fabaceae) leaf exhibited anti-trypanosomal activity by reducing parasitemia 
levels in mice (Tesfaye et al, 2015).  
 
1.10 Vaccination 
The ultimate goal of developing a vaccine for both HAT and AAT has not been accomplished to 
date. Early vaccine trials employed the use of VSG molecules since they exist in high 
abundance on the surface of trypanosomes. Unfortunately, due to antigenic variation displayed 
by the parasites and the short lived host antibody response, VSGs could not be used 
(Cornelissen et al, 1985; La Greca and Magez, 2011). Another potential source for vaccine 
candidates originated from the flagellar pocket of trypanosomes. The flagellar pocket is known 
to participate in endocytic processes and cell division and is a contributing factor to parasite 
virulence. Studies conducted showed that mice immunised with T. brucei rhodesiense or          
T. brucei flagellar pocket extract conferred partial protection to the mice (Mkunza et al, 1995; 
Radwanska et al, 2000). Unfortunately, protection was shown to be temporary and the idea of 
the flagellar pocket as a vaccine candidate was terminated. Cytoskeletal proteins such as actin 
and tubulin have also been investigated as vaccine candidates but met with little success. Using 
murine models, recombinant and non-recombinant forms of actin and tubulin were shown to 
provide partial protection against infection by induction of a host antibody response (Lubega et 
al, 2002; Li et al, 2007; 2009). Unsuccessful results were obtained when recombinant ISG65 
and ISG75 from T. brucei were used to vaccinate mice (Ziegelbauer and Overath, 1993). In 
another approach, vaccination of cation pump ATPase’s failed to induce long term protection 
(Ramey et al, 2009). Targeting the parasite itself showed limited success in developing a 
vaccine therefore an anti-disease vaccine was explored using the GPI anchor of VSG 
molecules. Mice treated with a liposome based GPI vaccine, increased IL-10 cytokine levels 
and alleviated clinical symptoms such as weight loss, anaemia, liver damage and motor skill 
damage but the vaccine could not provide complete and long term protection (Stijlemans et al, 




cysteine protease known as congopain was postulated to reduce the severity of AAT symptoms 
in immunised cattle (Authié et al, 2001). Mice immunised with a T. brucei DNA vector coding a 
bloodstream stage ISG were partially protected against low dose infection while remaining live 
mice demonstrated increased IgG2a antibody levels (Lança et al, 2011).  
Mice vaccinated with recombinantly expressed ISG75 extracellular domain resulted in increased 
levels of anti-ISG75 titers; however no protection was detected when challenged with T. brucei 
parasites. Further experiments indicated the lack of a B-cell memory response during an active 
infection suggesting suppression or elimination of specific antibody responses (Magez and 
Radwanska, 2014). In a separate study, mice vaccinated with DTPa vaccine Boostrix® were 
protected against bacterial infection however no protection was observed when the vaccinated 
mice where challenged with T. brucei and treated with Berenil®. These results indicated damage 
to the host B-cell compartment in the presence of trypanosomes (Radwanska et al, 2008). Each 
stage of the B-cell development process is associated with specific markers on the cell surface 
eg. Immunoglobulin M (IgM) is typically expressed on immature B-cells. Models depict the swift 
destruction of T1 B cells and marginal zone B cells which are known to lead to the production of 
IgM expressing cells. The destruction of T1 B cells prevents IgM B cell regeneration thus 
preventing protection from new variable antigens expressed by the parasite. Immunoglobulin M 
producing plasma cells are also destroyed after the first peak of parasitemia (Radwanska et al, 
2008; Bockstal et al, 2011). It is clear that the success of forthcoming vaccine trials will depend 
on eliciting a long term IgM response through increased B cell memory and the complete 
eradication of parasites during infection (Magez and Radwanska, 2014).  
 
1.11 Trypanosomal membrane proteins 
In this section, the most important trypanosomal membrane proteins that are either diagnostic or 
vaccine candidates will be discussed. These membrane proteins include variable surface 
glycoprotein, flagellum membrane proteins, p67 membrane glycoprotein and invariant surface 
glycoprotein.  
1.11.1 Variant surface glycoprotein 
The surface coat of trypanosomes is typically composed of VSGs (Ziegelbauer and Overath, 
1992; Barry and Carrington, 2004). The genome of the parasite contains 107 VSG genes that 
undergo antigenic variation (Mehlert et al, 1998). The glycoproteins are homodimers which are 




of the amino acid on a GPI anchor. The anchor is situated in the outer part of the plasma 
membrane. The VSG molecules pack densely to create a protective surface barrier (Overath et 
al, 1994b). Crystallography studies conducted on two T. brucei VSG variants, MiTat 1.2 and 
LiTat 1.24 concluded the presence of a conserved tertiary structure for all the VSG type 2 C-
terminal domains (Figure 1.10). The C-terminal domain begins with a short alpha helix followed 
by a turn which is connected to an anti-parallel beta sheet via a short loop. The results also 
suggested that VSG dimers are formed via N-terminal interactions. The N-terminal domain is 
made up of seven alpha helices and constitutes approximately 47% of the structure (Freymann 











Figure 1.10: Diagrammatic representation of the MiTat 1.2 VSG dimer. (A) One monomer is 
represented in grey and the other in blue. The C-terminal regions are shown in purple and the N-linked 
oligosaccharide is represented in red (PDB: 1VSG and 1XU6). (B) One monomer is shown in grey; the C 
terminal is represented in blue and the GPI anchor in orange. The green indicates the presence of a loop 
connecting the helix structures and the purple represents the end of the N terminal region. Adapted from 
(Schwede and Carrington, 2010; Schwede et al, 2015). 
 
The process of antigenic variation occurs when the parasite sequentially switches expression of 
one VSG gene for another. Each surface variant is identified as a variable antigen type which 
provides variation and prevents detection of the parasite from the host antibodies thereby 
protecting the parasite from death (Figure 1.11). Once the surface coat of the parasite has been 
altered, parasites expressing the new VSG surface coat reproduce and remain undetected from 
the previous host antibody immune response (Morrison et al, 2009). This phenomenon allows 
the parasite to escape the host immune response rendering the host defenceless against the 





the presence of VSG coated trypanosomes and is responsible for the elimination of parasites. 
Trypanosomes coated in VSG molecules are typically destroyed within a week before the 
production of a host IgG antibody response (Mugnier et al, 2016).   
 
 
Figure 1.11: Diagrammatic representation of a trypanosome parasitemia profile. Each parasitemia 
wave represents the change of proliferative slender parasite forms into arrested stumpy forms expressing 
different VATs on the trypanosome surface. (Matthews et al, 2015).  
 
 
The VSG genes are found on four different loci on mini chromosomes and located close to the 
telomeres. Variable surface glycoprotein genes are situated in the bloodstream form expression 
sites (BES) which contain a promoter and numerous expression site-associated genes (ESAGs) 
(Becker et al, 2004; Hertz-Fowler et al, 2008; Young et al, 2008). Approximately 25 genes are 
found in the metacyclic expression sites that are only active in metacyclic forms of the parasite, 
almost 1500 genes in the sub-telomeric arrays and roughly 200 genes in the diploid genome 
(Graham et al, 1999). From the many silent VSG genes, only 4% are complete genes, 21% are 
gene fragments and 65% are pseudogenes (Weirather et al, 2012). There are three different 
mechanisms of antigenic variation known as gene conversion, telomere exchange and 
transcriptional switching. Gene conversion involves replacing one VSG gene with a copy of 
another in the BES (Figure 1.12). In telomere exchange, there is crossing over of the VSG gene 
from the active BES to the silent BES and transcriptional switching involves the down regulation 
of the active BES followed by the activation of another bloodstream expression site (Borst and 






                 
 
Figure 1.12: Mechanisms of antigenic variation. (A) In gene conversion, the active VSG gene is 
replaced by another VSG gene copy. (B) Telomere switching allows the active VSG gene to be 
transferred to a silent site while the silent VSG is transferred to the active site. (C) In transcriptional 
switching, the active VSG gene is down regulated whilst another VSG is activated. (Adapted from 
Schwede and Carrington, 2010). 
 
 
Variable surface glycoproteins have a long half-life and undergo endocytic processing (Seyfang 
et al, 1990). The fundamental mechanism of T. brucei endocytosis occurs only in the region of 
the flagellar pocket and is mediated by clathrin (Allen et al, 2003). The VSGs journey from the 
endoplasmic reticulum (ER) through the Golgi apparatus and endosomes, and finally arrive at 
the cell surface (Gründfelder et al, 2002). Other components required for endocytosis include 
epsin (Ford et al, 2002), dynamin (Merrifield et al, 2002) and an adaptor complex (Boehm and 
Bonifacino, 2002). Variable surface glycoproteins are internalised by the trypanosome in large 
clathrin coated vesicles followed by the delivery of the cargo to early endosomes marked by ras-
related proteins in brain (Rab) (Pal et al, 2002, 2003; Field and Carrington, 2009). Mediated by 
a Rab11-positive carrier in the lumen of the cisternal endosomes, VSGs are recycled to the cell 
surface upon fusion of the Rab11 carrier to the flagellar pocket membrane (Jeffries et al, 2001; 
Gründfelder et al, 2003). Endocytosis and recycling of VSGs are reported to take place within 
twelve minutes (Engstler et al, 2004).   
Variable surface glycoproteins have contributed significantly to the improvement of diagnostic 
testing. These VSG based tests were utilised for the detection of T. evansi infections which 
cause surra in wild and domestic animals in Africa (Bauman and Zessin, 1992), Asia (Payne et 




al, 1991) and South America (Franke et al, 1994). One such VSG, known as RoTat 1.2, has 
been used in the development of ELISA/T. evansi test for the detection of anti-RoTat 1.2 
antibodies in infected sera (Büscher et al, 1995). A direct and indirect agglutination test, 
CATT/T. evansi (Songa and Hamers, 1988) and LATEX/T. evansi (Verloo et al, 1998) were also 
developed. The ELISA/T. evansi showed test specificity of 95% while CATT/T. evansi showed 
98% and LATEX/T. evansi 82% specificity (Verloo et al, 2000). The ELISA/T. evansi, CATT/T. 
evansi and LATEX/T. evansi use native VSG RoTat 1.2 proteins. Recombinant VSG RoTat 1.2 
has been evaluated as a potential diagnostic antigen and compared to CATT/T. evansi and 
LATEX/T. evansi. The results demonstrated no significant differences in test specificity and 
sensitivity suggesting the possible use of recombinant RoTat 1.2 instead of the native RoTat 1.2 
antigen (Lejon et al, 2005; Sengupta et al, 2014).  
In an attempt to eliminate the use of rodents for antigen production for serodiagnosis, 
recombinant T. b. gambiense VSG LiTat 1.3 and LiTat 1.5 were tested in an ELISA against sera 
from HAT infected patients and compared to native LiTat 1.3 and LiTat 1.5 (Rogé et al, 2014a). 
Individual native LiTat 1.3 and LiTat 1.5 proved superior to their recombinant forms. However, a 
combination of recombinant LiTat 1.3 and LiTat 1.5 produced promising results in replacing 
native LiTat antigens (Rogé et al, 2014a). Fragments of T. evansi VSG RoTat 1.2 were 
recombinantly expressed and could distinguish between the pre-immune and infected sera from 
goats experimentally infected with T. evansi (Rogé et al, 2013) and was used to develop a latex 
agglutination test for the diagnosis of T. evansi infections (Rogé et al, 2014b). The test is known 
as rLATEX/T. evansi and had demonstrated 82.4% sensitivity that was comparable to the 
CATT/T. evansi and had a higher specificity. The rLATEX/T. evansi test serves as an alternative 
diagnostic test with enhanced specificity using recombinantly produced antigens thus animals 
are not required for antigen production (Rogé et al, 2014b). 
The diagnostic potential of VSG LiTat 1.5 peptide from T. b. gambiense was examined and 
compared to native LiTat and LiTat 1.5 in an indirect ELISA against sera from HAT patients. The 
synthesised VSG peptide demonstrated diagnostic potential almost identical to native VSG and 
may have the potential to replace the native antigen in diagnostic testing (Van Nieuwenhove et 
al, 2013). Two diagnostic tests were developed for T. b. gambiense infections using native LiTat 





1.11.2 Flagellum membrane proteins 
The flagellum attachment zone is a domain through which the flagellum is attached to the cell 
body of the parasite. The flagellum plays a pivotal role in parasite motility, growth and the 
arranging of organelles which can be explored as therapeutic targets (Vickerman, 1969b; 
Sherwin and Gull, 1989; Kohl et al, 2003). The FLA1 protein is expressed by procyclic and BSF 
trypanosomes and localises in the flagellum as well as the flagellar pocket and is vital for 
flagellum attachment. Inhibition of FLA1 expression demonstrated a deficiency in flagellum 
attachment and inhibition of cytokinesis (LaCount et al, 2002). A putative calcium channel, 
FS179, located at the flagellum attachment zone plays a role in the attachment of the parasite 
flagellum (Oberholzer et al, 2011). Additionally, T. brucei FLA3 membrane protein associated 
with the flagellum attachment zone was recently identified by Woods and colleagues (Woods et 
al, 2013). The FLA3 membrane protein undergoes N-linked glycosylation and is only detected 
during the bloodstream stage of the parasite. The knockdown of the FLA3 gene resulted in 
defective attachment of the flagellum and prevented cytokinesis in slender forms of the parasite 
(Woods et al, 2013).   
Flagellar pocket associated receptor protein known as cysteine-rich acidic repetitive 
transmembrane protein (CRAM) is located on the surface of T. brucei procyclic flagellar pocket. 
The receptor comprises of a putative N-terminal peptide, an extracellular domain consisting of a 
12 residue cysteine rich repeat, a transmembrane domain and finally a C-terminal hydrophilic 
cytoplasmic region containing 41 amino acids (Lee et al, 1990). The cytoplasmic region was 
hypothesised to contain two domains: one domain located near the C terminus provides 
effective transportation of CRAM and the second domain plays a role in restricting CRAM to the 
flagellar pocket (Yang et al, 2000). The protein has a predicted molecular weight of 200 kDa and 
undergoes glycosylation. This receptor has been implicated to function as a lipoprotein receptor 
in T. brucei procyclic forms (Liu et al, 2000) while mutagenesis studies revealed its significant 
role in effective transport from the ER to the flagellar pocket during receptor mediated 
endocytosis (Yang et al, 2000; Qiao et al, 2006). 
The transferrin receptor (TfR) from T. brucei coded by ESAG6 and ESAG7 is exclusively 
expressed by BSF trypanosomes. The TfR is heterodimeric and located in the flagellar pocket 
with approximately 2 300 copies per cell (Salmon et al, 1994; Steverding et al, 1994, 1995). The 
receptor is GPI anchored to the flagellum membrane and attached to the ESAG6 gene product. 




bonding. Trypanosoma brucei uses TfR to scavenge transferrin from the host (Steverding et al, 
1998).  
 
1.11.3 p67 membrane glycoprotein 
Trypanosoma brucei p67, previously known as CB1-gp, is a lysosome-associated, type I 
membrane-like glycoprotein that undergoes excessive N-linked glycosylation (Brickman and 
Balber, 1993; Kelley et al, 1999). The transmembrane domain is composed of 19 residues and 
the cytoplasmic region consists of 24 residues (Kelley et al, 1999). In bloodstream forms, p67 
exists as a 100 kDa protein known as gp100. Following processing in the Golgi apparatus, 
gp100 is converted into full length gp150. The full length gp150 is directed to the flagellar pocket 
where it is internalised and transported to the lysosome for degradation (Langreth and Balber, 
1975; Lonsdale-Eccles and Grab, 1987; Brickman and Balber, 1994). Degradation products 
produced are gp75, gp42 and gp32. However, in procyclic forms, p67 does not undergo 
processing the Golgi apparatus and is transported directly to the lysosome (Kelley et al, 1995).  
 
1.11.4 Invariant surface glycoprotein 
Invariant surface glycoproteins are transmembrane proteins located on bloodstream form 
trypanosomes (Ziegelbauer and Overath, 1992). These glycoproteins are conserved among the 
subgenus Trypanozoon (T. b. gambiense, T. b. rhodesiense, T. equiperderm and T. evansi) and 
belong to either the ISG65 or ISG75 family (Tran et al, 2008). The identification and 
characterisation of T. brucei ISG65 and ISG75 showed that these molecules are only found on 
bloodstream forms and are sensitive to a trypsin-like proteolytic activity (Ziegelbauer and 
Overath, 1992; Overath et al, 1994a). There are approximately 50 000 and 70 000 copies of 
ISG75 and ISG65 respectively per cell (Tran et al, 2008). Other T. brucei ISG molecules 
discovered are ISG64, ISG70 (Jackson et al, 1993) and ISG100 (Nolan et al, 1997). Since the 
structure of the T. congolense homologue has not been solved, that of T. brucei ISG65 will be 
presented here. 
Both ISG65 and ISG75 polypeptides consist of four domains (Ziegelbauer et al, 1995; Eyford et 
al, 2011). The N-terminal hydrophobic signal sequence (28 amino acids) is cleaved resulting in 
a mature protein. The hydrophilic extracellular region is followed by a single transmembrane 
domain containing hydrophobic amino acid residues and a hydrophilic cytoplasmic region. 




cytoplasmic domain (Chung et al, 2004; Schwede et al, 2015). There are three conserved lysine 
residues located in the cytoplasmic domain of the ISG65 family (Chung et al, 2004). The 
predicted structure of T. brucei ISG65 cytoplasmic tail reveals an open coiled conformation with 
Lys62 fully exposed for interaction with cytosolic proteins  (Figure 1.13) (Chung et al, 2004). 
 
Figure 1.13: Predicted structure of ISG65 cytoplasmic tail. The C-terminus and transmembrane (TM) 
region is indicated with Lys62 exposed to the cytoplasm (Chung et al, 2004).  
 
Membrane trafficking is a vital process in the progression of the cell cycle, infectivity and 
immune evasion mechanisms (Field et al, 2007). Experiments revealed the presence of ISG65 
on the surface of endosomal membranes which is recycled faster than VSG molecules (Figure 
1.14) (Chung et al, 2004). Invariant surface glycoproteins are synthesised in the Golgi 
apparatus and directly transported to the parasite surface membrane. Membrane trafficking 
begins at the flagellar pocket, adjacent to the flagellar pocket collar containing bilbo1, a 
structure known to be necessary for biosynthesis of the flagellar pocket collar (Bonhivers et al, 
2008). Membrane bound ISG is internalised into clathrin coated early endosomes marked with 
Rab5 facilitated by EpsinR and transported to sorting endosomes assisted by Rab11 proteins. 
Upon arrival at the multivesicular body or late endosome, mediated by Rab4 and R11BP1 
protein, ISG is recycled back to the parasite surface or transported to the lysosome for 
degradation. In association with endosomal sorting complex required for transport and factors 
TbVps23 and TbVps28, ISG is degraded in the lysosome (Leung et al, 2008; Field and 
Carrington, 2009; Henne et al, 2011; Koumandou et al, 2012). 
Leung and colleagues depicted a model in which ISGs are internalised followed by 
ubiquitination and are targeted for endosomal degradation (Leung et al, 2011). The three lysine 




and regulation of the trafficking process mediated by ubiquitin and endosomal sorting complex 
required for transport (Chung et al, 2008; Leung et al, 2011). Recently, the ISG75 subfamily was 
associated with the uptake of suramin used for HAT treatment (Alsford et al, 2012). The suramin 
compound binds to ISG75 and is targeted for degradation in the lysosome via endocytosis 
where cathepsin L protease releases suramin from ISG75. Several suramin sensitive genes in 
T. brucei were inspected in the trafficking route of ISG75 which appeared crucial to suramin 
uptake (Zoltner et al, 2015). 
 
Figure 1.14: Membrane trafficking of T. brucei ISG and VSG in the flagellar pocket. (A) 
Trypanosome nucleus, kinetoplast and flagellum emerging from the flagellar pocket. (B) The endocytic 
pathway for ISG and VSG (see text for details; Field and Carrington, 2009).   
 
 
1.12 Application of ISG in diagnosis of trypanosomiasis  
Invariant surface glycoproteins do not undergo antigenic variation in comparison to VSG which 
makes them promising potential diagnostic antigens (Ziegelbauer and Overath, 1992; Tran et al, 
2008). Over the years, several ISG molecules have been examined for their potential to serve 




Invariant surface glycoproteins were explored in relation to T. evansi infections in order to 
develop a new diagnostic reference test (Tran et al, 2009). An ELISA based test using T. evansi 
recombinant ISG75 demonstrated 100% specificity and 94.6% sensitivity against T. evansi 
infected camel sera. These results were consistent with the results obtained from RoTat 1.2-
based assays: ELISA/T. evansi, CATT/T. evansi and the immune trypanolysis assay which was 
the gold standard of serological diagnosis (Tran et al, 2009). This assay could potentially be 
applied for diagnosis of all Trypanozoon subgenus members and could replace native antigen 
based tests (Tran et al, 2009). A 52 kDa invariant surface antigen from T. evansi was 
characterised and used to develop an assay for detection of the antigen in infected animal sera 
(El Hassan, 2014). The results showed early detection of the 52 kDa antigen in infected rabbits 
and rats and was depicted as a suitable candidate for T. evansi diagnosis (El Hassan, 2014). 
The gene coding for T. evansi ISG75 has also been explored in a PCR based diagnostic assay 
by screening blood from experimentally infected animals for trypanosomal nucleic acids 
(Rudramurthy et al, 2013). This ISG-75 gene based PCR assay identified T. evansi infections 
within 24 hours post infection and could prove useful in drug resistance and trypanocidal drug 
design (Rudramurthy et al, 2013). Additionally, the recombinant extracellular domain of            
T. evansi ISG75 has recently showed potential for use in serodiagnosis of AAT (Rudramurthy et 
al, 2015). The test results revealed 99.1% sensitivity and 98.47% specificity indicating once 
again the strong potential of ISG75 in AAT serodiagnosis.  
Since ISG75 is conserved among the Trypanozoon subgenus i.e. T. brucei, T. equiperdum and 
T. evansi (Tran et al, 2006), the extracellular domain of T. gambiense ISG75 was recombinantly 
produced and evaluated as a possible diagnostic antigen. Sera from T. brucei infected goat 
recognised recombinant ISG75 in an ELISA. Additionally, antibodies made against recombinant 
ISG75 detected native ISG75 from T. brucei, T. brucei gambiense, T. brucei rhodesiense,                      
T. equiperdum, T. evansi and T. congolense BSF parasite lysates (Tran et al, 2008). 
The development of a prototype lateral flow device by Sullivan and colleagues revealed 
encouraging results using recombinant ISG65-1 (rISG65-1) as a possible diagnostic antigen for                 
T. gambiense infections (Figure 1.15) (Sullivan et al, 2013). Using the ELISA technique, ISG64 
and ISG65 proteins had identified T. brucei gambiense infections well in comparison to                   
T. brucei rhodesiense infections. The ISG65-1 protein was used in the development of a lateral 
flow device which displayed sensitivity of 88% and specificity of 93%. The use of a lateral flow 





Figure 1.15: The prototype lateral flow device for the detection of T. b. gambiense infections. The 
rISG65-1 protein is immobilised on the nitrocellulose strip and the infected serum containing ant-ISG65 
IgG antibody is the added followed by a chase buffer. The reaction is developed using by colloidal gold-
coupled rISG65-1 (Sullivan et al, 2013). 
 
 
In respect to T. congolense ISG molecules, Eyford and colleagues conducted a study which 
provided identification of protein expression throughout T. congolense life cycle stages (Eyford 
et al, 2011). Membrane proteins identified included VSG, ISG65, ISG75 and TcIL3000.0.38630 
gene. Mochabo and co-workers have since identified TcIL3000.0.38630, as a stage specific 
gene that is abundantly expressed on the surface of T. congolense metacyclics and 
bloodstream forms. The study showed detection of anti-TcIL3000.0.38630 antibodies 7 days 
post infection in mice and could serve as an immunodiagnostic target (Mochabo et al, 2013).  
Fleming and colleagues have recently identified antigens for the diagnosis of T. congolense 
infections. Three proteins from the family of ISGs were evaluated in an ELISA against infected 
sera. Results showed all three proteins performed well in the ELISA while Tc38630 antigen 
demonstrated 87.2% sensitivity and 97.4% specificity when tested against a blinded panel of 
experimentally infected cattle sera. The results also indicated that Tc38630 antigen could be 
useful in monitoring the efficacy of drug treatments and provides promise for the development of 
a lateral flow test using ISG antigens (Fleming et al, 2014). 
Recently, ISGs from T. vivax were recombinantly expressed and purified for the manufacture of 




known as p310-gold colloid conjugate and an unrelated antibody bound to gold colloid to serve 
as a control. When the infected serum is applied to the pad along with the chase buffer, the 
p310-gold colloid conjugate flows up the strip and onto the p310 antigen immobilised on the test 
line. The anti-p310 antibodies from the infected serum bind on the test line as well as the p310-
gold conjugate from the conjugate pad resulting in a visible positive reaction (Figure 1.16). The 
lateral flow test revealed 92% sensitivity and 89.9% specificity and no cross reactivity was 
observed with T. congolense infected sera. These results show great promise in accurately 
diagnosing T. vivax infections. 
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Figure 1.16: TvY486_0045500 prototype lateral flow device for the detection of T. vivax infections. 
(A) The top line represents the control line containing an unrelated immobilised protein whereas the 
bottom is the test line containing T. vivax immobilised protein. (B) Diagrammatic representation of 







1.13 Objectives of the present study 
The overall objective of the current study is to evaluate recombinant T. congolense (IL 3000) 
ISG (TcISG) as a potential immunodiagnostic antigen for animal African trypanosomiasis. 
 
Specific aims: 
1. Obtaining adequate quantities of TcISG protein though cloning, expression and purification. 
2. Investigating the antigenicity of TcISG. 
3. Identification of native ISG from T. congolense (IL 3000) bloodstream form lysates. 
4. Evaluating the diagnostic potential of TcISG with non-infected and T. congolense infected 
sera.  
5. Exploring the cross reactivity of TcISG antigen and anti-T. brucei ISG and anti-T. b. 






CLONING AND RECOMBINANT EXPRESSION OF INVARIANT SURFACE GLYCOPROTEIN 
FROM TRYPANOSOMA CONGOLENSE 
 
2.1 Introduction 
Animal African trypanosomiasis is a devastating disease transmitted by trypanosome infected 
tsetse flies in Sub-Saharan Africa. Trypanosomes are kinetoplast Protozoa that cause direct 
and indirect losses in animal and crop farming particularly affecting the poorest rural 
communities (Swallow, 2000 & Eyford et al, 2011). The parasites evade host immune 
responses in a process known as antigenic variation through alteration of the surface coat 
expressing numerous variable antigen types (Morrison et al, 2009). Due to this process, the 
development of a vaccine is unlikely. Therapeutic and prophylactic drugs such as diminazene 
aceturate and phenanthridium have been employed to treat trypanosomiasis since the 1950s. 
However, drug resistance has become evident (Tsegaye et al, 2015). Improved diagnostic 
techniques are thus required for early detection of the parasite to provide accurate treatment. 
Most diagnostic tests are not species specific or compatible with field use (Uilenberg and Boyt, 
1998). In response to these challenges, trypanosomal proteins are being investigated as 
possible diagnostic targets. 
Invariant surface glycoproteins are transmembrane proteins located on the surface of 
trypanosome bloodstream forms. The ISGs are shielded by large VSG molecules which are also 
abundantly expressed on the parasite surface (Ziegelbauer and Overath, 1992; Overath et al, 
1994b). Unlike VSGs, ISGs do not undergo antigenic variation and are exclusively expressed in 
bloodstream forms making them attractive stage specific diagnostic antigens. The ISGs are 
attached to the parasite cell membrane via a GPI anchor and are composed of four domains 
(Figure 2.1) (Ziegelbauer et al, 1995; Eyford et al, 2011). To date, TcISG has not been classified 
under ISG65 or ISG75 family however sequence analysis of TcISG revealed the presence of 

















Figure 2.1: Predicted domains of T. congolense ISG (TcISG) polypeptide. (A) Amino acid sequence 
showing the signal peptide (SP) in bold red, the extracellular domain within a black dashed box followed 
by the transmembrane domain (TM) and intracellular transmembrane domain (ITM) in yellow and green 
respectively. Conserved ISG65-75 domains are indicated in blue with the predicted GPI anchor in pink. 
(B) Diagrammatic representation of TcISG predicted N-terminal signal peptide in red, followed by the 
extracellular domain, transmembrane domain in yellow and intracellular transmembrane domain in green. 
The numbers above the domains correspond to the amino acid residue in panel A. The ISG65-75 
conserved domains were detected within the extracellular domain of the TcISG protein sequence in the 
NCBI database (Appendix A) (Marchler-Bauer et al, 2015) while predicted transmembrane domains were 
detected using web-based TMHMM server v. 2.0 (http://www.cbs.dtu.dk/ services/TMHMM-2.0/) 
(Appendix B). 
 
The functions of ISGs are poorly understood and are yet to be accurately determined. 
Experiments conducted show rapid turnover and recycling of ISG molecules back to the 
parasite cell surface which associates ISGs with virulence. The remaining ISGs are internalised 
by endosomes and are targeted to lysosomes for degradation via ubiquitination (Chung et al, 
2004 & Leung et al, 2011).  
Over the years, recombinant DNA technology has played a significant role in therapeutics, 
vaccine development and diagnostics (Walsh, 2005; Stijlemans et al, 2007; Rogé et al, 2013). 
Thymine-Adenine (TA) cloning is frequently used due to its efficiency and simplicity originating 
from the presence of complementary 3'-thymine (T) vector overhangs which facilitates ligation to 
5'-adenine (A) overhangs on a PCR product. This eliminates the need for restriction enzymes 
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thereby reducing cost (Zhou and Gomez-Sanchez, 2000). TA cloning is also beneficial due to 
the presence of the lacZ gene in the multiple cloning site coding for a galactosidase enzyme 
which cleaves galactosidic bonds and assists in the identification of recombinant colonies using 
blue/white screening. Ligation of the PCR product into the vector interrupts the lacZ gene 
preventing E. coli JM109 cells from expressing the galactosidase enzyme thereby prohibiting 
the cleavage of galactosidase bonds within the isopropyl-β-D-thiogalactopyranoside (X-gal) 
substrate. This results in the growth of recombinant white bacterial colonies. Escherichia coli 
JM109 cells lacking the recombinant vector possess the complete lacZ gene expressing 
galactosidase thereby allowing cleavage of the X-gal substrate resulting in non-recombinant 
blue bacterial colonies. This unique property permits easy and quick screening of recombinant 
bacterial colonies during cloning (Messing et al, 1977; Norrander et al, 1983).  
Bacterial cells are a popular expression system because its genome is well characterised and 
can be subjected to genetic manipulation for increased protein yields (Hannig and Makrides, 
1998). Escherichia coli BL21 (DE3) cells lack the Lon and OmpT protease genes and therefore 
prevent degradation of extracellular proteins. The bacterial cells are also deficient in hsdSB (rB
–
mB
–) and dcm gene mutations thus preventing DNA methylation and plasmid degradation 
(Gottesman, 1996; Grodberg and Dunn, 1998, Rosano and Ceccarelli, 2014). The advantages 
of using E. coli as an expression system include: rapid growth rate, increased cell culture 
density, affordability, simple growth media and increased protein yields (Makrides, 1996; 
Sezonov et al, 2007). Additionally, recombinantly produced parasite proteins eliminate the use 
of animals for parasite propagation, are off high purity and can be easily produced on a large 
scale in a cost effective manner. Promising results were obtained when native trypanosomal 
antigens were replaced with recombinant proteins in diagnostic tests (Lejon et al, 2005; Van 
Nieuwenhove et al, 2013; Sengupta et al, 2014; Rogé et al, 2014b). 
In this chapter, the cloning, expression and purification of full length TcISG is reported. The 
gene coding for the signal peptide, extracellular domain, transmembrane domain and 
intracellular transmembrane domain was amplified using PCR from T. congolense (IL 3000) 
genomic DNA, cloned into pGEM®-T vector and consequently sub-cloned into pET-32a 
expression vector containing the thioredoxin and histidine affinity tags. The TcISG protein was 
recombinantly expressed within inclusion bodies using the E. coli BL21 (DE3) host expression 
system. TcISG was solubilised using anionic detergents and thereafter refolded and purified 




2.2 Materials and Methods 
2.2.1 Materials 
Molecular biology: The DE-52 Whatman® anion exchange cellulose resin was purchased from 
Whatman (England). High fidelity PCR enzyme with buffer, 10 mM dNTPs, 25 mM MgCl2, Taq 
polymerase, O’GeneRuler™ 1 kb DNA Ladder, T4 DNA ligase, BamH I, Xho I, isopropyl-β-D-
thiogalactopyranoside (X-gal), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (IPTG), 
dithiothreitol (DTT), TransformAid™ Bacterial Transformation Kit, GeneJet™ Plasmid Miniprep Kit 
and shrimp alkaline phosphatase were purchased from Fermentas (Vilnius, Lithuania). 
Escherichia coli cells, JM109 and BL21 (DE3) strain were obtained from New England Biolabs 
(Ipswitch, MA, USA). The ZymoResearch Clean and Concentrator™ kit was obtained from Zymo 
Research (Orange, CA, USA), Seakem®LE agarose was acquired from Lonza (Rockland, ME, 
USA) and ampicillin sodium salt was purchased from USB Corporation (Cleveland, OH, USA). 
The pGEM®-T cloning vector was obtained from Promega (Madison, WI, USA) and the pET-32a 
expression vector was purchased from Novagen (Darmstadt, Germany). Ethidium bromide and 
crystal violet were purchased from Sigma (St. Louis, MO, USA) and tryptone, yeast extract and 
bacteriological agar were acquired from Merck Biolab (Darmstadt, Germany). All commonly 
used reagents were of highest purity and purchased from Merck (Germany) and Sigma (St. 
Louis, MO, USA).  
Protein Purification and quantification: His-select® nickel affinity resin; 4-chloro-1-naphthol, 
lysozyme and Kodak BioMax light film were obtained from Sigma (St. Louis, MO, USA). 
PageRuler™ prestained protein ladder was acquired from Thermo Scientific (Lithuania). Amicon® 
Ultra-15 Centrifugal Filter device (Mr cut-off of 10 kDa) and BCA™ Protein Assay kit were 
purchased from Merck Millipore (Billerica, MA, USA). BioTrace™ nitrocellulose was obtained 
from PALL Corp (Ann Arbor, USA). Dialysis tubing with 10 kDa Mr cut-off was purchased from 
Pierce (Rockford, IL, USA) and Nunc-Immuno™ Maxisorp 96-well plates were obtained from 
Nunc Intermed (Roskilde, Denmark). 
Antibodies: mouse anti-6xHis antibody conjugated to HRPO was purchased from Roche 






2.2.2 Molecular weight marker calibration curves  
The molecular sizes of DNA and protein were determined by constructing calibration curves. 
The O’GeneRuler™ 1 kb DNA ladder was separated on a 1% (w/v) agarose gel and its 
migration measured and plotted (Figure 2.2 panel A). Commercially available PageRuler™ 
prestained protein ladder was electrophoresed on a 10% reducing SDS-PAGE gel and its 
migration was plotted against log of the molecular weight marker (Figure 2.2 panel B).  
 
 
Figure 2.2: Calibration curves showing distance travelled and relative mobility versus log of base 
pairs and molecular weight markers on agarose and SDS-PAGE gels. (A) The migration of 
O’GeneRuler
™
 1 kb DNA ladder on 1% (w/v) agarose gel was measured and the equation of the trendline 
given by y= -4.3658x + 17.778 with a correlation coefficient of 0.9796. (B) The PageRuler
™
 prestained 
protein ladder was separated on a 10% reducing SDS-PAGE gel and its migration plotted against log of 
the marker molecular weight. The equation of the trendline is y= -1.2344+ 2.7539 with a correlation 
coefficient of 0.9833.  
 
2.2.3 BCA protein assay for protein quantification   
Purified TcISG was quantified using the bicinchoninic acid (BCA) assay kit obtained from Pierce 
in Rockford, USA. The BCA assay is a biuret reaction based on the reduction of Cu+2 to Cu+ 
cuprous cation to produce a purple colored product in the presence of protein under alkaline 
conditions. The amount of Cu+ cuprous ions produced is directly proportional to the amount of 
protein present (Smith et al, 1985). The interaction of bicinchoninic acid from the BCA working 
reagent with peptide bonds and amino acids tyrosine, tryptophan and cysteine, produces the 
purple reaction product before quantification. Interference can be caused by compounds 
possessing similar functional groups to tyrosine, tryptophan and cysteine (Wiechelman et al, 
1988). The bovine serum albumin (BSA) protein standards were serially diluted ranging from 
2000 to 25 µg/ml. The BCA working reagent was made by combining reagents A and B 
according to a ratio of 50:1 (v/v). The BSA protein standard solutions (25 µl) and proteins of 
































































the working reagent at 37°C for 30 min. Absorbancies were measured spectrophotometrically at 
562 nm (Figure 2.3) using the VersaMax ELISA Microplate Reader (Molecular Devices CA, 
USA). 
 
Figure 2.3: Calibration curve for the BCA protein assay kit for the quantification of TcISG. Bovine 
serum albumin solutions (25 to 2000 µg/ml) were combined with the BCA working reagent and incubated 
at 37°C for 30 min before measuring the absorbance at 562 nm using the Versmax microplate reader. 
The equation of the trendline is y= 0.0007x with a correlation coefficient of 0.9976. The assay was done in 
triplicate. 
 
2.2.4 Preparation of trypanosomes 
BALB/c mice were intraperitoneally infected with viable T. congolense (IL 3000) parasites and 
parasitemia was monitored by daily tail pricks. Blood from the tail pricks were diluted in 
phosphate buffered saline (PBS) (100 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 137 mM 
NaCl, pH 7.2) and viewed microscopically for motile parasites in between the erythrocytes. 
When infection status reached approximately 70%, the mice were sacrificed using cardiac 
puncture and the infected blood was collected in heparinised tubes. Trypanosomes were 
purified from the blood using a DE-52 Whatman® anion exchange cellulose resin according to 
Lanham and Godfrey (1970). Briefly, DE-52 resin was mixed with phosphate buffered saline 
(PBS) (100 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl and 137 mM NaCl, pH 8.0) and allowed 
to settle. The resin was subsequently washed with one column volume of PBS, allowed to settle 
and one column volume of phosphate saline glucose (PSG) (57 mM Na2HPO4, 3 mM NaH2PO4, 
42 mM NaCl, 50 mM glucose and 1 mM hypoxanthine). An equal volume of PSG and infected 































from the resin using PSG (15 ml fractions), centrifuged (3 500 rpm for 15 min, 4°C) and 
resuspended in PSG containing 20% (v/v) glycerol. Trypanosomes were microscopically 
viewed, counted using a haemocytometer and stored at -80°C. 
 
2.2.5 Isolation of Genomic DNA 
Genomic DNA was isolated from T. congolense (IL 3000) bloodstream forms as described by 
Medina-Acosta and Cross (1993). Briefly, the pelleted trypanosomes were resuspended in 
TELT buffer [50 mM Tris-HCl pH 8.0, 62.5 mM Na2EDTA, 2.5 mM LiCl (150 µl)] and incubated 
at room temperature (RT) for 5 min. Phenol-chloroform [1:1 (v/v)] (150 µl) was added, mixed 
using an end-over-end rotator for 5 min at RT and the emulsion was centrifuged (17000 x g for 
10 min, 4°C). The top aqueous phase was recovered and twice the volume of 100% (v/v) ice 
cold ethanol was added and mixed using end-over-end rotation for 5 min at RT. Genomic DNA 
was pelleted by centrifugation (17000 x g, 10 min, 4°C), washed with 70% (v/v) ethanol and 
dried at 37° for 30 min. Genomic DNA was resuspended in TE buffer [100 mM Tris-HCl pH 7.5, 
10 mM Na2EDTA (30 µl)] containing RNAse (1 µg/ml) and incubated at 37°C for 45 min. 
Genomic DNA (3 µl) was combined with loading dye (1 µl) and electrophoresed on a 1% (w/v) 
agarose gel containing ethidium bromide (0.5 µg/ml) in Tris-Acetate-EDTA (TAE) buffer (40 mM 
Tris-HCl, 100 mM acetic acid, 1 mM Na2EDTA, pH 8.0).  
  
2.2.6 Cloning of TcISG gene into pGEM®-T vector  
Trypanosoma congolense ISG nucleotide sequence (Accession CCD12004) was obtained from 
GenBank (http://www.ncbi.nlm.nih.gov) for primer design (Appendix C). The forward primer      
(5’ AAGGATCCATGGGGATGCAACGTATTGTT 3’) contained a BamH I restriction site whereas 
the reverse (5’ CAGGCACACTTTTAACTTTATCCCTCGAGCT 3’) contained a Xho I site as 
represented by the underline. The start and stop codon sequences are indicated in bold. Using 
genomic DNA as the template for PCR, the TcISG gene was amplified in a 20 µl PCR reaction 
comprising of 1 x High Fidelity Taq polymerase buffer, 0.4 mM dNTPs, 0.2 µM forward primer, 
0.2 µM reverse primer, 3.13 mM MgCl2 and 2 U High Fidelity Taq Polymerase. The PCR 
reaction was performed using the following conditions: initial denaturation at 95°C for 10 min,  
35 cycles of denaturation at 95°C for 30 sec, annealing at 56°C for 30 sec and extension at 
72°C for 2 min. The final extension was carried out at 72°C for 7 min. The PCR product (5 µl) 
was combined with loading dye (2 µl) and analysed on a 1% (w/v) agarose gel containing 




TcISG was ligated into pGEM®-T cloning vector (Figure 2.4) using a vector to insert ratio of 3:1. 
The ligation mixture consisted of 1 x Ligation buffer, 50 ng pGEM®-T vector DNA, 13.202 ng/µl 
TcISG and T4 DNA Ligase (1 U) in a 10 µl reaction mix. The ligation mixture was mixed and 
incubated at 37°C for 1 h followed by incubation at RT for 16 h. The ligation mix was thereafter 
transformed into competent E. coli JM109 cells using the TransformAid™ Bacterial 
Transformation kit according to the manufacturer’s instructions. Briefly, E. coli JM109 cells were 
3 way streaked onto 2 x YT agar plates (1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) 
NaCl, 1.5% (w/v) bacteriological agar, pH 7.0) and allowed to grow at 37°C for 16 h. The freshly 
streaked E. coli JM109  were excised from the agar (4x4mm) and inoculated into pre-warmed 
C- medium (750 µl) and incubated at 37°C for 2 h with 220 rpm agitation. The cells were 
centrifuged (17000 x g, 1 min, RT), resuspended in T-solution (300 µl) and incubated on ice for 
5 min. The cells were centrifuged (17000 x g, 1 min, RT) and the supernatant discarded. 
Pelleted cells were subsequently resuspended in T-solution (120 µl) and incubated on ice for    
5 min. Competent E. coli JM109 cells were mixed with the ligation mixture (2.5 µl) and incubated 
on ice for 5 min. The cell mixture was immediately plated onto 2 x YT agar plates containing  
100 µg/ml ampicillin, 20 mg/ml X-gal and 100 mM IPTG before incubation at 37°C for 16 h. Blue 




-T vector map demonstrating the multiple cloning sites and antibiotic 
resistance. The vector has an origin of replication (ori), ampicillin resistance (Amp
r
), multiple cloning site 
with T7 and SP6 promoters and a lacZ gene (Promega manual). 
 
White colonies assumed to contain the recombinant vector were selected and grown in 2 x YT 




agitation. Vector DNA was isolated using the GeneJet™ Plasmid Miniprep kit as per the 
manufacturer’s instructions. Briefly, the cells were pelleted by centrifugation (6800 x g, 2 min, 
RT) and resuspended in resuspension solution (250 µl) containing RNAse A followed by the 
addition of lysis solution (250 µl). The resulting solution was mixed by inversion (6 times) and 
neutralisation solution (350 µl) was added and immediately mixed by inversion (6 times). The 
resuspension was centrifuged (17000 x g, 5 min, RT) and the supernatant transferred to the 
GeneJET™ spin column and centrifuged (17000 x g, 1 min, RT). The flow through was 
discarded and wash solution containing ethanol was subsequently added to the column followed 
by centrifugation (17000 x g, 1 min, RT). The wash was repeated and the flow through was 
discarded. The column was subjected to further centrifugation (17000 x g, 1 min, RT) to remove 
residual wash solution. The spin column was transferred to a sterile 1.5 ml microcentrifuge tube 
and elution buffer (50 µl) added directly onto the matrix and incubated for 2 min at RT. The DNA 
was eluted by centrifugation (17000 x g, 2 min, RT). The elution step was repeated to increase 
the overall yield. Recombinant pGEM®-T vector was visualised on a 1% (w/v) agarose gel 
containing ethidium bromide (0.5 µg/ml). Colony PCR was employed using isolated pGEM®-T 
vector DNA as template DNA in a 20 µl reaction. Amplification was conducted as described 
previously in Section 2.2.6 using gene and vector primers (T7 forward and SP6 reverse). The 
colony PCR products (5 µl) were combined with loading dye (2 µl) and analysed on a 1% (w/v) 
agarose gel containing ethidium bromide (0.5 µg/ml). Positive clones were sequenced at the 
Central Analytical Facility, Stellenbosch University.  
 
2.2.7 Sub-cloning of TcISG into pET-32a expression vector 
In a 50 µl reaction mixture, recombinant pGEM®-T vector was first digested with Xho I in its 
unique buffer at 37°C for 4 h followed by heat inactivation of the enzyme at 80°C for 20 min. 
The mixture was then cleaned and concentrated using the Zymo Research Clean & 
Concentrator™ kit according to the manufacturer’s instructions. Briefly, twice the volume of DNA 
Binding buffer was added to the DNA mixture, briefly vortexed and transferred to a Zymo-Spin™ 
Column in a collection tube for centrifugation (16 000 x g, 30 s, RT). The flow-through was 
discarded. DNA wash buffer (200 µl) was added to the column and centrifuged (16 000 x g,     
30 s, RT). The wash was repeated. DNA elution buffer (30 µl) was added directly onto the 
column matrix and incubated at RT for 1 min. The column was transferred to a sterile 1.5 ml 
microcentrifuge tube and centrifuged (16 000 x g, 30 s, RT). The cleaned and concentrated 




inactivation of the enzyme at 80°C for 20 min. The restriction digest was analysed on a 1% (w/v) 
agarose gel containing ethidium bromide (0.5 µg/ ml) in TAE buffer and consequently 
electrophoresed on a 1% (w/v) agarose gel in TAE buffer in which both the gel and buffer 
contained 10 µg/ ml crystal violet before excision of TcISG DNA. The gel was visualised on a 
light box and the TcISG DNA purified using the peqGOLD Gel Extraction kit as per the 
manufacturer’s instructions. Briefly, TcISG DNA was excised from the agarose gel, added to an 
equal volume of Binding buffer and incubated at 60°C until the gel dissolved. TcISG DNA 
solution (750 µl) was added onto a DNA spin column and centrifuged (10 000 x g, 1 min, RT). 
The flow through was discarded and binding buffer (300 µl) and wash buffer containing ethanol 
(750 µl) was added to the spin column, incubated at RT for 2 min and centrifuged (10 000 x g,   
1 min, RT). The flow through was discarded and the empty spin column centrifuged (10 000 x g, 
1 min, RT) to remove residual ethanol. TcISG DNA was eluted by placing the spin column in a 
sterile 1.5 ml microcentrifuge tube and elution buffer (30 µl) was added onto the matrix and 
centrifuged (5000 x g, 1 min, RT). Purified TcISG DNA was analysed on a 1% (v/v) agarose gel 
containing ethidium bromide (0.5 µg/ ml) in TAE buffer.  
A glycerol stock of E. coli BL21 (DE3) cells containing the pET-32a expression vector was 
streaked onto 2 x YT agar plates containing 100 µg/ ml ampicillin and incubated at 37°C for     
16 h. A single colony was cultured in 2 x YT (5 ml) broth containing ampicillin (100 µg/ml) at 
37°C for 16 h. The expression vector DNA was isolated using the GeneJet™ Plasmid Miniprep 
kit as per the manufacturer’s instructions (Section 2.2.6). The vector was subjected to a 
restriction digestion (65 µl) with Xho I in its unique buffer for 4 h at 37°C following heat 
inactivation of the enzyme at 80°C for 20 min. The mixture was cleaned and concentrated using 
the Zymo Research Clean & Concentrator™ kit according to the manufacturer’s instructions 
(Section 2.2.7). The cleaned and concentrated DNA (30 µl) was digested with BamH I in its 
unique buffer at 37°C for 4 h followed by heat inactivation of the enzyme at 80°C for 20 min and 
sequentially cleaned and concentrated using the Zymo Research Clean & Concentrator™. The 
restriction digest (3 µl) was analysed on a 1% (w/v) agarose gel containing ethidium bromide 
(0.5 µg/ ml) in TAE buffer. The vector was dephosphorylated using 1 U shrimp alkaline 
phosphatase at 37 °C for 1 h followed by heat inactivation of the enzyme at 65 °C for 15 min.  
TcISG was ligated into the pET-32a expression vector using a vector to insert ratio of 3:1 and    
T4 DNA Ligase (1 U) in a 10 µl reaction mix. The ligation mixture was incubated at 37°C for 1 h 
followed by an additional 16 h incubation at RT. The ligation mix was thereafter transformed into 




al, 2001). Briefly, E. coli BL21 (DE3) cells were streaked onto 2 x YT agar and incubated at 
37°C for 16 h. A single colony was inoculated into 2 x YT (5 ml) broth and cultured at 37°C for 
16 h with 200 rpm agitation. A 1:100 dilution of the overnight culture was prepared in 2 x YT 
broth (99 ml) and cultured until an optical density at 600 nm (OD600) of 0.3-0.4 was reached. The 
cell culture was transferred to ice cold sterile centrifuge tubes, incubated on ice for 10 min and 
centrifuged (4500 x g, 10 min at 4°C). The pellet was resuspended in ice cold sterile 0.1 M 
CaCl2 (40 ml) followed by centrifugation (4500 x g, 10 min at 4°C). The pellet was resuspended 
in CaCl2 (6 ml). Competent E. coli BL21 (DE3) cells were combined with the ligation mix (4 µl), 
incubated on ice for 30 min and heat shocked at 42°C for 90 s. Thereafter, the cells were 
combined with super optimal cataboliser medium [2% (w/v) tryptone, 0.5% (w/v) yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgSO4, 20 mM glucose (800 μl)] and incubated at 37°C for   
1 h with gentle agitation. The cells were plated onto pre-warmed 2 x YT agar plates containing 
100 µg/ ml ampicillin and incubated at 37°C for 16 h.  
Bacterial colonies were cultured in 2 x YT broth (5 ml) containing 100 µg/ ml ampicillin at 37°C 
for 16 h with 200 rpm agitation. The recombinant plasmid was isolated using the GeneJet™ 
Plasmid Miniprep kit as per the manufacturer’s instructions (Section 2.2.6). Positive clones were 
verified using colony PCR which entailed the use of both the gene specific primers and pET-32a 
vector primers (T7 forward and T7 reverse). Colony PCR was conducted as described 
previously except Taq polymerase was used instead of High Fidelity Taq polymerase. The PCR 
products (5 µl) were combined with loading dye (2 µl) and analysed on a 1% (w/v) agarose gel 
containing ethidium bromide (0.5 µg/ ml). Positive clones were sequenced at the Central 
Analytical Facility, Stellenbosch University. 
 
Figure 2.5: Map of the pET-32a expression vector showing the multiple cloning site. The vector 




2.2.8 Recombinant expression of TcISG  
Protein expression of TcISG-pET-32a clone was first optimised in 2 x YT broth. The TcISG-pET-
32a clone was streaked onto 2 x YT agar plates containing 100 µg/ ml ampicillin and grown at 
37°C for 16 h. A single colony was selected and grown in 2 x YT broth (5 ml) containing         
100 µg/ml ampicillin at 37°C for 16 h. The overnight culture was subsequently diluted [1:100] in 
2 x YT broth (99 ml) comprising of ampicillin (100 µg/ml) and cultured at 37°C with 200 rpm 
agitation until an OD600 of 0.5-0.6 was obtained. Protein expression was consequently induced 
using IPTG concentrations of 0.1 mM, 0.3 mM, 0.5 mM, 0.7 mM and 1 mM at 37°C for 4 h with 
200 rpm agitation. A final concentration of 100 µg/ ml ampicillin was added to the culture at the 
start of the induction period and 2 h post induction. Bacterial cells were centrifuged (5000 x g, 
10 min, 4°C) and the pellet was resuspended in PBS (140 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.2) containing 1% (v/v) Triton-x-100 and 1 mg/ml lysozyme. 
The cell suspension was incubated at 37°C for 1 h and frozen at -20°C for 16 h. The cells were 
thawed on ice and sonicated on ice (4 x 30 s) each at 10 s intervals and centrifuged (10 000 x g, 
20 min, 4°C). The supernatant and pellet were subjected to SDS-PAGE analysis (Section 
2.2.10).  
 
2.2.9 Protein solubilisation, refolding and purification 
Solubilisation was conducted as described by Schlager and colleagues (2012). The cells were 
thawed on ice and sonicated on ice (4 x 30 s) each at 10 s intervals and centrifuged (10 000 x g, 
20 min at 4°C). The bacterial pellet was resuspended in lysis buffer (8 mM Na2HPO4, 286 mM 
NaCl, 1.4 mM KH2PO4, 2.6 mM KCl, 1% (w/v) SDS, pH 7.4) containing 1 mM DTT. The 
suspension was sonicated on ice (2 x 2 min), incubated on ice for 30 min and centrifuged        
(10 000 x g, 20 min, 4°C). The supernatant containing solubilised TcISG was subsequently used 
for purification.  
Purification was performed by placing His-select® nickel affinity resin (1 ml) in a 10 ml 
chromatography column. The column was washed with 2 column volumes of dH2O and 
equilibrated with 5 column volumes of wash buffer (8 mM Na2HPO4, 286 mM NaCl, 1.4 mM 
KH2PO4, 2.6 mM KCl, 0.1% (w/v) sarkosyl, pH 7.4). Solubilised TcISG (10 ml) was mixed and 
incubated with the nickel resin at 4°C for 3 h using end-over-end rotation. Thereafter, the 
unbound proteins were collected and the column washed with 50 ml of wash buffer until an 
absorbance value of zero was obtained at 280 nm. Bound proteins were eluted using 10 ml 




sarkosyl, 50 mM imidazole, pH 7.4) and 1 ml fractions were collected. The column was 
subsequently washed with 2 column volumes of dH2O, 5 column volumes of 6 M guanidine 
hydrochloride, 2 column volumes of dH2O, 2 column volumes of 30% (v/v) ethanol and stored in 
2 ml 30% (v/v) ethanol at 4°C. Solubilised TcISG, unbound proteins and eluted fractions were 
analysed on a 10% reducing SDS-PAGE gel and visualised using Coomassie Blue staining 
(Section 2.2.10).  
 
2.2.10 SDS-PAGE 
Protein analysis was conducted using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) according to Laemmli (1970). Briefly, a discontinuous buffer 
system consisting of running gel buffer (1.5 M Tris-HCl, pH 8.8) and stacking gel buffer (500 mM 
Tris-HCl, pH 6.8) was used. Protein samples were prepared using an equal volume of reducing 
treatment buffer (125 mM Tris-HCl, pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-
mercaptoethanol) and boiled at 100°C for 2 min. Electrophoresis was conducted using the 
BioRad Mini protein III electrophoresis apparatus (BioRad, CA, USA) at 20 mA per gel in tank 
buffer (250 mM Tris-HCl buffer, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3). The SDS-PAGE gels 
were stained in Coomassie Blue staining solution (0.125% (w/v) Coomassie Blue R-250, 50% 
(v/v) methanol, 10% (v/v) acetic acid) for 16 h. The gels were then incubated in destaining 
solution (50% (v/v) methanol, 10% acetic acid) on an orbital shaker and stored in distilled water. 
The gels were photographed using the Sys Gene® imaging system (Syngene®, USA).  
 
2.2.11 Western Blotting 
Proteins were first electrophoresed on a 10% reducing SDS-PAGE gel and transferred onto a 
nitrocellulose membrane (Towbin et al, 1979) using the Mini Trans-Blot® Cell apparatus (Biorad, 
CA, USA). The nitrocellulose was then stained using Ponceau S solution (0.1% (w/v) Ponceau 
S, 15% (v/v) acetic acid) to detect the transferred proteins and washed with distilled water 
containing a drop of 0.5 M NaOH solution. All remaining steps were performed on an orbital 
shaker. The nitrocellulose membrane was thereafter incubated in Tris buffered saline (TBS)   
(20 mM Tris-HCl buffer, 200 mM NaCl, pH 7.4) containing 5% (w/v) low fat milk powder at RT 
for 1 h. The membrane was washed with TBS (3 x 5 min) and incubated with mouse anti-6xHis 
antibody conjugated to HRPO [1:8 000 diluted in 0.5% (w/v) BSA-TBS] at 4°C for 4 h. The 




naphthol, 0.1 % (v/v), methanol, 0.0015% (v/v) H2O2 in TBS) at RT in the dark and 
photographed using the Sys Gene® imaging system (Syngene®, USA).  
 
2.2.12 Dialysis  
TcISG protein from fractions 4 to 10 were pooled and dialysed against buffer (8 mM Na2HPO4, 
286 mM NaCl, 1.4 mM KH2PO4, 2.6 mM KCl, 0.1% (w/v) sarkosyl, pH 7.4) containing 5% (v/v) 
glycerol to prevent protein instability. The volume of dialysis buffer used was 5x the TcISG 
solution volume. Dialysis was carried out at 4°C for 3 h. The buffer was replaced and dialysed 
for a further 3 h at 4°C and subsequently replaced and left to dialyse at 4° for 16 h. The TcISG 
solution was then concentrated using an Amicon® Ultra-15 Centrifugal Filter device (Mr cut-off of 
10 kDa) as per the manufacturer’s instructions. Briefly, the protein solution was added to the 
filter and centrifuged (6 500 x g, 10 min, 4°C). TcISG was collected from the filter and stored at 
4° until required. 
 
2.3 Results 
2.3.1 Cloning of TcISG into pGEM®-T cloning vector 
Genomic DNA was isolated from T. congolense (IL 3000) bloodstream forms using phenol-
chloroform extraction and visualised on a 1% (w/v) agarose gel (Figure 2.6, panel A). Genomic 
DNA was used as a template in the amplification of the TcISG gene using PCR. Amplification 
was achieved using the designed primers and High Fidelity Taq polymerase with proofreading 
ability. Amplification of TcISG gene resulted in a single amplicon with an anticipated size of 




                                                 
 
Figure 2.6: Isolation of T. congolense (IL 3000) genomic DNA and amplification of TcISG gene 
using PCR. (A) Isolated genomic DNA and (B) the PCR product were electrophoresed on 1% (w/v) 
agarose gel containing 0.5 µg/ml ethidium bromide. 
 
 
The PCR product was subsequently ligated into pGEM®-T cloning vector using TA cloning and 
transformed into competent E. coli JM109 cells. Recombinant colonies were identified using 
blue/white screening followed by isolation of TcISG-pGEM®-T recombinant vector which served 
as template DNA for colony PCR (Figure 2.7). Colony PCR was used to screen for the presence 
of the TcISG gene within the recombinant cloning vector. Using gene specific primers, 
amplification of the vector DNA revealed the presence of a 1260 bp TcISG gene while the use 
of T7 and SP6 promotor vector primers revealed the presence of a 1500 bp PCR product for 
colonies 1, 3 and 5. These colonies therefore contained the TcISG-pGEM®-T recombinant 
vector and its DNA was isolated and sequenced using gene specific primers. The sequencing 
results of colony 5 (Appendix D) demonstrated 99% nucleotide sequence identity to the 































Figure 2.7: Colony PCR for screening of recombinant TcISG-pGEM
®
-T vector after transformation. 
The TcISG gene was ligated into pGEM
®
-T vector and transformed into competent E. coli JM109 cells. 
DNA was extracted from selected positive white colonies and used for colony PCR. The PCR products 
were amplified using the gene forward and reverse primers and the T7 promoter and SP6 vector primers. 
The DNA was analysed on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide. The arrows 
indicate positive clones.  
 
 
2.3.2 Sub-cloning of TcISG into pET-32a expression vector 
Using colony 5, a large scale restriction digest was conducted on the recombinant vector to 
isolate the TcISG gene from the pGEM®-T cloning vector. The first restriction digest using Xho I 
resulted in a single linearilised vector at a size of 5000 bp (Figure 2.8 panel A, lane 1). Following 
the second digest using BamH I, two bands consistent with the expected vector and TcISG 
gene sizes were observed with sizes of 3000 bp and 1260 bp respectively (Figure 2.8 panel A, 
lane 2). The TcISG gene was analysed on a 1% (w/v) agarose gel containing crystal violet, 
excised from the agarose gel, purified using the peqGOLD Gel Extraction Kit and subsequently 
analysed on a 1% (w/v) agarose gel containing ethidium bromide (Figure 2.8 panel B). Double 
restriction digestion was performed on pET-32a expression vector in preparation for sub-
cloning. The digest was performed using BamH I and Xho I to produce compatible sticky ends 
for ligation of the TcISG gene. Following restriction digestion, the pET-32a vector was 
dephosphorylated using alkaline phosphatase to prevent vector re-ligation following restriction 
digestion. 
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Figure 2.8: Analysis of restriction digestion and purification of the TcISG-pGEM-T
®
 clone. (A) Lane 
1, the TcISG- pGEM
®
-T vector DNA was isolated from colony 5 and digested using Xho I for 4 h at 37°C. 
Lane 2, the DNA was cleaned and concentrated and digested with BamH I for 4 h at 37°C. Following 
each restriction digest, the enzymes were inactivated for 20 min at 80°C. The DNA was electrophoresed 
on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide. (B) Using crystal violet, TcISG was 




The TcISG gene was ligated into the pET-32a expression vector and transformed into E. coli 
BL21 (DE3) cells. The DNA from TcISG-pET-32a recombinant colonies was isolated and used 
as template DNA for colony PCR. Using gene specific primers, colonies 2 and 3 (Figure 2.9) 
contained the 1260 bp TcISG gene and amplification using the T7 forward and T7 reverse 
vector primers revealed the presence of a 1900 bp band (Figure 2.9). This size of 1900 bp was 
expected due to the amplification of vector DNA adjacent to the TcISG insert on either ends. 
The DNA from colonies 2 and 3 was isolated and sequenced using T7 forward and T7 reverse 
vector primers. Highest sequence identity was obtained from colony 3 showing 99% with the 
TcIL3000.0.29290 nucleotide sequence (Appendix E) and 98.1% with the amino acid sequence 






























Figure 2.9: Analysis of colony PCR for screening of recombinant pET-32a vector containing the 
ligated TcISG gene after transformation. The TcISG gene was ligated into the pET-32a expression 
vector and transformed into competent E. coli BL21 (DE3) cells. DNA was extracted from selected 
positive white colonies and used for colony PCR. The PCR products were amplified using the forward and 
reverse gene primers and the T7 forward and T7 reverse vector primers. The DNA was analysed on a 1% 
(w/v) agarose gel containing 0.5 µg/ml ethidium bromide. The arrows indicate positive clones.  
 
2.3.3 Recombinant expression, solubilisation, refolding and purification 
2.3.3.1 Optimisation of recombinant TcISG expression 
A bacterial system was used to recombinantly express TcISG at 37°C using IPTG induction. 
Expression was monitored hourly before and after IPTG induction and analysed on a 10% 
reducing SDS-PAGE gel. Protein expression was optimised using a range of IPTG 
concentrations to obtain increased TcISG yields. TcISG was identified as a histidine-tagged 
fusion protein on an SDS-PAGE gel at a size of approximately 66 kDa during the induction 
period and was expressed in the pellet within inclusion bodies (Figure 2.10 panels A, C, E and 
G). The SDS-PAGE results were further authenticated by western blots which detected the 
hourly expression of TcISG using a mouse anti-6xHis-HRPO conjugate antibody (Figure 2.10 
panels B, D, F and H). A concentration of 1 mM IPTG was selected for large scale TcISG 
expression since TcISG could be detected well during 4 hours of protein expression in 
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Figure 2.10: Recombinant expression of TcISG in a pET-32a expression vector. TcISG was 
expressed in 2 x YT medium at 37°C for 4 h. Protein expression and solubility was monitored hourly 
following induction with 0.1, 0.3, 0.5, 0.7 and 1 mM IPTG (A, C, E and G) on a 10% reducing SDS-PAGE 
gel and visualised with Coomassie blue staining. Western blot analysis (B, D, F and H) was conducted 
with mouse anti-6xHis-HRPO conjugate antibody [1:8000] and incubated with 4-chloro-1-naphthol-H2O2 
chromogen-substrate solution. M: PageRuler™ prestained protein marker, NI: non-induced, SN: 
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2.3.3.2 Solubilisation, refolding and purification of TcISG 
The pellet containing the TcISG fusion protein was solubilised using SDS and sarkosyl followed 
by refolding and purification on a nickel affinity resin. Protein purification was analysed on a 
10% reducing SDS-PAGE gel and visualised with Coomassie blue staining. In comparison to 
the solubilised pellet which was incubated with the nickel resin, the unbound fraction contained 
increased amounts of TcISG. Following washing of the resin, bacterial host proteins were 
present in fractions 1, 2 and 3 with little to no bacterial proteins present from fractions 4 to 10 
(Figure 2.11 panel A). A western blot probed with mouse anti-6xHis-HRPO conjugate antibody 
detected purified His-tagged 66 kDa TcISG protein in fractions 1-10 (Figure 2.11 panel B). A 
single protein band of approximately 55 kDa was detected in the solubilised pellet, unbound 
fraction and fractions 1 and 2. Fraction 2 contained E. coli host proteins which were detected by 
the mouse anti-6xHis-HRPO conjugate antibody. No bands were detected in the non-induced 
bacterial lysate. Purified TcISG was used for antibody production as described in Chapter 3. 
 
 
Figure 2.11: Purification of TcISG using nickel affinity chromatography. (A) TcISG was solubilised, 
purified and analysed by 10% reducing SDS-PAGE stained with Coomassie blue and by western blot (B), 
probed with mouse anti-6xHis-HRPO conjugate antibody [1:8000] and incubated with 4-chloro-1-
naphthol-H2O2 chromogen-substrate solution. M: PageRuler
™
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Trypanosoma congolense ISG (TcIL3000.0.29290) was first identified by Fleming and co-
workers (2014) and only the extracellular domain was recombinantly expressed in the pET-15b 
vector using IPTG induction, purified using nickel affinity chromatography and tested as a 
diagnostic antigen in an ELISA. The recombinant ISG was able to distinguish between infected 
and non-infected cattle sera from experimentally infected cattle (Fleming et al, 2014). In the 
present study, the gene coding for the entire sequence of Trypanosoma congolense ISG 
(TcISG) (TcIL3000.0.29290) including all 4 domains (Figure 2.1) was amplified and cloned into 
a pGEM®-T cloning vector in order to produce a high copy number of TcISG-pGEM®-T vector 
replicates. Large scale protein expression was performed at 37°C for 4 hours using 1 mM IPTG 
for inducing TcISG expression in pET-32a expression vector in E. coli BL21 (DE3) cells. The 
use of lactose for protein expression presents a low-cost advantage to IPTG and can also 
function as a carbon source in addition to an inducer (Neubauer and Hofmann, 1994). However, 
lactose is more suited for large scale industrial produced recombinant proteins (Zhang et al, 
2000). Soluble TcISG was attained for antibody production in chickens. Heterologous protein 
expression is commonly performed in the pET system using IPTG induction (Donovan et al, 
1996) and has been used previously for ISG expression: Trypanosoma brucei gambiense VSG 
LiTat 1.3 was expressed as a 52 kDa histidine-tagged fusion protein (Tran et al, 2008), 
Trypanosoma brucei ISG (Lança et al, 2011), Tc38630 ISG (Fleming et al, 2014), Trypanosoma 
evansi ISG75 with a size of 55 kDa (Rudramurthy et al, 2015) and several ISG domains from   
T. brucei gambiense ISG65, ISG75 and ISG64 (Sullivan et al, 2013).  
TcISG encodes a 419 amino acid protein with a predicted molecular weight of 46 kDa according 
to Compute pI/Mw on the Expasy server (https://www.expasy.org) (Gasteiger et al, 2005). 
TcISG was expressed as a histidine-tagged fusion protein approximately 66 kDa in size within 
inclusion bodies using a pET-32a expression vector in E. coli BL21 (DE3) cells. This size was 
much larger than the predicted molecular weight of 46 kDa. This may be attributed to the 
presence of the thioredoxin tag (LaVallie et al, 2000) and 6xHis tag (Murphy and Doyle, 2005; 
Correa and Oppezzo, 2015). Although, the tendency of ISG65 and ISG75 to migrate slower 
than expected on an SDS-PAGE gel resulting in larger sized proteins has been reported 
(Ziegelbauer et al, 1992; Jackson et al, 1993; Tran et al, 2008; Baiyegunhi, 2013). Ziegelbauer 
and colleagues suggested that this tendency is due to the presence of several negatively 
charged amino acids present in ISG proteins thus reducing the binding of ISGs to SDS. This 




predicted (Ziegelbauer et al, 1992). Attempts were made to sub-clone TcISG into the pET-28a 
and pGEX-4T-1 expression vectors to compare protein expression profiles however; 
recombinant colonies were only obtained by using the pET-32a vector.  
Protein expression performed at lower temperatures reduces protein aggregation and favours 
protein solubility (Schein, 1989; Sahdev et al, 2008) therefore protein expression was also 
carried out at 30°C, 25°C and 20°C in an attempt to obtain soluble TcISG, however, the protein 
was still expressed within inclusion bodies. Inclusion bodies are formed as a result of protein 
misfolding through the interaction of hydrophobic residues during overexpression of the protein 
leading to protein aggregation (Wetzel, 1994; Flink, 1998). TcISG is characterised as a 
transmembrane protein hence it possesses several hydrophobic residues (Ziegelbauer et al, 
1995) that could contribute to the formation of protein aggregates (Mitraki et al, 1991). 
Recombinant protein expression in inclusion bodies is undesirable as it requires solubilisation 
and correct refolding to produce functional proteins. Furthermore, solubilisation techniques need 
to be adapted for each protein (Zhu et al, 2013). Although undesirable, protein expression in 
inclusion bodies can be advantageous as they are not susceptible to proteolytic degradation 
and are easily isolated by centrifugation as was found in this study (Idicula-Thomas and Balaji, 
2007).  
TcISG was solubilised using anionic SDS and sarkosyl detergents according to Schlager and 
co-workers (2012). The technique is based on using SDS and sonication for solubilisation of 
inclusion bodies. TcISG was subsequently purified on a nickel affinity resin using 50 mM 
imidazole in the presence of sarkosyl. Sarkosyl is a mild detergent used during protein 
solubilisation and allows refolding of proteins that are present in high concentrations (Burgess, 
1996; Kudou et al, 2011). The method of protein solubilisation and refolding is similar to cloud-
point extraction, a technique typically used to purify and concentrate membrane proteins (Arnold 
and Linke, 2007).  
The presence of significant amounts of TcISG in the unbound fraction during nickel affinity 
purification is attributed to the reduced binding efficiency of TcISG His-tagged fusion protein to 
the nickel resin caused by SDS and sarkosyl detergents in addition to the reducing agent, DTT, 
employed during the solubilisation process. Repeated use of the affinity resin in the presence of 
detergents and reducing agents is known to remove nickel ions from the affinity matrix over time 
(Palmer and Wingfield, 2004). The affinity matrix was frequently recharged with nickel ions in an 




be purified using Co2+–carboxylmethyl-aspartate affinity resin (Bornhorst and Falke, 2000) 
however, purification of TcISG was unsuccessful using the His-Select® Cobalt affinity resin 
(Sigma). Nevertheless, purification using SDS and sarkosyl detergents proved successful. 
Affinity tags are typically used to avert the production of protein aggregation and improve protein 
purification (Sørensen and Mortensen, 2005) however, overexpression of the histidine tag leads 
to the production of inclusion bodies due to the formation of a free loop area (Zhu et al, 2013). 
The use of the histidine affinity tag allows for successful solubilisation and purification of 
insoluble proteins under denaturing conditions as displayed in this study and interference during 
downstream applications is less probable due to its small size (Bornhorst and Falke, 2000, 
Schlager et al, 2012). Studies have demonstrated increased protein solubility by the use of 
maltose binding protein, N-utilisation substance protein A and thioredoxin tag while the use of 
glutathione-S-transferase resulted in reduced protein solubility. Such tags are much larger in 
size and may not always produce soluble proteins once it is removed thus smaller affinity tags 
such as the one used in this study are preferred (Rosano and Ceccarelli, 2014).  
Several bacterial host proteins or degradation products were present in the first three fractions 
obtained from imidazole elution from the nickel affinity resin similar to the results obtained by 
Schlager and colleagues (Schlager et al, 2012). Rogé and co-workers have reported the 
presence of degradation products following expression of T. brucei gambiense ISG75 using the 
Pichia pastoris yeast expression system followed by purification using anti-E tag affinity matrix. 
Attempts to eliminate the degradation products were unsuccessful (Rogé et al, 2013). 
Furthermore, degradation products were also evident subsequent to expression of recombinant 
VSG LiTat 1.3 in Pichia pastoris and purification using a nickel charged nitrilotriacetic acid 
agarose resin identical to the resin used in this study (Rogé et al, 2014a). In a separate study 
conducted by Tran and co-workers, the extracellular domain of T. brucei gambiense ISG75 was 
recombinantly expressed using the pET system (Tran et al, 2000). Highly pure ISG75 was 
difficult to obtain using the nickel affinity matrix in combination with ion exchange 
chromatography, hydrophobic interaction and molecular exclusion chromatography (MEC). A 
streptavidin-tag and nickel affinity chromatography was then used to enhance purification (Tran 
et al, 2008). Despite the fact that degradation products were detected in this study, it was only 
found in three fractions therefore it was possible to obtain pure protein from fractions 4-10 and 
the use of more than one purification technique was not required in comparison to the above 




S200 matrix  in an attempt to separate the 66 kDa purified TcISG from the 55 kDa lower 
molecular weight band however, separation was unsuccessful.  
Due to the presence of the unidentified 55 kDa protein in fractions 1-3, only fractions 4-10 were 
pooled and dialysed against imidazole deficient buffer containing 5% (v/v) glycerol. This was 
done to prevent protein precipitation during the concentration steps and promote long term 
storage of recombinantly expressed proteins (Sawanoa et al, 1992; Kim et al, 2006; Vagenende 
et al, 2009). 
The expression of TcISG could be improved by using eukaryotic expression systems such as 
yeast. Pichia pastoris yeast vectors were not considered for this study since the intellectual 
property restrictions placed on the vectors would conflict with the possibility of developing TcISG 
for diagnostics therefore E. coli BL21 (DE3) cells were used instead. Yeast expression systems 
such as Pichia pastoris (Cregg et al, 2000; Zhou et al, 2006), Saccharomyces cerevisiae 
(Hitzeman et al, 1981) and Schizosaccharomyces pombe (Giga-Hama and Kumagai, 1999; 
Kumar and Singh, 2004) are suitable for heterologous expression since it shares several 
features with higher eukaryotes. The advantages of yeast expression systems include: 
increased growth rate and simple and inexpensive growth media comparable to the E. coli 
expression system. However, the yeast system produces correctly folded soluble proteins that 
undergo post translational modifications and are secreted into the culture media in comparison 
to bacterial host systems (Daly and Hearn, 2005). The Leishmania tarentolae expression 
system has recently provided great promise in improving the expression of trypanosomal 
proteins and potentially replacing native antigens in rapid serodiagnostic testing. The system is 
based on electroporation of the LEXSYS vector hyg2 containing the desired gene into LEXSYS 
host strain p10. Recombinant proteins can be processed as close to the native type by 
undergoing post translational modifications in an organism related to the Trypanosoma species. 
Soluble recombinant proteins that are similar to the native proteins are produced using a simple 
culture media without the use of animals and expensive equipment thereby reducing the cost 
factor and promoting safer working conditions (Rooney et al, 2015). 
In this study, the TcISG transmembrane protein containing all four domains was cloned and 
recombinantly expressed as a histidine-tagged fusion protein in E. coli BL21 (DE3) cells. 
Soluble TcISG was obtained using SDS and sarkosyl detergents and was refolded and purified 
using a nickel chelate affinity resin. Purified TcISG was used for antibody production and 




served as an antigen for testing whether anti-TcISG N-terminal peptide antibodies recognise the 
whole protein in an ELISA and western blot. Furthermore, TcISG was tested as a diagnostic 
antigen to discriminate between T. congolense infected and non-infected cattle sera. These 






PRODUCTION AND AFFINITY PURIFICATION OF ANTI-TcISG CHICKEN ANTIBODIES, 
IMMUNODETECTION OF NATIVE ISG AND INDIRECT ANTIBODY DETECTION ELISA 
 
3.1 Introduction 
Animal African trypanosomiasis (AAT) is considered a neglected disease that affects various 
animals resulting in thousands of deaths each year and leads to financial loss hence accurate 
diagnosis and effective treatment are critical (Eyford et al, 2011). Direct and indirect diagnostic 
techniques are used for the detection of motile parasites in infected blood samples. Such 
techniques cannot differentiate between parasite species and inconsistent results can be 
obtained due to the lack of sensitivity (Chappuis et al, 2005). Serodiagnostic testing such as 
indirect fluorescent antibody test (IFAT), enzyme-linked immunosorbent assay (ELISA) and 
agglutination tests such as card agglutination test (CATT) offer detection of trypanosome-
induced antibodies present in infected sera in a cost effective manner. These techniques can 
also screen numerous serums using an uncomplicated procedure (Voller et al, 1975; Luckins, 
1977; Songa and Hamers, 1988; Nantulya and Lindwvist, 1989). A major drawback to some 
ELISA based tests is the requirement for trypanosome lysate obtained through sub-inoculation 
of laboratory animals which can result in non-reproducible results and especially for human-
infective forms, poses a risk to laboratory personnel (Greiner et al, 1997; Hopkins et al, 1998; 
Rebeski et al, 2000; Desquesnes et al, 2009).   
Recently, recombinant trypanosomal proteins have been used in rapid serodiagnostic testing 
which obviates the use of animals and infectious parasites thereby reducing health risks and 
expenses. Recombinantly produced invariant surface glycoprotein (ISG) have presented great 
promise in replacing native ISGs from T. congolense, T. evansi and T. brucei gambiense in 
diagnostic tests (Tran et al, 2008; Tran et al, 2009; Fleming et al, 2014; Rudramurthy et al, 
2015). Other recombinant trypanosomal antigens investigated for serodiagnostic testing include: 
variable surface glycoprotein (VSG) RoTat 1.2 from T. brucei gambiense (Lejon et al, 2005; 
Rogé et al, 2013; Rogé et al, 2014b; Sengupta et al, 2014),  VSG LiTat 1.5 from T. brucei 
gambiense (Van Nieuwenhove et al, 2013) and GM6, flagellar associated-protein from T. vivax 





Lateral flow tests have become increasingly popular and offer rapid testing in the field without 
requiring expensive equipment or trained personnel. These tests are also easily designed and 
manufactured to be robust for field use, can often be stored for 12-24 months without cooling 
conditions and can accommodate small sample volumes with the option of scaling up to cater 
for larger volumes. Results can be determined visually or through electronic systems (O’Farrell, 
2009). Lateral flow tests, HAT Sero-strip and HAT Sero-K-set use native VSG LiTat 1.3 and 
LiTat 1.5 native proteins from T. brucei gambiense (Büscher et al, 1991; 2014). The Surra Sero 
K-SeT lateral flow test uses a recombinant fragment of VSG RoTat 1.2 to detect anti-RoTat 1.2 
antibodies from T. evansi infected blood, serum and plasma (Birhanua et al, 2015). Sullivan and 
co-workers have also developed a T. brucei gambiense recombinant ISG65 based lateral flow 
device (Sullivan et al, 2013). Until recently, lateral flow tests for AAT did not exist, however, 
Fleming and colleagues have produced a prototype lateral flow test using recombinantly 
produced ISG from T. vivax as the test antigen (Fleming et al, 2016). Lateral flow systems are 
yet to be developed for the diagnosis of T. congolense infections.  
Egg yolk Immunoglobulin Y (IgY) technology is used to generate antibodies in chickens. 
Chicken antibodies are isolated from the egg yolks using precipitants such as polyethylene 
glycol (PEG) (Polson et al, 1980), dextran sulfate, ammonium sulfate, sodium sulfate, sodium 
citrate and caprylic acid (Meenatchisundaram and Michael, 2010). Isolation can also be 
achieved using chloroform and affinity chromatography. Polyethylene glycol precipitation is 
effective and yields increased amounts of highly pure antibodies (Meenatchisundaram and 
Michael, 2010). Generating polyclonal antibodies in chickens does not require bleeding of 
animals thus preventing stress on the animal; isolation is simple and rapid with various isolation 
techniques available and increased quantities of highly specific antibodies are obtained in 
comparison to generating immunoglobulin G (IgG) in rabbits (Pauly et al, 2011).  
Epitope mapping is a technique used to identify specific antibody binding sites or epitopes in a 
protein. The epitopes are exposed to the immune system and can take the form of continuous 
epitopes which are linear peptides capable of binding antibodies raised against the complete 
protein or discontinuous epitopes comprising of amino acids located further apart from each 
other but brought together through protein folding (Barlow et al, 1986). Epitope mapping is 
useful in investigating the structure of proteins, parts of an enzyme that are inhibited by 
antibodies as well as identifying specific regions on a protein capable of eliciting an immune 
response for use as diagnostic antigens or vaccine candidates. The peptide corresponding to 




chances of detecting the native protein using anti-peptide antibodies is increased if the peptide 
is accessible to the immune system, has a length of 15-20 amino acids, has structural features 
that resemble the native protein, is flexible and contains polar and charged amino acids 
residues. The presence of glycine and proline residues also increases the chance of detecting 
native proteins by imitating the conformation of the native structure (Trier et al, 2012). Anti-
peptide antibodies are capable of detecting the denatured protein in a western blot, while 
detection of the native protein can be done using flow cytometry, immunoprecipitation and 
immunohistochemistry as well as ELISA.  
In this study, antibodies were generated in chickens against recombinantly expressed TcISG 
and a TcISG-N-terminal peptide. The IgY was isolated using PEG precipitation and affinity 
resins prepared by immobilising TcISG and TcISG N-terminal peptide on the affinity matrix. 
Chicken antibodies were assessed in ELISAs followed by the detection of native TcISG using 
western blots. The ability of recombinant TcISG to differentiate between non-infected and 
infected cattle sera was evaluated in an indirect ELISA and the detection of TcISG using anti-  
T. b. brucei ISG and anti-T. b. gambiense VSG antibodies was also investigated. 
 
3.2 Materials and Methods 
3.2.1 Materials 
Preparation of chicken IgY antibodies: Freund’s complete and incomplete adjuvants as well 
as bovine serum albumin (BSA) were obtained from Sigma (St. Louis, MO. USA). Polyethylene 
glycol (PEG) Mr 6 000 was acquired from Merck (Darmstadt, Germany) and the BIOTEK
® 
ELx50™ Microplate washer was purchased from BioTek Instruments Inc. (USA). Nunc-Immuno™ 
Maxisorp 96-well plates were purchased from Nunc Intermed (Roskilde, Denmark) while the 
2,2′-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) was purchased from Roche 
(Mannheim, Germany). Whatman No. 1 filter paper was purchased from Whatman International 
Ltd (UK), the Aminolink® and SulfoLink® matrix were obtained from Pierce (Rockford, IL, USA) 
and Sephadex G-10, G-25 and sodium hydroborocyanide were obtained from Sigma (St. Louis, 





Antibodies: mouse anti-6xHis antibody HRPO conjugate antibody was obtained from Roche 
(Mannheim, Germany). Rabbit anti-chicken IgY conjugated to HRPO and rabbit anti-bovine IgG 
(A8917) conjugate antibody were purchased from Sigma (Munich, Germany). Chicken anti-      
T. brucei ISG65 IgY, chicken anti-T. brucei ISG75 IgY, chicken anti-T. b. gambiense RoTat 1.2 
IgY, week 0 and week 4, chicken anti-T. b. gambiense LiTat 1.3 IgY week 0 and week 4, and 
chicken anti-T. b. gambiense LiTat 1.5 IgY week 0 and week 7 were obtained through in-house 
preparations (Mnkandla, 2013 and Baiyegunhi, 2013). 
T. congolense-infected sera: Infected and non-infected cattle sera were obtained from ClinVet 
International (PTY) LTD, Bloemfontein, South Africa. 
Western blot: The Mini Trans-Blot® Cell apparatus was purchased from Biorad (CA, USA). 
BioTrace™, nitrocellulose membrane was obtained from PALL Corp (Ann Arbor, USA) while 4-
choloro-1-naphthol and Kodak BioMax light film were acquired from Sigma (St. Louis, MO, 
USA). PageRuler™ prestained protein ladder was purchased from Pierce (Rockford, IL, USA). 
  
3.2.2 Selection of TcISG N-terminal peptide  
The complete protein sequence of TcISG was analysed using the Predict7 (Carmenes et al, 
1989) epitope prediction software which analyses the surface probability, antigenicity, 
hydrophilicity and flexibility of the protein sequence. The PEP6 software [developed by Leonard 
K, BSc (Hons) Computer Science, University of KwaZulu-Natal] takes into consideration the 
flexibility of the amino acid residues by predicting protein mobility (Karplus and Schulz, 1985), 
uses the hydrophilicity scale developed by Hopp and Woods (1981) while the surface 
accessibility plot is in accordance with Emini and co-workers (1985) and was thus used in 
addition to Predict7. A region corresponding to increased surface probability and hydrophilicity 
values was selected for antibody production. Since the peptide contained an internal lysine 
residue, a cysteine residue was added to the N-terminus of TcISG to facilitate conjugation to 








3.2.3 Immunisation of chickens with TcISG N-terminal peptide  
3.2.3.1 Coupling of TcISG N-terminal peptide to rabbit albumin using MBS 
Four milligrams of TcISG N-terminal peptide was dissolved in dimethyl sulfoxide (DMSO) (50 µl) 
and reducing buffer [100 mM Tris-HCl, 1 mM Na2EDTA, 0.02% (w/v) NaN3, pH 8.0 (500 µl)] 
followed by the addition of 10 mM DTT (500 µl). The mixture was incubated at 37°C for 1.5 h. 
The reduced peptide was separated from DTT using a Sephadex G-10 column (15 x 110 mm, 
0.7 ml/min) previously equilibrated with 60 ml MEC buffer (100 mM NaH2PO4, 0.02 % (w/v) 
NaN3, pH 7.0). Using MEC buffer, fractions (500 µl) were collected and tested for the presence 
of reduced peptide by combining each fraction (10 µl) with 10 µl Ellman’s reagent [(2 mg 5,5'-
Dithio-bis-(2-nitrobenzoic acid)] prepared in 500 µl Ellmans reagent buffer (100 mM Tris-HCl,     
1 mM Na2EDTA, 0.1% (w/v) SDS, pH 8.0). Reactions resulting in a yellow color indicated the 
presence of reduced peptide and were pooled (Kitagawa and Aikawa, 1976).  
Rabbit albumin (RA) (3.16 mg) was dissolved in PBS (140 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.2 (500 µl)] while MBS (0.58 mg) was dissolved in DMF 
(dimethylformamide) (200 µl) and PBS (300 µl). Both mixtures were combined in a 1: 40 molar 
ratio of MBS to rabbit albumin and gently mixed at 37 °C for 30 min. The rabbit albumin-MBS 
mixture was loaded onto a Sephadex G-25 column (15 x 130 mm) previously equilibrated with 
MEC buffer. Using MEC buffer, eluted fractions (1 ml) were collected and measured 
spectrophotometrically at 280 nm for the presence of the activated rabbit albumin carrier. 
Fractions with absorbance values above 0.3 were pooled and immediately combined with the 
reduced peptide followed by gentle stirring at RT for 2 h and incubated further at 4°C using end-
over-end rotation for 16 h. The solution was distributed into 4 equal aliquots and stored at -20°C 
until immunisation.  
 
3.2.4 Immunisation of chickens for antibody production  
Antibodies against the recombinant TcISG and TcISG N-terminal peptide conjugated to rabbit 
albumin were produced in chickens. Purified TcISG and TcISG N-terminal peptide were 
separately combined with Freund’s complete adjuvant (1:1) followed by trituration to form a 
stable emulsion. Two chickens were immunised intramuscularly on both sides of the breast 
bone with purified TcISG (100 µg/ml) and another two chickens were immunised with TcISG N-
terminal peptide conjugated to rabbit albumin (1.25 ml). Using Freund’s incomplete adjuvant, 







prior to immunisation and all eggs collected daily over a period of 16 weeks were stored at 4°C 
until required.  
 
3.2.5 Isolation of IgY antibodies from egg yolks 
The chicken immunoglobulins (IgY) were isolated from egg yolks using polyethylene glycol 
precipitation described by Goldring and Coetzer (2003). Briefly, egg yolks were separated from 
albumin under running water. The egg yolk volume was determined and twice the volume of IgY 
buffer (100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.6) and 3.5% (w/v) PEG 6000 was added and 
mixed using magnetic stirring. The mixture was centrifuged (4 420 x g, 30 min, 4°C) to remove 
the lipid fraction and the supernatant filtered through cotton wool until a clear filtrate was 
obtained. To the filtrate, 8.5% (w/v) PEG 6000 was added and mixed thoroughly followed by 
centrifugation (12 000 x g, 10 min, 4°C). The pellet was subsequently dissolved in IgY buffer 
equivalent to the original egg yolk volume and 12% (w/v) PEG 6000 was added and mixed. The 
mixture was centrifuged (12 000 x g, 10 min, 4°C). The resulting pellet was dissolved in final IgY 
buffer (100 mM NaH2PO4, 0.1% (w/v) NaN3, pH 7.6) equivalent to one sixth of the original egg 
yolk volume and stored at 4°C. Using spectrophotometry, the concentration of the IgY was 
determined at 280 nm using an extinction coefficient of                        =  1.25 (Goldring 
and Coetzer, 2003). 
 
3.2.6 Enzyme-linked immunosorbent assay  
Production of anti-TcISG IgY and anti-TcISG N-terminal peptide IgY antibodies were monitored 
and evaluated using the ELISA. The 96 well Nunc-Immuno™ Maxisorp ELISA plates were 
coated with recombinant TcISG (1 µg/ml, 100 µl per well) or TcISG N-terminal peptide (5 µg/ml) 
prepared in PBS and incubated at 4°C for 16 h. The solution was discarded and the wells 
blocked with 0.5% (w/v) BSA in PBS-0.1% (v/v) Tween-20 blocking buffer (200 µl per well) at 
37°C for 1 h. Wells were subsequently washed thrice with PBS containing 0.1% (v/v) Tween-20 
using the BIOTEK® ELx50™ Microplate washer. Wells were incubated with anti-TcISG or anti-
TcISG peptide IgY primary antibody prepared in blocking buffer (100 µg/ml, 100 µl per well) at 
37°C for 2 h. Wells were washed as described previously followed by incubation with rabbit anti-
chicken IgY-HRPO secondary antibody conjugate prepared in blocking buffer (1:15000, 100 µl 
per well) at 37°C for 1 h. Wells were washed thrice with PBS containing 0.1% (v/v) Tween-20 
and incubated with chromogen-substrate solution [0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in 




in the dark before absorbance analysis at 405 nm using the FLUOStar Optima microplate 
reader (BMG Labtech, Offenburg, Germany).   
 
3.2.7 Affinity purification of anti-TcISG IgY and anti-TcISG N-terminal peptide IgY  
3.2.7.1 Coupling of TcISG to Aminolink® affinity column 
AminoLink® coupling resin (2 ml) was added to a 10 ml chromatography column and allowed to 
settle. The storage solution was allowed to drain and the resin equilibrated with coupling buffer 
[150 mM Na3C6H5O7.2H2O, 50 mM Na2CO3, pH 10 (6 ml)]. Purified TcISG (8 mg/ ml) was 
diluted in coupling buffer (4 ml) and 100 µl of this dilution was kept to determine the coupling 
efficiency. The resin was mixed with TcISG at RT for 4 h using end-over-end rotation. The 
column was allowed to remain stationary at RT for 16 h. The unbound fraction was collected 
and a coupling efficiency of 50% was obtained therefore 4 mg/ml of TcISG coupled to the resin. 
The resin was washed with AminoLink® coupling buffer [100 mM NaH2PO4, 150 mM NaCl, pH 
7.2 (6 ml)] to obtain a neutral pH. In the fume hood, AminoLink® buffer [100 mM NaH2PO4,     
150 mM NaCl, pH 7.2 (2 ml)] and cyanoborohydride [5 M NaCNBH3 in 1 M NaOH (40 µl)] was 
gently mixed with the resin and incubated at 4°C for 16 h using end-over-end rotation. The resin 
was washed with quenching buffer [1 M Tris-HCl, pH 7.4 (4 ml)]. In the fume hood, 2 ml 
quenching buffer and cyanoborohydride [5 M NaCNBH3 in 1 M NaOH (40 µl)] were gently mixed 
with the resin and incubated at RT for 30 min using end-over-end rotation. The resin was 
washed with PBS until an absorbance of zero at 280 nm was obtained. The resin was washed 
with 6 ml of IgY buffer (100 mM NaH2PO4, 0.02% (w/v) NaN3, pH7.6) and stored in 2 ml of the 
IgY buffer at 4°C until required.  
 
3.2.7.2 Coupling of TcISG N-terminal peptide to Sulfolink® affinity column 
The TcISG N-terminal peptide (5 mg) was reduced as described in Section 3.2.3.1. The 
SulfoLink® coupling resin (1 ml) was placed into a 10 ml affinity column and washed with 6 ml 
coupling buffer (50 mM Tris-HCl, 5 mM EDTA, pH 8.5). The resin was mixed with the reduced 
peptide at RT for 15 min using end-over-end rotation and subsequently allowed to remain 
stationary for 30 min at RT and washed with 3 ml coupling buffer. To the resin, 50 mM L-
Cysteine made in Sulfolink® coupling buffer (1 ml) was added and mixed at RT for 15 min using 
end-over-end rotation and allowed to remain stationary at RT for 30 min. The resin was 
thereafter washed with 1 M NaCl (16 ml) followed by IgY buffer [100 mM NaH2PO4, 0.02% (w/v) 





 3.2.7.3 Purification of anti-TcISG IgY and anti-TcISG N-terminal IgY antibodies  
The Aminolink® and SulfoLink® resins were equilibrated with 6 ml PBS and antibodies with high 
antibody titres determined by ELISA (Section 3.2.6) were pooled and filtered through Whatman 
No. I filter paper. The pooled antibodies were applied to the column and cycled at RT for 16 h 
(0.5 ml/min). The unbound antibodies were collected and the resin was washed with PBS until 
the absorbance at 280 nm reached zero. Bound antibodies (900 µl fractions) were eluted with 
elution buffer (0.1 M glycine-HCl, 0.02% (w/v) NaN3, pH 2.8) into microcentrifuge tubes 
containing neutralisation buffer  [1 M NaH2PO4, 0.02% (w/v) NaN3, pH 8.5 (100 µl)] and gently 
mixed by inversion. The absorbance of each fraction was measured at 280 nm and fractions 
containing purified IgY antibodies were pooled and stored in the presence of 0.1% (w/v) sodium 
azide at 4°C until required. The resin was subsequently washed with 20 ml PBS, 10 ml IgY 
buffer (100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.6) and stored in 2 ml of IgY buffer at 4°C 
until required.  
 
3.2.8 Silver staining 
The detection of small quantities of protein (300-500 ng) was achieved using the silver staining 
technique according to Blum and co-workers (1987).  All steps were carried out at RT. Following 
SDS-PAGE, the electrophoresis gel was soaked in fixing solution (50% (v/v) methanol, 12% 
(v/v) acetic acid, 0.5% (v/v) formaldehyde) for 16 h on an orbital shaker. The gel was 
subsequently incubated (3 x 20 min) in wash solution (50% (v/v) ethanol) followed by soaking in 
pre-treatment solution (0.4% (w/v) Na2S2O3.5H2O) for 1 min. The gel was rinsed in distilled 
water (3 x 20 s) and soaked in impregnation solution (0.2% (w/v) AgNO3, 0.75% (v/v) 37% 
formaldehyde) for 20 min. Following rinsing with distilled water (3 x 20 s), the gel was incubated 
in developing solution (6% (w/v) Na2CO3, 0.004% (w/v) Na2S2O3.5H2O, 0.5% (v/v) 37% 
formaldehyde) until the first bands became visible. The developing solution was then replaced 
with distilled water until the colour of the bands had developed accordingly. The development of 
the bands was terminated using stopping solution (50% (v/v) methanol, 12% (v/v) acetic acid) 
for 10 min and the gel stored in 50% (v/v) methanol. Gels were photographed using the Sys 





3.2.9 Western Blot analysis of TcISG fusion protein 
TcISG fusion protein was electrophoresed on a 10% reducing SDS-PAGE gel (Section 2.2.10) 
and transferred onto a nitrocellulose membrane using the Mini Trans-Blot® Cell apparatus 
(Biorad, CA, USA). Subsequent steps were performed as described in Section 2.2.11. The blot 
was incubated with antibodies depicted in Table 1.3, detected using chromogen-substrate 
solution (0.06% (w/v) 4-chloro-1-naphthol, 0.1% (v/v), H2O2 in TBS) at RT in the dark and 
photographed using the Sys Gene® imaging system (Syngene®, USA).  
Table 3.1: Antibodies used for the detection of TcISG in a western blot. 
Primary antibody Secondary antibody 
mouse anti-6xHis-HRPO [1:8000] none 
chicken anti-TcISG IgY  rabbit anti-chicken IgY- HRPO 
chicken anti-TcISG N-terminal peptide IgY rabbit anti-chicken IgY- HRPO 
T. congolense infected cattle sera [1:100] rabbit anti-bovine IgG-HRPO 
 
 
3.2.10 Western blot analysis of T. congolense lysate 
Trypanosoma congolense (IL3000) BSFs were obtained by centrifugation of the culture medium 
(2000 x g, 15 min, RT), resuspended in PBS and centrifuged (2000 x g, 5 min, RT). The 
resuspension and centrifugation steps were repeated. Parasites were resuspended in lysis 
buffer (20 mM Tris-HCl buffer pH 7.2, 10 mM Na2EDTA, 1% (v/v), Triton X-100) containing L-
trans-epoxysuccinyl-leucylamido (4-guanidino) butane E64 (10 μM) and an equivalent volume of 
reducing treatment buffer was added and boiled at 100°C for 10 min. Parasite lysate proteins 
were separated on a 10% reducing SDS-PAGE gel and transferred onto nitrocellulose. The 
subsequent western blot steps were conducted as described in Section 2.2.11. The blot was 
incubated with primary antibodies: affinity purified chicken anti-TcISG IgY and chicken anti-
TcISG N-terminal peptide IgY (10 µg/ml) antibodies. Rabbit anti-chicken IgY [1:5000] secondary 
antibody and chromogen-substrate solution (0.06% (w/v) 4-chloro-1-naphthol, 0.1% (v/v), (v/v) 
H2O2 in TBS) was used as a detection system. Blots were photographed using the Sys Gene
® 





3.2.11 Detection of anti-ISG antibodies in infected sera using indirect ELISA  
The detection of anti-ISG antibodies in T. congolense infected cattle sera was conducted by 
coating 96 well Nunc-Immuno™ Maxisorp ELISA plates with recombinant TcISG (5 µg/ml, 100 µl 
per well) prepared in PBS. Samples were tested in quadruplicate and negative controls included 
wells coated with PBS with no antigen present. Subsequent steps were performed as described 
in Section 3.2.6. Wells were incubated with sera from infected, non-infected and drug treated 
cattle (1:50 and 1:100) prepared in blocking buffer (100 µl per well) at 37°C for 2 h. A no serum 
control was also included. Blocking buffer was added to these wells. Wells were then washed as 
described previously followed by incubation with rabbit anti-bovine IgG antibody conjugated to 
HRPO prepared in blocking buffer (1:5000, 100 µl per well) at 37°C for 1 h. Subsequent steps 
were performed as described in Section 3.2.6. 
 
3.2.12 Cross reactivity of TcISG with trypanosomal ISG and VSG antibodies 
3.2.12.1   Enzyme-linked immunosorbent assay  
The ability of TcISG to be detected by antibodies produced against ISG and VSG molecules 
from T. brucei and T. brucei gambiense was investigated. Nunc-Immuno™ Maxisorp ELISA 
plates were coated with TcISG (1 µg/ml; 100 µl per well) prepared in PBS and incubated at 4°C 
for 16 h. Subsequent steps were performed as described in Section 3.2.6 and wells were 
probed with chicken anti-TcISG IgY collected weeks 3-8 post first immunisation from chicken 2, 
anti-TcISG IgY pre-immune, chicken anti-TcISG N-terminal peptide IgY collected weeks 10-16 
post first immunisation from chicken 2, chicken anti-TcISG N-terminal peptide IgY pre-immune, 
chicken anti-T. brucei ISG65 IgY, chicken anti-T. brucei ISG75, chicken anti-T. b. gambiense 
VSG RoTat 1.2, week 0 and week 4, chicken anti-T. b. gambiense VSG LiTat 1.3 IgY week 0 
and week 4 and chicken anti-T. b. gambiense VSG LiTat 1.5 IgY week 0 and week 7 [0.316-100 
µg/ml prepared in blocking buffer]. Wells were washed as described previously followed by 
incubation with rabbit anti-chicken IgY secondary antibody conjugated to HRPO prepared in 
blocking buffer [1:15000, 100 µl per well] at 37°C for 1 h.  Subsequent steps were performed as 
described in Section 3.2.6.  
 
3.2.12.2   Dot blot analysis of antibody cross reactivity 
Nitrocellulose strips were spotted with TcISG (1, 5, 10, 50 and 100 µg/ml) and air dried. 




probed with chicken anti-TcISG IgY, chicken anti-TcISG IgY pre-immune, chicken anti-TcISG N-
terminal peptide IgY, chicken anti-TcISG N-terminal peptide IgY pre-immune, chicken anti-       
T. brucei ISG65 IgY, chicken anti-T. brucei ISG75, chicken anti-T. b. gambiense VSG RoTat 
1.2, week 0 and week 4, chicken anti-T. b. gambiense VSG LiTat 1.3 IgY week 0 and week 4, 
and chicken anti-T. b. gambiense VSG LiTat 1.5 IgY week 0 and week 7 [0.316 µg/ml and 100 
µg/ml]. Wells were washed as described previously followed by incubation with rabbit anti-IgY-
HRPO [1:5000] and 4-chloro-1-naphthol·H2O2 chromogen-substrate solution. Blots were 




3.3.1 Production of chicken anti-TcISG IgY antibodies 
Chicken anti-TcISG IgY antibodies were isolated from a single egg collected at the start of each 
week post first immunisation and used in an ELISA to monitor antibody production over the 
period of 16 weeks. Following the first booster injection at week 2, both chickens began 
producing antibodies as seen by the rapid increase in absorbance values (Figure 3.1). Antibody 
production by chicken 1 increased from week 2 to 6 and thereafter remained consistent with a 
slight decrease during week 10. Peak antibody production was detected during weeks 5, 7 and 
9 from eggs from chicken 2 with a minor decrease during weeks 6, 8 and 10 and production 
remained constant thereafter.  
 
Figure 3.1: Production of anti-TcISG IgY antibodies over a period of 16 weeks. Antibodies were 
isolated from a single egg at the start of each week. ELISA plates were coated with TcISG (1 μg/ml) and 
probed with anti-TcISG IgY (100 µg/ml) from chickens 1 and 2. Rabbit anti-chicken IgY-HRPO conjugate 
[1:15000] and chromogen-substrate solution (0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in citrate-phosphate 
buffer, pH 5.0) was used to develop the reaction for 30 min in the dark. The absorbance readings at      
405 nm represent the average of duplicate experiments. Arrows represent immunisation at week 0 































3.3.2 Purification of chicken anti-TcISG antibodies 
To obtain an anti-TcISG IgY antibody preparation with improved specificity, eggs collected 
during weeks corresponding to increased antibody production were pooled and purified using 
the AminoLink® resin coupled with purified TcISG. The antibody pools included: weeks 3-7, 
weeks 8-12 and weeks 9-16 from chicken 1 (Figure 3.2, panel A) and weeks 3-8 and weeks 9-
16 from chicken 2 (Figure 3.2, panel B). The respective IgY pools were cycled through the 
AminoLink®-TcISG resin and specific antibodies were eluted using an acidic pH and elution 
monitored spectrophotometrically at 280 nm. High absorbance indicating increased antibody 
concentration was detected from fractions 3-5 (Figure 3.2, panel A and panel B). All pools 
contained a significant amount of antibodies as seen by the increased absorbance values for 
eluates from all pools from both chickens.  
 
Figure 3.2: Elution profiles for affinity purification of chicken anti-TcISG IgY antibodies. Antibodies 
from (A) chicken 1 and (B) chicken 2 were purified using the AminoLink
®
 resin coupled to TcISG. The 
resin was washed with PBS and bound antibodies were eluted using elution buffer (0.1 M glycine, 0.02% 
NaN3, pH 2.8) into microcentrifuge tubes containing 100 µl neutralisation buffer (1 M NaH2PO4, 0.02% 
NaN3, pH 8.5). Absorbance was monitored at 280 nm. Arrows indicate the start of low pH elution. 
 
Affinity purification of anti-TcISG IgY antibodies and their ability to recognise recombinant TcISG 
antigen was investigated in a ELISA. All antibody pools from chicken 1 and 2 displayed 
increased antibody titres compared to the unbound and pre-immune IgY fractions (Figure 3.3). 
Highest absorbance values were observed from affinity purified antibody from chicken 1 weeks 
3-7 (Figure 3.3, panel A) and weeks 8-12 (Figure 3.3, panel B) as well as from chicken 2 weeks 
3-9 (Figure 3.3, panel D). Antibody titres from chicken 1 weeks 9-16 (Figure 3.3, panel C) and 





























































       
 
 
Figure 3.3: ELISA analysis of affinity purified anti-TcISG IgY antibodies. Wells were coated with 
TcISG (1 μg/ml in PBS) and probed with affinity purified chicken anti-TcISG IgY, crude IgY, unbound 
fraction and pre-immune diluted from 0.08-12.59 µg/ml. (A) Weeks 3-7 chicken 1. (B) Weeks 8-12 
chicken 1. (C) Weeks 9-16 chicken 1. (D) Weeks 3-9 chicken 2. (E) Weeks 10-16 chicken 2. Rabbit anti-
chicken IgY-HRPO conjugate [1:15000] and chromogen-substrate solution (0.05% (w/v) ABTS, 0.0015% 
(v/v) H2O2 in citrate-phosphate buffer, pH 5.0) was used to develop the reaction for 45 min in the dark. 












































































































































3.3.3 Production of chicken anti-TcISG N-terminal peptide IgY 
The peptide selected for antibody production corresponds to amino acid residues 320-338 
which is located within the extracellular domain of TcISG for maximum exposure to the chicken 
immune system (Figure 3.4). The peptide possessed highest hydrophilicity and surface 
probability at the C-terminus and contained a lysine residue within the sequence therefore the 
peptide was coupled at the N-terminus by replacing the asparagine residue (indicated by the 
arrow) with a cysteine residue to assist coupling of the peptide to rabbit albumin using MBS for 
antibody production in chickens. 
Figure 3.4: Analysis of N-terminal TcISG N-terminal peptide using Predict7 program. The surface 
probability and hydrophilicity is plotted on the primary axis while antigenicity and flexibility is displayed on 
the secondary axis. The three letter amino acid residues are indicated on the horizontal axis.  
 
Antibodies made against TcISG N-terminal peptide was isolated from a single egg collected at 
the start of each week over the course of 16 weeks and examined in an ELISA. Antibody 
production began two weeks post immunisation for both chickens as observed by the increased 
absorbance values (Figure 3.5). No eggs were laid by chicken 1 during week 3 however; 
antibody production remained relatively constant with minor decreases during weeks 6 and 11. 
After week 2, consistent antibody production was detected from chicken 2 with a dramatic 
decrease during week 9. Antibody production then increased during week 10 and displayed a 
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Figure 3.5: Production of chicken anti-TcISG N-terminal peptide IgY antibodies over a period of 16 
weeks. Antibodies were isolated from a single egg collected at the start of each week. ELISA plates were 
coated with TcISG N-terminal peptide (5 μg/ml in PBS) and probed with anti-TcISG N-terminal peptide 
IgY (100 µg/ml) from chickens 1 and 2. Rabbit anti-chicken IgY-HRPO conjugate antibody [1:15000] and 
chromogen-substrate solution was used to develop the reaction for 30 min in the dark. The absorbance 
readings at 405 nm represent the average of duplicate experiments. Arrows represent immunisation at 
week 0 followed by booster injections at week 2, 4 and 6.  
  
 
3.3.4 Purification of chicken anti-TcISG N-terminal peptide IgY 
Antibodies made against TcISG N-terminal peptide were purified on a SulfoLink® resin 
immobilised with TcISG N-terminal peptide. The antibody pools comprised of weeks 4-9 and 
weeks 10-16 from chicken 1 (Figure 3.6, panel A) and weeks 3-9 and 10-16 from chicken 2.  
(Figure 3.6, panel B). Increased absorbance relating to high antibody concentration was 
detected from fractions 2-4 from chicken 1 antibody pools (Figure 3.6, panel A) and fractions 2-3 
from chicken 2 (Figure 3.6, panel B). The highest absorbance readings were detected from 
chicken 1, weeks 10-16 and chicken 2, weeks 3-9. Nonetheless, all pools contained a 
considerable amount of antibodies as seen by the increased absorbance values from all 







































Figure 3.6: Elution profiles for affinity purification of chicken anti-TcISG N-terminal peptide IgY 
antibodies. Antibodies from (A) chicken 1 and (B) chicken 2 were purified using the SulfoLink®-TcISG N-
terminal peptide immobilised resin. The resin was washed with PBS and bound antibodies were eluted 
using elution buffer (0.1 M glycine, 0.02% NaN3, pH 2.8) into microcentrifuge tubes containing 100 µl 
neutralisation buffer (1 M NaH2PO4, 0.02% NaN3, pH 8.5). Absorbance was monitored at 280 nm. Arrows 
indicate the start of low pH elution. 
 
Affinity purification of anti-TcISG N-terminal peptide IgY antibodies and their specificity was 
evaluated in a ELISA with different concentrations of TcISG antigen and the respective 
antibodies. Antibody pools from chicken 1 and 2 exhibited high antibody titres compared to the 
crude IgY fraction, unbound and pre-immune fractions (Figure 3.7). However, the absorbance 
decreased greatly from a log concentration of 0.5 for chicken 1 weeks 3-7 (Figure 3.7, panel A), 
0.3 for chicken 1 weeks 8-12 (Figure 3.7, panel B), 0.3 for chicken 2 weeks 3-9 chicken (Figure 

































































    
 
 
Figure 3.7: ELISA analysis of affinity purified chicken anti-TcISG N-terminal peptide IgY 
antibodies. ELISA plates were coated with TcISG N-terminal peptide (1 μg/ml in PBS) and probed with 
affinity purified anti-TcISG N-terminal peptide IgY, crude IgY, unbound fraction and pre-immune diluted 
from 0.08-12.59 µg/ml. (A) Weeks 3-7 chicken 1. (B) Weeks 8-12 chicken 1. (C) Weeks 9-16 chicken 1. 
(D) Weeks 3-9 chicken 2. (E) Weeks 10-16 chicken 2. Rabbit anti-chicken IgY-HRPO conjugate          
[1:15000] and chromogen-substrate solution (0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in citrate-phosphate 
buffer, pH 5.0) was used to develop the reaction for 45 min in the dark. The absorbance readings at     





















































































































3.3.5 Evaluation of chicken antibodies by western blot 
The concentrations of TcISG antigen and chicken anti-TcISG IgY were optimised in a dot blot 
which showed detection using as little as 1 µg/ml TcISG and 0.5 µg/ml chicken anti-TcISG IgY 
(Appendix I). The chicken antibodies were subsequently evaluated in a western blot against 
recombinant TcISG. The TcISG antigen was electrophoresed on a reducing SDS-PAGE gel and 
silver stained which presented a single band corresponding to TcISG protein (Figure 3.8, panel 
A). No lower molecular weight proteins existed after dialysis and storage in glycerol (Section 
2.2.12). Detection of recombinant TcISG was evident in the western blot probed with affinity 
purified chicken anti-TcISG IgY and chicken anti-TcISG N-terminal peptide IgY antibodies 
(Figure 3.8, panel B). The mouse anti-6xHis-HRPO conjugate antibody was used as a positive 
control; while the pre-immune antibody, no primary antibody and no secondary antibody were 
used a negative controls and showed no non-specific reactions (results not shown). 
                                   
Figure 3.8: Western blot analysis of TcISG using chicken anti-TcISG IgY and chicken anti-TcISG N-
terminal peptide IgY antibodies. TcISG (5 µg/ml) was analysed on a (A) 10% reducing SDS-PAGE gel 
and visualised with silver staining and (B) by western blot probed with mouse anti-6xHis-HRPO [1:8000], 
affinity purified chicken anti-TcISG (weeks 3-9 chicken 2) [0.3 µg/ml] and chicken anti-TcISG N-terminal 
peptide IgY (weeks 3-7 chicken 1) [0.5 µg/ml]. Blots were developed rabbit anti-chicken IgY-HRPO 
conjugate [1:5000] conjugate and 4-chloro-1-naphthol·H2O2 chromogen-substrate solution. M: 




























3.3.6 Western blot analysis of T. congolense lysate 
Affinity purified chicken anti-TcISG IgY and chicken anti-TcISG N-terminal peptide IgY were 
tested for their capacity to detect native ISG from T. congolense (IL 3000) bloodstream form 
parasites. The parasite lysate was analysed on a reducing SDS-PAGE gel resulting in the 
presence of several proteins following Coomassie Blue staining (Figure 3.9, panel A). Western 
blot analysis showed detection of a single protein approximately 67 kDa in size with both affinity 
purified chicken anti-TcISG IgY (Figure 3.9, panel C) and chicken anti-TcISG N-terminal peptide 
IgY (Figure 3.9, panel D). The size was much larger than the predicted 46 kDa. An unrelated 
His-tagged fusion protein was used as a negative control in this experiment and was detected 
only with mouse anti-6xHis-HRPO conjugate antibody (Figure 3.8, panel B).  
 
Figure 3.9: Detection of native ISG in T. congolense (IL 3000) bloodstream form lysate. (A) Parasite 
proteins and an unrelated His-tagged protein were separated on a reducing 10% SDS-PAGE gel, 
visualised with silver staining and analysed by western blot probed with (B) mouse anti-6xHis-HRPO 
conjugate antibody [1:8000], (C) affinity purified chicken anti-TcISG (weeks 3-9 chicken 2) [10 µg/ml] and 
(D) chicken anti-TcISG N-terminal peptide IgY (weeks 3-7 chicken 1) [10 µg/ml]. Blots were developed 
using rabbit anti-chicken IgY-HRPO conjugate antibody [1:5000] and 4-chloro-1-naphthol·H2O2 
chromogen-substrate solution. M: PageRuler™ prestained protein marker. 
 
 
3.3.7 Antibody detection by indirect ELISA 
An indirect ELISA was subsequently employed to determine if recombinant TcISG could 
discriminate between T. congolense infected and non-infected cattle sera. An ELISA plate was 
coated with TcISG and tested against sera from non-infected cattle, T. congolense infected and 




















































coated with TcISG were subtracted from the experimental absorbance and plotted. The results 
showed increased absorbance of 0.29 from the infected serum (1:50) indicating detection of 
anti-ISG antibodies (Figure 3.10). A lower absorbance of 0.045 was obtained with the serum 
from drug treated cattle (1:50) while absorbance from non-infected cattle was less than 0.03. 
These results were further validated in a western blot. A single protein band of TcISG was 
observed in a silver stained SDS-PAGE gel (Figure 3.11, panel A) and a duplicate gel 
containing TcISG transferred onto a nitrocellulose membrane and probed with the sera. 
Detection of TcISG was evident using infected serum while no detection was observed with 
non-infected serum and serum from drug treat cattle (Figure 3.11, panel B). 
 
Figure 3.10: Detection of anti-ISG IgG antibodies from T. congolense infected sera in an indirect 
ELISA. A microtitre plate was coated with TcISG (5 µg/ml) and probed with sera from non-infected cattle, 
T. congolense infected and cattle treated with trypanocidal drugs [1:50 and 1:100]. Anti-bovine IgG-HRPO 
conjugate antibody [1:5000] and chromogen-substrate solution (0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in 
citrate-phosphate buffer, pH 5.0) was used to develop the reaction for 45 min in the dark. The absorbance 
readings at 405 nm represent the average of quadruplicate experiments. A no coat antigen control and no 

































Figure 3.11: Detection of anti-ISG IgG antibodies from T. congolense infected sera in a western 
blot. (A) TcISG (5 µg/ml) was analysed on a 10% reducing SDS-PAGE gel and silver stained and a 
duplicate gel was transferred onto (B) nitrocellulose and probed with sera from non-infected cattle sera, 
T. congolense infected sera and sera from cattle treated with a trypanocidal drug [1:100]. Anti-bovine IgG-
HRPO conjugate antibody [1:5000] and 4-chloro-1-naphthol·H2O2 chromogen-substrate solution was 
used to develop the blot. M: PageRuler™ prestained protein marker. 
 
 
3.3.8 Cross reactivity of anti-trypanosomal ISG and VSG antibodies with TcISG 
TcISG was detected with highest specificity using chicken anti-TcISG IgY followed by chicken 
anti-TcISG N-terminal peptide IgY (Figure 3.12, panel A). No cross reactivity was observed 
using chicken antibodies against: T. brucei ISG65 and ISG75 (Figure 3.12, panel A),                 
T. b. gambiense VSG RoTat 1.2 and T. b. gambiense VSG LiTat 1.3 and LiTat 1.5 (Figure 3.12, 
panel B). These antibodies were further evaluated in a dot blot were only chicken anti-TcISG 
IgY and chicken anti-TcISG N-terminal peptide IgY detected the TcISG antigen (Figure 3.13). 
 







































































Figure 3.12: Cross reactivity of anti-trypanosomal ISG and VSG antibodies. ELISA plates were 
coated with TcISG (1 µg/ml) and probed with (A) ISG antibodies: anti-TcISG IgY weeks 3-8 from chicken 
2, anti-TcISG IgY pre-immune, anti-TcISG N-terminal peptide IgY weeks 10-16 from chicken 2, anti-
TcISG N-terminal peptide IgY pre-immune, anti-Tb ISG65 IgY, anti-Tb ISG75, (B) VSG antibodies: Tbg 
RoTat 1.2 week 0 and week 4, Tbg LiTat 1.3 week 0 and week 4, Tbg LiTat 1.5 week 0 and week 7. All 
antibodies were made in chickens and were serially diluted from 0.316-100 µg/ml in blocking buffer. 
Rabbit anti-IgY-HRPO conjugate [1:15000] and chromogen-substrate solution (0.05% (w/v) ABTS, 
0.0015% (v/v) H2O2 in citrate-phosphate buffer, pH 5.0) was used to develop the reaction for 45 min in the 
dark. The absorbance readings at 405 nm represent the average of duplicate experiments. A no coat 




Figure 3.13: Dot blot analysis of cross reactivity of anti-ISG antibodies and anti-VSG antibodies 
with TcISG antigen. Nitrocellulose strips were spotted with various concentrations of TcISG probed with 
anti-TcISG IgY weeks 3-8 from chicken 2, anti-TcISG IgY pre-immune, anti-TcISG N-terminal peptide IgY 
10-16 from chicken 2, anti-TcISG N-terminal peptide IgY pre-immune, anti-Tb ISG65 IgY, anti-Tb ISG75, 
VSG antibodies: Tbg RoTat 1.2 week 0 and week 4, Tbg LiTat 1.3 week 0 and week 4 and Tbg LiTat 1.5 
week 0 and week 7 (0.316 µg/ml and 100 µg/ml). All antibodies were made in chickens and blots were 
developed rabbit anti-IgY-HRPO conjugate antibody [1:5000] and 4-chloro-1-naphthol·H2O2 chromogen-
























Log 10 {[IgY] (µg/ml)} 
anti-Tbg RoTat 1.2 wk 0
anti-Tbg RoTat 1.2 wk 4
anti-Tbg LiTat 1.3 wk 0
anti-Tbg LiTat 1.3 wk 4
anti-Tbg LiTat 1.5 wk 0
anti-Tbg LiTat 1.5 wk 7



























Recombinant TcISG was expressed and purified as described in Chapter 2, Section 2.2.8 and 
used to immunise chickens for antibody production. Freund’s adjuvant was used to stimulate the 
immune system by increasing the immunogenicity of the antigen (Freund, 1956; Singh and 
O′Hagan, 2003). Chicken antibodies are considered favorable since it does not activate 
complement proteins present in mammalian sera thereby reducing potential interferences and 
preventing false positive results. Additionally, IgY does not cross react with mammalian IgM or 
IgG, human anti-mouse IgG antibodies, rheumatoid factors and anti-nuclear antibodies (Larsson 
et al, 1993; Schade et al, 2005).   
High anti-TcISG IgY antibody titres were obtained after two injections with TcISG antigen at the 
start of week 3 and was maintained until week 16 with a further two booster injections at weeks 
4 and 6. The concept that the greater the phylogenetic distance between the immune system 
and the antigen source, the larger the immune response elicited (Horton et al, 1985; Olovsson 
and Larsson, 1993) may explain the large quantity of antibodies produced by avian chicken 
against protozoan TcISG. Antibody yield is also superior in chickens since 20 eggs are laid 
monthly on average with each egg containing approximately 100 mg of antibodies (Akita and 
Nakai, 1992) and possesses greater affinity for its respective antigen compared to antibodies 
made in rabbits (Schade et al, 1996). Chicken anti-TcISG IgY antibodies were affinity purified 
using an affinity resin on which TcISG was immobilised to obtain TcISG specific antibodies. 
Initial preparation of the AminoLink®-TcISG resin with a coupling protocol using pH 7.2 led to 
very low coupling efficiency. A neutral pH was preferred to ensure stability of the TcISG protein 
and it is also the pH routinely used to couple IgY to the AminoLink® resin. For this reason, 
coupling protocol using pH 10 was explored as it offers improved protein immobilisation to the 
resin by establishing a Schiff base bond between the functional aldehyde groups on the agarose 
beads and primary amines present on TcISG in accordance with the AminoLink® Plus Coupling 
Resin manual (Thermo Scientific, USA). This approach was successful. Increased amounts of 
TcISG IgY were purified and displayed improved specificity for TcISG antigen compared to the 
crude IgY samples and unbound fractions in an ELISA.  
Peptide antibodies offer specific recognition of amino acid sequences present on a protein 
which is beneficial for the detection of specific regions on the protein (Hancock and O’Reilly, 
2005). In this study, TcISG N-terminal peptide located within the extracellular domain of TcISG 
was selected based on the Predict7 epitope prediction program (Carmenes et al, 1989) which 




sequence. An extracellular region located on TcISG pertaining to increased hydrophilicity and 
surface probability values with the possibility of residing on the surface of the protein was 
chosen for synthesis (Appendix G and H). These two features were vital for maximum exposure 
to the chicken immune system for antibody production. Peptides are not large enough to ellicit 
an immune response therefore the TcISG peptide was coupled to rabbit albumin using MBS 
before immunisation of chickens for antibody production (Lateef et al, 2007). Increased chicken 
anti-TcISG N-terminal peptide antibody titres were detected from both chickens over the course 
of 16 weeks post immunisation. No eggs where laid by chicken 2 during week 3. Studies have 
shown that Freund’s complete adjuvant and Freund’s incomplete adjuvant can reduce or 
completely prevent chickens from laying eggs for several weeks (Bollen and Hau, 1999).  
Large amounts of chicken anti-TcISG N-terminal peptide IgY were affinity purified and 
demonstrated increased specificity in an ELISA in comparison to the crude IgY samples. Lower 
absorbance readings were detected when higher concentrations of chicken anti-TcISG N-
terminal peptide IgY were utilised in an ELISA plate coated with TcISG. This is attributed to the 
prozone or “hook” effect which is a phenomena caused by high antibody concentrations in the 
presence of low antigen concentrations resulting in excessive antibody binding sites. This leads 
to univalent antibody binding to the antigen and thus low signal instead of the typical multivalent 
binding that cross links one antigen to the next leading to higher absorbance readings (Sateesh, 
2003).  
Affinity purified chicken anti-TcISG IgY and chicken anti-TcISG N-terminal peptide IgY 
antibodies were able to detect recombinant TcISG in a western blot. Next, both antibodies were 
tested against T. congolense bloodstream form lysate for detection of native ISG. Histidine 
affinity tags are small in size and seldom affect the downstream applications of recombinant 
protein use (Graslund et al, 2008). However, an unrelated histidine-tagged fusion protein was 
used as a control to demonstrate the specificity of anti-TcISG IgY. Chicken anti-TcISG IgY did 
not recognise the unrelated histidine-tagged fusion protein thus the antibody was specific for 
TcISG epitopes. Chicken anti-TcISG IgY and chicken anti-TcISG N-terminal peptide IgY 
detected a single band from the parasite lysate approximately 67 kDa in size which was larger 
than the predicted size of 46 kDa. Potential glycosylation of native TcISG i.e TcISG expressed 
by trypanosomes can be speculated since trypanosomes can post translationally glycosylate its 




Furthermore, TcISG possess conserved domains from the ISG65 and ISG75 superfamily and 
Ziegelbauer and co-workers have confirmed N-linked glycosylation of ISG65 and ISG75 from   
T. brucei at Asn155 and Asn334 for ISG65 and Asn134 for ISG75 (Ziegelbauer et al, 1992). N-
linked glycosylation is a process where glycans are attached to the Asn residue in consensus 
sequences: Asn-X-Ser / Asn-X-Thr where X can be any amino acid except proline (Imperiali and 
O’Conner, 1999). Sequence analysis of TcISG revealed 5 potential glycosylation sites 
possessing the consensus sequence with positions of: Asn55, Asn123, Asn133, Asn141 and Asn327 
within the extracellular domain of TcISG. Potential glycosylation sites are typically located within 
the extracytosolic domain and more than ten residues from the transmembrane domain 
(Landolt-Marticorena and Reithmeier, 1994) which favors the perception that native TcISG may 
undergo N-linked glycosylation. Proteins can possess more than one consensus sequence; 
however, not all sites are glycosylated as some sites may be unsuitable since asparagine must 
be located near the luminal end of the endoplasmic reticulum (Landolt-Marticorena and 
Reithmeier, 1994). Glycosylation of ISGs have also been reported in T. b. gambiense ISG75 
(Rogé et al, 2013), T. b. gambiense ISG65 (Baiyegunhi, 2013), T. brucei ISG100 (Nolan et al, 
1997), T. brucei ISG64 and ISG70 (Jackson et al, 1993) while five potential glycosylation sites 
were identified from T. congolense Tc38630 ISG by Mochabo and colleagues (2013). 
Preliminary tests were conducted to determine the diagnostic potential of TcISG in an indirect 
antibody detection ELISA. Antibodies from infected T. congolense cattle serum as well as serum 
from drug treated cattle identified recombinant TcISG in comparison to the non-infected cattle 
serum. This result demonstrated the capability of recombinant TcISG to distinguish between 
infected and non-infected cattle sera. The results were confirmed in a western blot where TcISG 
was recognised using infected cattle serum while no detection was observed using non-infected 
serum and serum from drug treated cattle. Even though a signal was detected using serum from 
drug treated cattle in the ELISA, the concentrations of TcISG and serum used in a western blot 
were possibly too low for recognition. Low ELISA signal can be attributed to the use of low 
concentrations of TcISG. Additionally, ISGs are shielded by large VSG molecules therefore 
more antibodies are made against the VSGs compared to ISGs (Ziegelbauer and Overath, 
1993; Schwede et al, 2015).  Further testing of TcISG against a blinded panel of infected cattle 
sera will need to be conducted to determine the sensitivity and specificity of using TcISG as a 
diagnostic antigen. 
The recognition of TcISG using antibodies produced against ISG and VSG from various 




specificity using chicken anti-TcISG IgY and chicken and TcISG N-terminal peptide IgY 
antibodies. No further cross reactions was detected using chicken anti-T. brucei ISG65 and 
ISG75 as well as T. b. gambiense VSG RoTat 1.2, VSG LiTat 1.3 and VSG LiTat 1.5. 
Antibodies used in the cross reactivity ELISA such as T. brucei ISG65 and ISG75 were made 
specifically against the ISG extracellular domain therefore recognition of epitopes present on 
other domains of TcISG would not have occurred thus contributing to the lack of cross reactivity. 
Additionally, TcISG does not possess significant sequence similarity to T. brucei or                   
T. b. gambiense ISGs as evident from the NCBI-BLAST search analysis which only returned 
hits from T. congolense unnamed proteins and with less than 26% identity from T. brucei and    
T. b. gambiense ISGs (Appendix J). Multiple sequence alignment of T. brucei and                     
T. b. gambiense ISG sequences displaying highest query cover showed very little sequence 
identity and similarity (Appendix K) thus correlates with the lack of cross reactivity between 
TcISG antigen and T. brucei and T. b. gambiense ISG antibodies. Since TcISG was not 
recognised by antibodies from other Trypanosoma species, it suggests that TcISG could be 
used for species identification in diagnostic testing of Trypanosoma mixed infections. Although 
more experiments are required to validate the absence of cross reactivity between 
Trypanosoma species, the lack of ISG sequence identity and similarity among species is less 
than 10% and 20% respectively (Jackson et al, 2013).   
In conclusion, antibodies were generated in chickens against TcISG and TcISG N-terminal 
peptide and analysed using a dot blot, ELISAs and western blots. Both antibodies were 
produced in large quantities and affinity purified preparations displayed increased specificity for 
their respective antigens. Native T. congolense ISG (TcIL3000.0.29290) was detected using 
both chicken anti-TcISG IgY and chicken anti-TcISG N-terminal peptide IgY. Additionally, anti-
ISG IgG antibodies from T. congolense infected cattle serum detected TcISG in an antibody 
detection indirect ELISA and no detection was observed using non-infected cattle serum. These 
results were further confirmed in a western blot. No cross reactivity was detected between 
TcISG antigen and antibodies against T. brucei ISG65 and ISG75 and T. b. gambiense VSGs: 
RoTat 1.2, LiTat 1.3 and LiTat 1.5. However the experiment could be improved by coating the 
ELISA plate with T. brucei ISG65 and ISG75, T. b. gambiense RoTat 1.2 antigen and               
T. b. gambiense LiTat 1.3 and LiTat 1.5 antigens to show how each antigen is recognised by its 








Animal African trypanosomiasis (AAT) also known as ‘Nagana’ is a neglected disease prevalent 
in poor remote countries in Sub-Saharan Africa. Nagana is mainly caused by T. congolense and 
T. vivax parasites which affects livestock while T. brucei gambiense and T. brucei rhodesiense 
are human pathogens causing human African trypanosomiasis (Schofield and Kabayo, 2008). 
Animal African trypanosomiasis accounts for major financial losses in animal and crop farming 
and is transmitted by hematophagous tsetse flies located within the tsetse fly belt with 
approximately 37 countries considered unsuitable for cattle farming (Kuzoe, 1993; Baral, 2010).  
Trypanosoma congolense alternates its life cycle stages between the host bloodstream and the 
tsetse fly midgut. Each life cycle stage is characterised by the expression of a different surface 
coat known as a variable antigen type coding for a variable surface glycoprotein (VSG) in a 
process called antigenic variation (Gruszynski et al, 2006). Antigenic variation and the lack of B 
cell memory which typically leads to a long term IgM response makes vaccine development 
unlikely, therefore effective control of the disease is required (Magez and Radwanska, 2014). 
Trypanocidal drugs such as diminazene, isometamidium and homidium have been used since 
the 1950s however; drug resistance is rapidly increasing (Kuriakose and Uzonna, 2014). 
Insecticide spraying and sterile insect technique are typically employed to control tsetse fly 
populations but have met with variable degrees of success (Dyck et al, 2005; Torr et al, 2007; 
Vreysen et al, 2013).  
In association with effective disease control, accurate diagnosis is essential. Direct and indirect 
detection of trypanosomes in infected blood samples are not species specific or sensitive 
diagnostic tests. Molecular techniques such as polymerase chain reaction (PCR), loop-mediated 
isothermal amplification (LAMP) and fluorescence in situ hybridisation testing using nucleic acid 
probes offer increased specificity since specific genes are targeted for diagnosis (Notomi et al, 
2000; Desquesnes and Dávila, 2002; Radwanska et al, 2002). However, these tests are not 
suitable for field use, are expensive and trained personnel are required to perform the test and 
interpret the results (Deborggraeve and Büscher, 2010). Serological tests provide increased 
sensitivity and specificity in the detection of trypanosome-induced antibodies in infected sera. 
Antibody detection tests such as enzyme-linked immunosorbent assay (ELISA), indirect 




diagnose HAT infections due to their affordability, simplicity and suitability for field use (Voller et 
al, 1975; Songa and Hamers, 1988; Nantulya and Lindwvist, 1989). Such tests use native 
trypanosome proteins thus requiring either in vivo or in vitro cultivation of parasites which results 
in a lack of standardisation testing, raises ethical concerns for propagation of parasites in 
laboratory animals and poses as a health risk to personnel (Greiner et al, 1997; Hopkins et al, 
1998; Desquesnes et al, 2009).   
In response to these challenges, trypanosome virulence associated proteins have been 
identified with the potential to replace native antigens. Variable surface glycoproteins are 
abundantly expressed on trypanosome bloodstream forms and are capable of stimulating an 
antibody response (Cornellissen et al, 1985; La Greca and Magez, 2011) thus possessing key 
features of an ideal diagnostic antigen (Hutchinson et al, 2004). Variable surface glycoprotein 
based tests such as ELISA/T. evansi (Büscher et al, 1995) and LATEX/T. b. gambiense (Verloo 
et al, 2001) are predominantly used for the detection of anti-VSG RoTat 1.2 antibodies in HAT 
patient sera. However, both tests may lead to misdiagnosis since the parasite is capable of 
switching its surface coat to express a different VSG molecule than the VSG used in the test 
(Tran et al, 2008) therefore a surface protein that does not undergo antigenic variation would 
serve as a better alternative (Hutchinson et al, 2004).  
Invariant surface glycoproteins (ISGs) are transmembrane proteins expressed on trypanosome 
bloodstream forms with an estimated 70 000 copies of ISG65 and 50 000 copies of ISG75 per 
cell and these proteins do not exhibit antigenic variation (Ziegelbauer and Overath, 1992; Tran 
et al, 2008). Invariant surface glycoproteins are also immunogenic since they are capable of 
eliciting an antibody response (Ziegelbauer and Overath, 1993) and have been proposed as a  
possible DNA vaccine candidate by activating a humoral response, conferring partial protection 
to immunised mice and stimulating a Th1 antibody profile (Lança et al, 2011). Due to these 
features, ISGs have been proposed as an alternate immunodiagnostic antigen to VSGs. In the 
present study, Trypanosoma congolense ISG (TcISG) was cloned and recombinantly expressed 
with the aim of testing its diagnostic potential for animal African trypanosomiasis.  
The DNA construct prepared for this purpose included all four domains of TcISG (Figure 2.1) 
and was recombinantly expressed as a histidine-tagged fusion protein within inclusion bodies in 
E. coli BL21 (DE3) cells using IPTG induction. Other ISGs that have been recombinantly 





Table 4.1: Summary of Trypanosoma ISG expression and purification details and their applications. 
Trypanosoma 
species 









pET-1b in E. coli   
Origami B (DE3) cells 
 












T. b. brucei  GVR 
35/1.5 
ISG pET-28a in E. coli BL21 
(DE3) cells 
 
None 60 DNA construct coding for ISG was 
tested as a vaccine candidate 




T. brucei gambiense ISG75 P. pastoris M5 yeast  
strain 
Anti-E tag affinity matrix  40-45 & 
60-65 















pET vectors in E.coli  
BL21(DE3) RIPL cells 
 
Nickel affinity matrix 42 
43 




Development of lateral flow device 
using ISG65-1 ISG 
 








T. congolense (IL3000) 
 















pET15b in E. coli BL21-




Nickel affinity matrix 
Molecular exclusion 
chromatography 
Not reported Identification of immunodiagnostic 
antigens 
Fleming et al, 2014 
T. evansi ISG75 pET-28a in E. coli 
BL21 Star (DE3) pLysS 
cells 
 
Nickel affinity matrix 
 





T. brucei ISG65 Leishmania tarentolae   
LEXSYS pLEX hyg2 
vector in  LEXSYS host 
strain p10 
Nickel affinity matrix 
 
50–60 Expression of  proteins from 
kinetoplastid organisms 





T. vivax (ILRAD V34) TvY486_0019690 
TvY486_0045500 
pET-15b in E. coli BL21-
CodonPlus (DE3) RIPL 
cells 
Nickel affinity matrix 
 
Not reported Development of lateral flow device 
using TvY486_0045500 
 




Inclusion body formation was attributed to the hydrophobic nature (Ziegelbauer et al, 1995) of 
TcISG (Ziegelbauer et al, 1995; de Groot et al, 2008). The expression of recombinant proteins 
enters several pathways that are regulated at a transcriptional and translational level and a high 
copy number of the gene of interest in association with a strong promoter and increased 
concentrations of the inducer such as IPTG can also lead to protein aggregation since the 
bacterial cells experience increased levels of metabolic burden (Allen et al, 1992; Bakau, 1993). 
Typically, inclusion bodies also form when expression of the target protein exceeds 2% of the 
total cellular proteins (Mitraki et al, 1991).  
Purification of proteins expressed within inclusion bodies undergoes four steps: isolation and 
solubilisation of inclusion bodies followed by refolding of the solubilised protein and purification. 
Inclusion bodies were isolated using centrifugation and sonication while solubilisation of TcISG 
was accomplished by use of SDS and sarkosyl detergents according to Schalger and co-workers 
(2012). TcISG could have been solubilised using urea and guanidine hydrochloride which are 
commonly used chaotropic agents, however, both detergents are considered strong protein 
denaturants and possible protein aggregation may occur during the refolding process which is 
undesirable. Solubilisation with urea also requires several dialysis steps thus large amounts of 
buffers are needed and protein loss can occur which is not feasible for large scale protein 
solubilisation (Singh et al, 2012). Sarkosyl is a mild solubilisation agent and is preferred over 
urea and guanidine hydrochloride because it does not completely denature the inclusion bodies 
that possess native-like secondary structures significant for protein functionality. Additionally, 
protein aggregation is restricted during the refolding process and yields increased quantities of 
bioactive proteins (Singh et al, 2012). 
Following solubilisation, TcISG was subjected to on-column refolding and purification using a 
nickel chelate resin under denaturing conditions. On-column refolding does not require large 
volumes of refolding buffer; high protein concentrations can be applied to the resin and removal 
of the denaturant is achieved simultaneous to protein purification (Jungbauer et al, 2004; Li et al, 
2004). Protein aggregation usually occurs during refolding steps therefore certain additives are 
used to prevent this. Common additives include guanidine hydrochloride (Tsumoto et al, 2003), 
urea (Singh and Panda, 2005), arginine (Buchner and Rudolph, 1991; Xia et al, 2007), glycine 
(Ou et al, 2002), proline (Samuel et al, 2000), sucrose (Kim et al, 2006), sorbitol (Majumder et al, 
2001), polyethylene glycol (Cleland et al, 1992) and glycerol (Sawano et al, 1992). Since TcISG 
was refolded using affinity chromatography in the presence of sarkosyl detergent, protein 




The TcISG fusion protein migrated at a size of approximately 66 kDa on a reducing SDS-PAGE 
gel and possible bacterial proteins were detected within the first three fractions eluted from the 
affinity resin. Additionally, a protein approximately 55 kDa in size was present in the solubilised 
TcISG fraction, unbound fraction and eluted fractions 1-2. Since this protein was detected using 
anti-histidine antibody, it is speculated to be a bacterial protein that interacted with the 
hydrophobic residues from TcISG during solubilisation, refolding and purification procedures. 
Furthermore, E. coli cellular proteins rich in histidine possess a high affinity for nickel ions and 
can therefore bind and co-elute with the target protein (Schmitt et al, 1993, Bornhorst and Falke, 
2002). Expression and purification of T. brucei gambiense ISG75 resulted in degradation 
products. Edman degradation revealed the presence of cleavage sites (Rogé et al, 2013) 
therefore for future studies it will be worthwhile to determine potential cleavage sites in TcISG 
which could facilitate identification of the 55 kDa protein. Due to the inability to identify the 55 
kDa protein, only fractions containing the 66 kDa fusion protein was used further in this study.  
Interestingly, the size of recombinant TcISG is approximately 66 kDa and was larger than the 
anticipated predicted size of 46 kDa calculated from the amino acid residues constituting TcISG. 
A larger size of T. brucei ISG65 and ISG75 was also observed during SDS-PAGE analysis by 
Ziegelbauer and co-workers (1992) while native T. brucei ISG70 was reported to migrate slower 
than expected and was depicted as a diffuse band (Jackson et al, 1993). This irregularity is 
commonly referred to as ‘gel shifting’ (Shi et al, 2012). Invariant surface glycoproteins 65 and 
ISG75 possess numerous negatively charged amino acids which may contribute to the reduced 
binding of SDS to the ISGs resulting in slow migration compared to the standard molecular 
weight markers thus the ISGs appear larger than expected (Ziegelbauer et al, 1992). Gel shifting 
was also observed with other trypanosomal proteins such as T. brucei VSG AnTat 1.1A (Nolan 
et al, 2000). Additionally, Using the ProtParam program on the Expasy server 
(http://web.expasy.org/protparam/), amino acid sequence analysis of TcISG demonstrated a total 
of 53 negatively charged amino acids (aspartate and glutamate) which constitutes 13% of the 
total protein and thus correlates with the concept of reduced binding TcISG to SDS. 
Analysis of the TcISG amino acid sequence, led to the identification of TcISG N-terminal peptide, 
predicted to be hydrophilic and surface exposed and was coupled to rabbit albumin using MBS 
for antibody production in chickens. Polyclonal anti-TcISG and anti-TcISG N-terminal peptide 
antibodies were produced in chickens since large quantities of antibodies can be obtained from 
chicken egg yolks using a variety of simple isolation and purification methods (Pauly et al, 2011). 




immobilised with recombinant TcISG antigen and TcISG N-terminal peptide respectively. Large 
quantities of antibodies were obtained and demonstrated increased specificity in an ELISA 
compared to the non-affinity purified antibodies. One of the main benefits of using chickens to 
generate antibodies instead of mammals is the isolation of antibodies from egg yolks which 
obviates bleeding of the animal and hence this approach to antibody production is recommended 
by the European Centre for the Validation of Alternative Methods (Schade et al, 1996). 
Additionally, IgY antibodies remain stable for more than ten years in a buffer containing a 
preservative such a sodium azide without losing its titre (Carlander et al, 1999), display 
increased stability over a variety of salt concentrations and pH and are often used in 
immunofluorescence and immunohistochemistry studies since they are able to recognise and 
bind to multiple epitopes on a chemically fixed sample (Lipman et al, 2005). Furthermore, 
polyclonal antibodies are produced against numerous epitopes which increases the possibility of 
detecting the recombinant and native protein however, cross reactivity may arise (Trier et al, 
2012). In this case monoclonal antibodies are preferred but these antibodies are typically 
generated in mice therefore bleeding of the animal is required and the production process is 
complex. Alternatively, anti-peptide antibodies offer increased specificity since antibodies are 
raised against a specific region or epitope on a protein (Pauly et al, 2011; Trier et al, 2012). 
Affinity purified anti-TcISG IgY and anti-TcISG N-terminal peptide IgY identified native ISG from 
T. congolense bloodstream form lysates in a western blot. The expected size of 46 kDa, as 
calculated from the TcISG amino acid sequence, was not detected but instead a larger size of 
approximately 67 kDa was observed. In this study, a prokaryotic expression system was used to 
express recombinant TcISG therefore post translational glycosylation could not occur. However, 
in trypanosomes, native ISGs can undergo glycosylation therefore the amino acid sequence of 
TcISG was examined for potential glycosylation sites. Five possible N-linked glycosylation sites 
containing the consensus sequences Asn-X-Ser/Asn-X-Thr (Imperiali and O’Conner, 1999) were 
identified in the TcISG amino acid sequence. This would explain the larger size of native TcISG 
found in trypanosomes. 
Other ISGs that undergo glycosylation are T. brucei ISG64 and ISG70 (Jackson et al, 1993),     
T. brucei ISG100 (Nolan et al, 1997), T. b. gambiense ISG75 (Rogé et al, 2013) and T. b. 
gambiense ISG65 (Baiyegunhi, 2013). Furthermore, Mochabo and colleagues (2013) have 
determined five possible glycosylation sites in T. congolense Tc38630 ISG. Considering the 
potential of native TcISG to undergo glycosylation, a eukaryotic expression may be more useful 




proteolytic processing and protein folding can be achieved using a eukaryotic expression system 
(Macauley-Patrick et al, 2005). Eukaryotic expression systems include insect cells such as the 
baculovirus infected cell line (Contreras-Gomez et al, 2014), mammalian cells such the human 
embryo kidney and Chinese hamster ovary (Khan, 2013) as well as yeast such as Pichia 
pastoris and Saccharomyces cerevisiae (Strausberg and Strausberg, 2001; Bornert et al, 2012). 
Insect and mammalian expression systems have complex growth media and cultivation 
conditions are time consuming therefore yeast cells offer a suitable alternative as a simple and 
affordable growth medium with increased yield of soluble proteins (Macauley-Patrick et al, 2005). 
Soluble T. b. gambiense ISG75 has been expressed in P. pastoris with a yield of 10 mg/ L of 
culture media (Rogé et al, 2013). However, the limited license issues with using P. pastoris for 
recombinantly expressing proteins for use in a diagnostic test (Research Corporation 
Technologies, Tuscon, AZ, USA) necessitates the search for intellectual property free 
recombinant expression systems. 
Seeing that native TcISG was detected by both chicken anti-TcISG IgY and chicken anti-TcISG 
N-terminal peptide IgY antibodies, immunoprecipitation and immuno-affinity chromatography can 
be used to isolate native TcISG from bloodstream form parasite lysates (Lipman et al, 2005) and 
tested for glycosylation using Endoglycosidase H enzyme. Immuno-localisation experiments 
ought to be conducted in the future for the detection of native TcISG. Moreover, studies have 
reported localisation of ISGs on the surface of trypanosomes (Ziegelbauer et al, 1992, 
Baiyegunhi, 2013). 
The extracellular domain of T. congolense ISG (TcISG) with the gene name TcIL3000.0.29292, 
could discriminate between infected and non-infected cattle sera in an ELISA but was however 
not evaluated further (Fleming et al, 2014). In the present study TcISG expressed with all four 
domains was able to differentiate between non-infected and T. congolense infected cattle sera in 
an ELISA and western blot.  
To further examine the diagnostic potential of TcISG, an inhibition ELISA can be performed 
using recombinant TcISG antigen or chicken anti-TcISG IgY (Figure 4.1 panel B and C). The 
ELISA plate will be coated with TcISG and incubated with infected cattle serum containing anti-
TcISG IgG antibodies that will bind to TcISG (Figure 4.1, panel A) compared to non-infected 
cattle serum which will not contain anti-TcISG IgG antibodies and will therefore be washed away. 
Chicken anti-TcISG IgY will subsequently be added and washed away since antibodies from the 
infected serum (anti-TcISG IgG) would have already bound to TcISG. If non-infected cattle 




site will be available (Figure 4.1, panel C). Rabbit anti-chicken IgY-HRPO conjugate antibody is 
used as a detection antibody. Decreased ELISA signal is obtained when using infected cattle 
serum since chicken anti-TcISG IgY-HRPO conjugate antibody is washed away.  
The inhibition ELISA test requires antibody production against the antigen in question and anti-
trypanosomal antibodies from different species can be tested using a single detection antibody in 
comparison to the indirect ELISA (Figure 4.1, panel A) which requires a single species enzyme 
conjugate (Crowther, 1995). The inhibition ELISA test offers increased sensitivity possibly due to 
the detection of both IgM and IgG compared to an indirect ELISA that only detects IgG 
antibodies (Bossard et al, 2010). 
It must be noted that anti-trypanosomal antibodies can persist in the bloodstream of an infected 
animal after treatment with trypanocidal drugs or self-cure, hence antibody detection tests 
cannot detect active infections (Boulangé et al, 2002). For future work, an antigen detection 
ELISA can be developed which permits the detection of trypanosomal antigens circulating in the 
blood of infected animals and hence identify active infections (Nantulya & Lindqvist, 1989). The 
antigen detection ELISA would entail coating the microtiter plate with chicken anti-TcISG IgY and 
probing with infected bovine serum or blood containing circulating trypanosomal antigens (Figure 
4.2). Rabbit anti-bovine IgG-HRPO conjugate antibody and chromogen-substrate solution will be 













Figure 4.1: Diagrammatic representation of an indirect and inhibition ELISA. (A) Indirect ELISA and 
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Figure 4.2: Schematic diagram of an antigen detection ELISA test. T. congolense ISG in infected 
serum or a blood sample is captured by chicken anti-TcISG IgY and detected by rabbit anti-bovine IgG-




In the present study, TcISG antigen was not detected by either anti-T. brucei ISG65 and ISG75 
or antibodies against T. b. gambiense VSGs RoTat 1.2, LiTat 1.3 and LiTat 1.5. The NCBI-
BLAST search of TcISG returned hits to T. congolense unnamed proteins, T. brucei and T. b. 
gambiense ISGs with less than 26% identity to the TcISG sequence. Sequence similarity and 
identity of ISGs among trypanosome species is less than 20% and 10% respectively (Jackson et 
al, 2013). Diagnosis of T. congolense and T. vivax infections using an indirect antibody detection 
ELISA plate coated with whole parasite lysate has been developed (Rebeski et al, 1999), 
however, the use of native proteins or parasite lysate is not recommended therefore recombinant 
proteins such TcISG can potentially be used as a species specific diagnostic antigen. 
Recombinant TcISG can also be tested against a blinded T. congolense and T. vivax infected 
sera panel in an indirect and inhibition ELISA format to further verify the diagnostic potential of 
TcISG.   
Other potential T. congolense diagnostic antigens are 69 kDa protein, a member of the 70 kDa 
heat shock protein (hsp70) family (Boulangé et al, 2002), maltose binding protein-HSP70/BiP 
(Bossard et al, 2010), TcP46 invariant antigen (Zhou et al, 2014) and Tc38630 ISG (Gene ID: 








sites & incubate 
with test serum



















stone to evaluate T. congolense ISGs for use in lateral flow systems similar to the p310 lateral 
flow test established for diagnosis of T. vivax infections (Fleming et al, 2016) with the ultimate 
goal of developing rapid antigen detection tests for AAT diagnosis.  
The use of phage display technology has not yet been explored for T. congolense ISGs and can 
be used for the production of anti-TcISG single-chain variant fragments which will eliminate the 
need to immunise animals. Phage display antibodies such as the Nkuku® library are produced 
with high specificity and in large quantities using simple expression methods thus reducing cost 
and time constraints (Van Wyngaardt et al, 2004). The signal peptide of ISGs is understood to 
undergo cleavage upon maturation of ISG. Since the construct used in the present study 
included the signal peptide, extracellular domain, transmembrane region and intracellular 
transmembrane region, it will be worthwhile to generate anti-peptide antibodies against these 
domains to monitor its processing to determine it significance since characterisation of ISGs are 
poorly reported. Crystallisation studies can also be conducted for resolution of the TcISG 
structure to completely understand the function of ISGs as structural information on this protein 
is lacking.  
In conclusion, encouraging results were obtained in the present study as TcISG discriminated 
between T. congolense non-infected and infected cattle sera in an antibody detection indirect 
ELISA and was not recognised by anti-T. brucei ISGs and anti-T. b. gambiense VSGs 
antibodies. Additionally, anti-TcISG IgY and TcISG N-terminal peptide IgY antibodies were 
produced in large quantities with high specificity and can be further evaluated in antibody and 
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Appendix A:  
Prediction of T. congolense ISG conserved domains 
 
 
Conserved domain predictions from Trypanosoma congolense (TcIL3000.0.29290, Accession 







Hits with scores that pass a domain-specific threshold (specific hits) are drawn in bright green 





pfam11727: ISG65-75  
Invariant surface glycoprotein 
This family is found in Trypanosome species, and appears to be one of two invariant 
surface glycoproteins, ISG65 and ISG75 that are found in the mammalian stage of 
the parasitic protozoan. The sequence suggests the two families are polypeptides 
with N-terminal signal sequences, hydrophilic extracellular domains, single trans-
membrane alpha-helices and short cytoplasmic domains. They are both expressed in 
the bloodstream form but not in the midgut stage. Both polypeptides are distributed 











Appendix B:  
Prediction of T. congolense ISG transmembrane domains 
 
Domain predictions of Trypanosoma congolense (TcIL3000.0.29290, Accession CCD12004) 
using the web-based TMHMM server v. 2.0 (http://www.cbs.dtu.dk/ services/TMHMM-2.0/). 
 
 
# TcISG Length: 419 
# TcISG Number of predicted TMHs:  1 
# TcISG Exp number of AAs in TMHs: 34.93968 
# TcISG Exp number, first 60 AAs:  12.02008 
# TcISG Total prob of N-in:        0.60616 
# TcISG POSSIBLE N-term signal sequence 
TcISG TMHMM2.0 outside      1   367 
TcISG TMHMM2.0 TMhelix    368   390 



















Appendix C:  
The DNA sequence coding for T. congolense ISG 
 
Trypanosoma congolense (IL3000) ISG DNA sequence (TcIL3000.0.29290) was retrieved from 
GenBank (http://www.ncbi.nlm.nih.gov) with Accession CCD12004. The forward and reverse 
primers are highlighted in blue and start and stop codons are underlined in bold.  
 
   1 ATGGGGATGC AACGTATTGT TTGTGTTGGA TCGCTTTTGG TGGCTGTGTT 
  51 GCTTTCCGGA GGGGCCACTG GGAATGCTGG CAATTCTAAT GGTGTCTGTA  
 101 GACTGAATGA GAACGCTGCA GGACTCTTGT GTACCATTGC CAAACTTGTG  
 151 GAAAAGGCCA AGAATATTAC TGAAAATCAT GACTACAAGG ATATTGACGA  
 201 AACATGGGGT TACGTGGCAC TGCATAAGGA AGTGGTTGAT CACCGAGTAA  
 251 AAAATTTACC AGATATAATT GAGACAGCTA AAGCAAAAGG AACTTTGACG  
 301 GTTAAGGATG CCGAACATCT GACGACGCTT TATCTTGACG CACATAACAA  
 351 GAATACTCAG CAACATAATA AGTCCAAAGC AGCCATGGAT GCACACAACA  
 401 AAACACATGA GGATGCAAAG AATTCAACAG CGTTGGCGCT GGGTGAAGGC  
 451 TACGTCACAG GTAACTGCAA CATGGTCTCA TCGCTCCTGG GTATCCTCCA  
 501 GTGCTATGTT AAAGGTGAAC AACCGCACAG TAACCTCAAT GTGGAAACAC  
 551 TTTGTAAAGA AAAGAACTAT AATTTGGATG AAAGCCAACA TACACTTCTC 
 601 ACAAACTGCA ATAAAATAGG CAATCGCAAA ACGTACTGCA ACGGCACCGG  
 651 TGCAGCACTC AAAGTAGCAC TGGACAAGTG GAATGGAATG GACAAGAAAA  
 701 AGGCCGCTGA TAATGGAAAC TGTGAGGTCA AAAAGGATTG GGAAGAGCGC  
 751 ACCAAGAAGG CCCAAGAACA CATGAGCCGT CTGGACGAGC ACGTACAGAT  
 801 CATACACGAC GCCAAACTCT TGACTACCGC CTACTTCTCC ATCGTTGACA  
 851 AAATAAAGAC TGGTGTTGAA AACGGCAAAC CCATGAAAGT AATTGTCGCC  
 901 AATGCGCGTG AGGCCGGTCA AAAGGGCGCC AAAGTTGTGG TGGAAAAGCT  
 951 TAGTGTAAAC ACAGAGAATG ACCCCCATAA CACAACCAAA CCGCTGGTGG  
1001 AGGAGGAAGA AGTCAATGTC AACGTCCAAC TCGATGGGCT GAAGTTTGAT  
1051 GAGGATGAAA ATGGCCCTGC CCATTCAAAG GAGAGCTTCC CAAAAATTTA  
1101 CATTTATCTC TTATCTATTC TTCTCCCGCT CTTCTGCCTG GTCATGGGCA  
1151 TTACCCTGTA TTGCCTCATC AGTAAACCCA GGTCCTCACA CCCAGAGAAG 
1201 AGCATCCCGG TGGATGGTGC CACTATGAAC AAGGCTGGAG ATACACAGGC  










Appendix D:  
Nucleotide sequence alignment of pGEM®-T-TcISG and TcIL3000.0.29290. 
 
EMBOSS Needle Pairwise nucleotide sequence alignment of T. congolense ISG Clone 
(obtained from sequencing of pGEM®-T-TcISG) [Clone] with TcIL3000.0.29290 gene (Accession 
CCD12004) [ISG].   
 
Aligned_sequences: 2 
# 1: ISG 
# 2: Clone 
 
# Length: 1260 
# Identity:    1247/1260 (99.0%) 
# Similarity:  1247/1260 (99.0%) 
# Gaps:           0/1260 ( 0.0%) 
# Score: 7214.0 
 
ISG                1 ATGGGGATGCAACGTATTGTTTGTGTTGGATCGCTTTTGGTGGCTGTGTT     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone              1 ATGGGGATGCAACGTATTGTTTGTGTTGGATCGCTTTTGGTGGCTGTGTT     50 
 
ISG               51 GCTTTCCGGAGGGGCCACTGGGAATGCTGGCAATTCTAATGGTGTCTGTA    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone             51 GCTTTCCGGAGGGGCCACTGGGAATGCTGGCAATTCTAATGGTGTCTGTA    100 
 
ISG              101 GACTGAATGAGAACGCTGCAGGACTCTTGTGTACCATTGCCAAACTTGTG    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            101 GACTGAATGAGAACGCTGCAGGACTCTTGTGTACCATTGCCAAACTTGTG    150 
 
ISG              151 GAAAAGGCCAAGAATATTACTGAAAATCATGACTACAAGGATATTGACGA    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            151 GAAAAGGCCAAGAATATTACTGAAAATCATGACTACAAGGATATTGACGA    200 
 
ISG              201 AACATGGGGTTACGTGGCACTGCATAAGGAAGTGGTTGATCACCGAGTAA    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            201 AACATGGGGTTACGTGGCACTGCATAAGGAAGTGGTTGATCACCGAGTAA    250 
 
ISG              251 AAAATTTACCAGATATAATTGAGACAGCTAAAGCAAAAGGAACTTTGACG    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            251 AAAATTTACCAGATATAATTGAGACAGCTAAAGCAAAAGGAACTTTGACG    300 
 
ISG              301 GTTAAGGATGCCGAACATCTGACGACGCTTTATCTTGACGCACATAACAA    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            301 GTTAAGGATGCCGAACATCTGACGACGCTTTATCTTGACGCACATAACAA    350 
 
ISG              351 GAATACTCAGCAACATAATAAGTCCAAAGCAGCCATGGATGCACACAACA    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            351 GAATACTCAGCAACATAATAAGTCCAAAGCAGCCATGGATGCACACAACA    400 
 
ISG              401 AAACACATGAGGATGCAAAGAATTCAACAGCGTTGGCGCTGGGTGAAGGC    450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            401 AAACACATGAGGATGCAAAGAATTCAACAGCGTTGGCGCTGGGTGAAGGC    450 
 
ISG              451 TACGTCACAGGTAACTGCAACATGGTCTCATCGCTCCTGGGTATCCTCCA    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            451 TACGTCACAGGTAACTGCAACATGGTCTCATCGCTCCTGGGTATCCTCCA    500 
 
ISG              501 GTGCTATGTTAAAGGTGAACAACCGCACAGTAACCTCAATGTGGAAACAC    550 
KEY: 
 






                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            501 GTGCTATGTTAAAGGTGAACAACCGCACAGTAACCTCAATGTGGAAACAC    550 
 
ISG              551 TTTGTAAAGAAAAGAACTATAATTTGGATGAAAGCCAACATACACTTCTC    600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            551 TTTGTAAAGAAAAGAACTATAATTTGGATGAAAGCCAACATACACTTCTC    600 
 
ISG              601 ACAAACTGCAATAAAATAGGCAATCGCAAAACGTACTGCAACGGCACCGG    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            601 ACAAACTGCAATAAAATAGGCAATCGCAAAACGTACTGCAACGGCACCGG    650 
 
ISG              651 TGCAGCACTCAAAGTAGCACTGGACAAGTGGAATGGAATGGACAAGAAAA    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            651 TGCAGCACTCAAAGTAGCACTGGACAAGTGGAATGGAATGGACAAGAAAA    700 
 
ISG              701 AGGCCGCTGATAATGGAAACTGTGAGGTCAAAAAGGATTGGGAAGAGCGC    750 
                     ||||||||||.||||||||||||||.|||||||||||||||||||||||| 
Clone            701 AGGCCGCTGAGAATGGAAACTGTGAAGTCAAAAAGGATTGGGAAGAGCGC    750 
 
ISG              751 ACCAAGAAGGCCCAAGAACACATGAGCCGTCTGGACGAGCACGTACAGAT    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||. 
Clone            751 ACCAAGAAGGCCCAAGAACACATGAGCCGTCTGGACGAGCACGTACAGAG    800 
 
ISG              801 CATACACGACGCCAAACTCTTGACTACCGCCTACTTCTCCATCGTTGACA    850 
                     |||||||.|||||||||||||||||||||||||||||||||||||||||| 
Clone            801 CATACACAACGCCAAACTCTTGACTACCGCCTACTTCTCCATCGTTGACA    850 
 
ISG              851 AAATAAAGACTGGTGTTGAAAACGGCAAACCCATGAAAGTAATTGTCGCC    900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            851 AAATAAAGACTGGTGTTGAAAACGGCAAACCCATGAAAGTAATTGTCGCC    900 
 
ISG              901 AATGCGCGTGAGGCCGGTCAAAAGGGCGCCAAAGTTGTGGTGGAAAAGCT    950 
                     |||||||||||||||||||||||.||.||||||||||||||||||||||| 
Clone            901 AATGCGCGTGAGGCCGGTCAAAAAGGTGCCAAAGTTGTGGTGGAAAAGCT    950 
 
ISG              951 TAGTGTAAACACAGAGAATGACCCCCATAACACAACCAAACCGCTGGTGG   1000 
                     ||||.||.||||||..|||||||||||||||||||||||||||||.|||| 
Clone            951 TAGTATAGACACAGNNAATGACCCCCATAACACAACCAAACCGCTTGTGG   1000 
 
ISG             1001 AGGAGGAAGAAGTCAATGTCAACGTCCAACTCGATGGGCTGAAGTTTGAT   1050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone           1001 AGGAGGAAGAAGTCAATGTCAACGTCCAACTCGATGGGCTGAAGTTTGAT   1050 
 
ISG             1051 GAGGATGAAAATGGCCCTGCCCATTCAAAGGAGAGCTTCCCAAAAATTTA   1100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone           1051 GAGGATGAAAATGGCCCTGCCCATTCAAAGGAGAGCTTCCCAAAAATTTA   1100 
 
ISG             1101 CATTTATCTCTTATCTATTCTTCTCCCGCTCTTCTGCCTGGTCATGGGCA   1150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone           1101 CATTTATCTCTTATCTATTCTTCTCCCGCTCTTCTGCCTGGTCATGGGCA   1150 
 
ISG             1151 TTACCCTGTATTGCCTCATCAGTAAACCCAGGTCCTCACACCCAGAGAAG   1200 
                     ||||||||||||||||||||.||||||||||||||||||||||||||||| 
Clone           1151 TTACCCTGTATTGCCTCATCNGTAAACCCAGGTCCTCACACCCAGAGAAG   1200 
 
ISG             1201 AGCATCCCGGTGGATGGTGCCACTATGAACAAGGCTGGAGATACACAGGC   1250 
                     ||||||||.||||||||||||||||||||||||||||||||||||||||| 
Clone           1201 AGCATCCCNGTGGATGGTGCCACTATGAACAAGGCTGGAGATACACAGGC   1250 
 
ISG             1251 ACACTTTTAA   1260 
                     |||||||||| 





Appendix E:  
Nucleotide sequence alignment of pET-32a-TcISG and TcIL3000.0.29290 
EMBOSS Needle Pairwise nucleotide sequence alignment of T. congolense ISG Clone 
(obtained from sequencing of pET-32a-TcISG) [Clone] with TcIL3000.0.29290 gene (Accession 
CCD12004) [ISG].   
            
  
 Aligned_sequences: 2 
 1: ISG 
 2: Clone 
 
 Length: 1260 
 Identity:    1247/1260 (99.0%) 
 Similarity:  1247/1260 (99.0%) 
 Gaps:           0/1260 ( 0.0%) 
 Score: 7208.0 
 
 
ISG                1 ATGGGGATGCAACGTATTGTTTGTGTTGGATCGCTTTTGGTGGCTGTGTT     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone              1 ATGGGGATGCAACGTATTGTTTGTGTTGGATCGCTTTTGGTGGCTGTGTT     50 
 
ISG               51 GCTTTCCGGAGGGGCCACTGGGAATGCTGGCAATTCTAATGGTGTCTGTA    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone             51 GCTTTCCGGAGGGGCCACTGGGAATGCTGGCAATTCTAATGGTGTCTGTA    100 
 
ISG              101 GACTGAATGAGAACGCTGCAGGACTCTTGTGTACCATTGCCAAACTTGTG    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            101 GACTGAATGAGAACGCTGCAGGACTCTTGTGTACCATTGCCAAACTTGTG    150 
 
ISG              151 GAAAAGGCCAAGAATATTACTGAAAATCATGACTACAAGGATATTGACGA    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            151 GAAAAGGCCAAGAATATTACTGAAAATCATGACTACAAGGATATTGACGA    200 
 
ISG              201 AACATGGGGTTACGTGGCACTGCATAAGGAAGTGGTTGATCACCGAGTAA    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            201 AACATGGGGTTACGTGGCACTGCATAAGGAAGTGGTTGATCACCGAGTAA    250 
 
ISG              251 AAAATTTACCAGATATAATTGAGACAGCTAAAGCAAAAGGAACTTTGACG    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            251 AAAATTTACCAGATATAATTGAGACAGCTAAAGCAAAAGGAACTTTGACG    300 
 
ISG              301 GTTAAGGATGCCGAACATCTGACGACGCTTTATCTTGACGCACATAACAA    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            301 GTTAAGGATGCCGAACATCTGACGACGCTTTATCTTGACGCACATAACAA    350 
 
ISG              351 GAATACTCAGCAACATAATAAGTCCAAAGCAGCCATGGATGCACACAACA    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            351 GAATACTCAGCAACATAATAAGTCCAAAGCAGCCATGGATGCACACAACA    400 
 
ISG              401 AAACACATGAGGATGCAAAGAATTCAACAGCGTTGGCGCTGGGTGAAGGC    450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            401 AAACACATGAGGATGCAAAGAATTCAACAGCGTTGGCGCTGGGTGAAGGC    450 
 
ISG              451 TACGTCACAGGTAACTGCAACATGGTCTCATCGCTCCTGGGTATCCTCCA    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 










ISG              501 GTGCTATGTTAAAGGTGAACAACCGCACAGTAACCTCAATGTGGAAACAC    550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            501 GTGCTATGTTAAAGGTGAACAACCGCACAGTAACCTCAATGTGGAAACAC    550 
 
ISG              551 TTTGTAAAGAAAAGAACTATAATTTGGATGAAAGCCAACATACACTTCTC    600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            551 TTTGTAAAGAAAAGAACTATAATTTGGATGAAAGCCAACATACACTTCTC    600 
 
ISG              601 ACAAACTGCAATAAAATAGGCAATCGCAAAACGTACTGCAACGGCACCGG    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            601 ACAAACTGCAATAAAATAGGCAATCGCAAAACGTACTGCAACGGCACCGG    650 
 
ISG              651 TGCAGCACTCAAAGTAGCACTGGACAAGTGGAATGGAATGGACAAGAAAA    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            651 TGCAGCACTCAAAGTAGCACTGGACAAGTGGAATGGAATGGACAAGAAAA    700 
 
ISG              701 AGGCCGCTGATAATGGAAACTGTGAGGTCAAAAAGGATTGGGAAGAGCGC    750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            701 AGGCCGCTGATAATGGAAACTGTGAGGTCAAAAAGGATTGGGAAGAGCGC    750 
 
ISG              751 ACCAAGAAGGCCCAAGAACACATGAGCCGTCTGGACGAGCACGTACAGAT    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||. 
Clone            751 ACCAAGAAGGCCCAAGAACACATGAGCCGTCTGGACGAGCACGTACAGAA    800 
 
ISG              801 CATACACGACGCCAAACTCTTGACTACCGCCTACTTCTCCATCGTTGACA    850 
                     |||||||.|||||||||||||||||||||||||||||||||||||||||| 
Clone            801 CATACACCACGCCAAACTCTTGACTACCGCCTACTTCTCCATCGTTGACA    850 
 
ISG              851 AAATAAAGACTGGTGTTGAAAACGGCAAACCCATGAAAGTAATTGTCGCC    900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            851 AAATAAAGACTGGTGTTGAAAACGGCAAACCCATGAAAGTAATTGTCGCC    900 
 
ISG              901 AATGCGCGTGAGGCCGGTCAAAAGGGCGCCAAAGTTGTGGTGGAAAAGCT    950 
                     |||||||||||||||||||||||.|..||||||||||||||||||||||| 
Clone            901 AATGCGCGTGAGGCCGGTCAAAAAGAAGCCAAAGTTGTGGTGGAAAAGCT    950 
 
ISG              951 TAGTGTAAACACAGAGAATGACCCCCATAACACAACCAAACCGCTGGTGG   1000 
                     ||||.||||||||||.|||||||||||||||||||||||||||||||||| 
Clone            951 TAGTATAAACACAGAAAATGACCCCCATAACACAACCAAACCGCTGGTGG   1000 
 
ISG             1001 AGGAGGAAGAAGTCAATGTCAACGTCCAACTCGATGGGCTGAAGTTTGAT   1050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone           1001 AGGAGGAAGAAGTCAATGTCAACGTCCAACTCGATGGGCTGAAGTTTGAT   1050 
 
ISG             1051 GAGGATGAAAATGGCCCTGCCCATTCAAAGGAGAGCTTCCCAAAAATTTA   1100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone           1051 GAGGATGAAAATGGCCCTGCCCATTCAAAGGAGAGCTTCCCAAAAATTTA   1100 
 
ISG             1101 CATTTATCTCTTATCTATTCTTCTCCCGCTCTTCTGCCTGGTCATGGGCA   1150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone           1101 CATTTATCTCTTATCTATTCTTCTCCCGCTCTTCTGCCTGGTCATGGGCA   1150 
 
ISG             1151 TTACCCTGTATTGCCTCATCAGTAAACCCAGGTCCTCACACCCAGAGAAG   1200 
                     ||||||||||||||||||||.||||||||||||||||||||||||||||| 
Clone           1151 TTACCCTGTATTGCCTCATCCGTAAACCCAGGTCCTCACACCCAGAGAAG   1200 
 
ISG             1201 AGCATCCCGGTGGATGGTGCCACTATGAACAAGGCTGGAGATACACAGGC   1250 
                     ||||||||.|||||||||||||||||.||||||||||..||||.|||||| 
Clone           1201 AGCATCCCCGTGGATGGTGCCACTATTAACAAGGCTGCGGATAAACAGGC   1250 
 
ISG             1251 ACACTTTTAA   1260                             
                     |||||||||| 




Appendix F:  
Protein sequence alignment of pET-32a-TcISG and TcIL3000.0.29290 
 
EMBOSS Needle Pairwise protein sequence alignment of T. congolense ISG Clone (obtained 
from sequencing of pET-32a-TcISG) [Clone] with TcIL3000.0.29290 ISG gene (Accession 
CCD12004) [ISG].  
 
 
 Aligned_sequences: 2 
 1: ISG 
 2: Clone 
 
 Length: 419 
 Identity:     411/419 (98.1%) 
 Similarity:   411/419 (98.1%) 
 Gaps:           0/419 ( 0.0%) 
 Score: 2153.0 
 
 
ISG                1 MGMQRIVCVGSLLVAVLLSGGATGNAGNSNGVCRLNENAAGLLCTIAKLV     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone              1 MGMQRIVCVGSLLVAVLLSGGATGNAGNSNGVCRLNENAAGLLCTIAKLV     50 
 
ISG               51 EKAKNITENHDYKDIDETWGYVALHKEVVDHRVKNLPDIIETAKAKGTLT    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone             51 EKAKNITENHDYKDIDETWGYVALHKEVVDHRVKNLPDIIETAKAKGTLT    100 
 
ISG              101 VKDAEHLTTLYLDAHNKNTQQHNKSKAAMDAHNKTHEDAKNSTALALGEG    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            101 VKDAEHLTTLYLDAHNKNTQQHNKSKAAMDAHNKTHEDAKNSTALALGEG    150 
 
ISG              151 YVTGNCNMVSSLLGILQCYVKGEQPHSNLNVETLCKEKNYNLDESQHTLL    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            151 YVTGNCNMVSSLLGILQCYVKGEQPHSNLNVETLCKEKNYNLDESQHTLL    200 
 
ISG              201 TNCNKIGNRKTYCNGTGAALKVALDKWNGMDKKKAADNGNCEVKKDWEER    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone            201 TNCNKIGNRKTYCNGTGAALKVALDKWNGMDKKKAADNGNCEVKKDWEER    250 
 
ISG              251 TKKAQEHMSRLDEHVQIIHDAKLLTTAYFSIVDKIKTGVENGKPMKVIVA    300 
                     ||||||||||||||||.||.|||||||||||||||||||||||||||||| 
Clone            251 TKKAQEHMSRLDEHVQXIHXAKLLTTAYFSIVDKIKTGVENGKPMKVIVA    300 
 
ISG              301 NAREAGQKGAKVVVEKLSVNTENDPHNTTKPLVEEEEVNVNVQLDGLKFD    350 
                     ||||||||.|||||||||.||||||||||||||||||||||||||||||| 
Clone            301 NAREAGQKXAKVVVEKLSXNTENDPHNTTKPLVEEEEVNVNVQLDGLKFD    350 
 
ISG              351 EDENGPAHSKESFPKIYIYLLSILLPLFCLVMGITLYCLISKPRSSHPEK    400 
                     ||||||||||||||||||||||||||||||||||||||||.||||||||| 
Clone            351 EDENGPAHSKESFPKIYIYLLSILLPLFCLVMGITLYCLIXKPRSSHPEK    400 
 
ISG              401 SIPVDGATMNKAGDTQAHF    419 
                     ||||||||.|||.|.|||| 










Appendix G:  









Figure A 1: Analysis of TcISG extracellular domain using the Predict7 program. (A) TcISG Amino 
acid residues 150-200 (B) 250-300 and (C) 300-250. The surface probability and hydrophilicity is plotted 
on the primary axis while antigenicity and flexibility is displayed on the secondary axis. TcISG N-terminal 
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Appendix H:  






Figure A 2: Analysis of TcISG N-terminal peptide using PEP6 program. (A) The surface accessibility, 











Appendix I:  





Figure A 3: Dot blot optimisation of TcISG and chicken anti-TcISG IgY antibodies. The nitrocellulose 
membrane was cut into strips and spotted with TcISG (1-10 μg/ml in duplicate) and probed with chicken 
anti-TcISG IgY (0.5-10 μg/ml). Blots were developed rabbit anti-chicken IgY-HRPO conjugate [1:5000] and 
4-chloro-1-naphthol·H2O2 chromogen-substrate solution. Controls included: pre-immune antibody and the 
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Appendix J:  
NCBI-BLAST search result for TcISG sequence (TcIL3000.0.29290) 
 















VALUE IDENTITY ACCESSION 
unnamed protein product [Trypanosoma congolense 
IL3000] 862 862 100% 0 100% CCD12004.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 834 834 100% 0 97% CCD12655.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 539 539 93% 0 71% CCD17109.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma congolense IL3000] 530 530 99% 0 63% CCD16307.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 468 468 99% 
1.00E-
160 59% CCD12686.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 393 393 93% 
3.00E-
131 54% CCD16692.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 392 392 97% 
4.00E-
131 50% CCD13471.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 363 363 43% 
4.00E-
123 97% CCD12882.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 354 354 69% 
7.00E-
118 61% CCD13936.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 331 331 97% 
5.00E-
107 44% CCD13472.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 327 327 97% 
2.00E-
105 44% CCD17385.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 325 325 97% 
1.00E-
104 44% CCD13473.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 295 295 89% 1.00E-93 45% CCD16831.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 269 269 45% 4.00E-86 71% CCD15064.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 228 228 96% 9.00E-66 35% CCD15069.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 214 214 96% 5.00E-61 34% CCD14465.1 
unnamed protein product [Trypanosoma congolense 




unnamed protein product [Trypanosoma congolense 
IL3000] 179 179 41% 2.00E-50 55% CCD11875.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 160 160 38% 3.00E-44 57% CCD11868.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 149 149 37% 5.00E-40 48% CCD17495.1 
hypothetical protein, unlikely [Trypanosoma 
congolense IL3000] 144 144 27% 2.00E-38 62% CCD16166.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 141 141 35% 4.00E-37 58% CCD11876.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 144 144 94% 3.00E-35 27% CCD12049.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 133 133 33% 7.00E-34 48% CCD16162.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 132 132 94% 1.00E-30 25% CCD17383.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 126 126 76% 5.00E-28 27% CCD13429.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 120 120 68% 2.00E-27 29% CCD12050.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 116 116 62% 2.00E-26 29% CCD15617.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 120 120 99% 5.00E-26 24% CCD13470.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 93.2 93.2 32% 6.00E-19 40% CCD17055.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 95.1 95.1 74% 2.00E-18 25% CCD16246.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 87.8 87.8 73% 9.00E-16 25% CCD12052.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 82.8 82.8 92% 1.00E-13 23% 
XP_01177172
9.1 
65 kDa invariant surface glycoprotein [Trypanosoma 
brucei brucei TREU927] 82.4 82.4 86% 2.00E-13 23% XP_951583.1 
65 kDa invariant surface glycoprotein [Trypanosoma 
brucei brucei TREU927] 82 82 86% 2.00E-13 23% XP_951586.1 
65 kDa invariant surface glycoprotein [Trypanosoma 
brucei brucei TREU927] 81.6 81.6 86% 3.00E-13 23% XP_951585.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 80.9 80.9 94% 5.00E-13 23% 
XP_01177173
4.1 
65 kDa invariant surface glycoprotein [Trypanosoma 
brucei brucei TREU927] 80.5 80.5 86% 7.00E-13 23% XP_951584.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 78.6 78.6 92% 3.00E-12 23% 
XP_01177173
1.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 77.8 77.8 87% 6.00E-12 23% 
XP_01177173
9.1 





65 kDa invariant surface glycoprotein [Trypanosoma 
brucei brucei TREU927] 77 77 93% 1.00E-11 22% XP_951582.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 76.6 76.6 87% 1.00E-11 23% 
XP_01177173
2.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 74.3 74.3 92% 6.00E-11 24% 
XP_01177172
8.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 74.3 74.3 79% 1.00E-10 23% CCD16641.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 73.6 73.6 87% 1.00E-10 22% 
XP_01177174
5.1 
variant surface glycoprotein [Trypanosoma brucei] 72.8 72.8 87% 2.00E-10 25% AAF14218.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 72.8 72.8 87% 2.00E-10 24% 
XP_01177174
3.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 72.4 72.4 79% 4.00E-10 23% CCD15441.1 
unnamed protein product [Trypanosoma congolense 
IL3000] 68.6 68.6 79% 5.00E-09 23% CCD15440.1 
65 kDa invariant surface glycoprotein [Trypanosoma 
brucei] 68.6 68.6 87% 5.00E-09 25% AAA30147.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 67.8 67.8 92% 9.00E-09 20% 
XP_01177174
8.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 67.4 67.4 87% 1.00E-08 23% 
XP_01177174
6.1 
65 kDa invariant surface glycoprotein, putative 
[Trypanosoma brucei gambiense DAL972] 67.4 67.4 87% 1.00E-08 25% 
XP_01177174
1.1 
65 kDa invariant surface glycoprotein [Trypanosoma 
brucei brucei TREU927] 65.9 65.9 93% 4.00E-08 20% XP_951587.1 
65 kDa invariant surface glycoprotein, fragment 
















Appendix K:  
Multiple sequence alignment of TcISG, T. b. gambiense ISG65 and T. brucei ISG65 
Multiple sequence alignment of T. congolense ISG (TcISG) (Accession CCD12004.1), T. b. 
gambiense (Tbg) ISG65, putative (Accession XP_011771734.1) and T. brucei  brucei (Tbb) 
ISG65 using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/).  
 
TcISG      -MGMQRIVCVGSLLVAVLLSGGATGNAGNSNGVCRLNENAAGLLCTIAKLVEKAKNITEN 
Tbg        MMKYLLVFAIIATRIPVLLVIGSED--NRVPGDKKLTKEEAAALCKMKHLADKVAKERSQ 
Tbb        MMKYLLVFAIIATRIPALLVIGSED--NRVPGDKKLTKEGAAALCKMKHLADKVAEERSQ 
            *    :..: :  : .**  *: .  ..  *  :*.:: *. **.: :*.:*. :  .: 
 
TcISG      HDYKDIDETWGYVALHKEVVDHRVKNLPDIIETAKAKGTLTVKDAEHLTTLYLDAHNKNT 
Tbg        ELKDRTQNFAGYIEFELYRIDYWLEKLNGPKGRKDGYAKLSDSDIEKVKEIFNKAKDGIT 
Tbb        ELKDRTQNFAGYIEFELYRIDYWLEKLNGPKGRKDGYAKLSDSDIEKVKEIFNKAKDGIA 
           .  .  ::  **: :.   :*: :::* .     .. ..*: .* *::. :: .*::  : 
 
TcISG      QQHNKSKAAMDAHNKTHEDAKNSTALALGEGYVTGNCNMVSSLLGILQCY--VKGEQPHS 
Tbg        KQLPEAKKAGEEAGKLHTEVKKAAENARGQDLD-DDTAKSTGLYRVLNWYCITKEERHNA 
Tbb        KQLPEAKKAGEEAEKLHTEVKKAAANARGQDLD-EYRQKSTGLYRVLNWYCITKEERHNA 
           :*  ::* * :   * * :.*:::  * *:.         :.*  :*: *  .* *: :: 
 
TcISG      NLNVETLCKEKNYNLDESQHTLLTNCNKIGNRKTYCNGTGAALKVALDKWNGMDKKKAA- 
Tbg        TPNCDGIQFRKHYL---SVNRSAIDCSSTGYKEDYD-WSANALQVALNSWENVKPKKLES 
Tbb        TPNCDGIQFRKHYL---SVNRSAIDCSSTGYEENYD-WSANALQVALNSWENVKPKKLES 
           . * : :  .*:*    * :    :*.. * .: *   :. **:***:.*:.:. **    
 
TcISG      -------------DNGNCEVKKDWEERTKKAQEHMSRLDEHVQIIHDAKLLTTAYFSIVD 
Tbg        AGSDKNCNIGQSSESHPCTMTEEWQTPYKETVEKLRELEDAYQRGKKAHDAMLGYANTAY 
Tbb        AGSDMNCNIGQSSESHPCTMTEEWQTPYKETVEKLRELEDAYQRGKKAHDAMLGYANTAY 
                        :.  * :.::*:   *:: *:: .*::  *  :.*:    .* . .  
 
TcISG      KIKTGVENGKPMKVIVANAREAGQKGAKVVVEKLSVNTENDPHNTTKP----------LV 
Tbg        AVNTKVEQEKPLTEVIAAAKEAGKKGAKIIIPAAAPATPTNSTKNEDSASTEHVDRGIAT 
Tbb        AVNTKVEQEKPLTEVIAAAKDAGKKGAKIIIPAAAPATPTNSTKNEDSASTEHVDRGIAT 
            ::* **: **:. ::* *::**:****:::   :  * .:  :. .            .  
 
TcISG      EEEE--VNVNVQLDGLKFDEDENGPAHSKESFPKIYIYLLSILLPLFCLVMGITLYCLIS 
Tbg        NETQVEVGIDADFDSLLD-A--TEAAEVTRRHQRTAMIILAVLVPAIILVVTAVAFFIMV 
Tbb        NETQVEVGIDADFDSLLD-A--TEAAEVTRRHQRTAMIILAVLVPAIILVVTAVAFFIMV 
           :* :  *.::.::*.*      .  *. .. . :  : :*::*:* : **:  . : ::  
 
TcISG      KPRSSHPEKSIPVDGATMNKAGDTQAHF--420 
Tbg        KRRRNNSQD---VDTGKA-EGGVSSVKVVM 
Tbb        KRRRNSSKD---VDTGKA-EGGVSSVKVVM 
           * * .  :.   ** ..  :.* :..:.   
 
